drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3 values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB12015 | DB12095 | 1,033 | 179 | [
"DDInter53",
"DDInter1760"
] | Alpelisib | Telotristat ethyl | Alpelisib is a phosphatidylinositol 3-kinase (PI3K) inhibitor with potent antitumor activity. It works by selectively inhibiting class I PI3K p110α, which is the catalytic subunit of PI3K, a lipid kinase that plays a role in various biological processes, including proliferation, survival, differentiation, and metabolism. Alpelisib was designed to target this enzyme that appears to be mutated at a rate of nearly 30% in human cancers, leading to hyperactivation. There are several isoform-specific PI3K inhibitors that are under clinical development or currently approved, such as [idelalisib] used for chronic lymphocytic leukemia (CLL). Approved by the FDA in May 2019, alpelisib is the first approved PI3K inhibitor indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK | Telotristat ethyl is a prodrug of telotristat that was approved by the FDA in March 2017 as Xermelo. It was previously referred to as telotristat etiprate, the hippurate salt form; however, the FDA recommends the use of the name of the neutral form rather than that of the salt.[A252937, A252942] Currently, telotristat ethyl is used to treat carcinoid syndrome diarrhea from neuroendocrine tumors that are inadequately controlled by short-acting somatostatin analog (SSA) treatment. Neuroendocrine cells are cells that secrete regulatory peptides and biogenic amines in response to chemical, neural, or other types of stimuli. Neuroendocrine tumors (NET) arising from these cells can therefore secrete chemical mediators into the bloodstream to cause side effects in distant sites, a phenomenon called carcinoid syndrome. The most common peptides and amines secreted by NET are histamines, tachykinins, kallikrein, and serotonin. Overexposure to serotonin can cause severe diarrhea, one of the main clinical symptoms of carcinoid syndrome. Serotonin is metabolized in the urinary metabolite 5-hydroxy indole acetic acid (u5-HIAA), and high levels of u5-HIAA is associated with poor survival outcome in patients with NET. The first line treatment of carcinoid syndrome diarrhea is SSA, but symptoms still reoccur over the course of the disease. | Moderate | 1 | [
[
[
1033,
24,
179
]
],
[
[
1033,
63,
1517
],
[
1517,
24,
179
]
],
[
[
1033,
24,
971
],
[
971,
63,
179
]
],
[
[
1033,
64,
129
],
[
129,
... | [
[
[
"Alpelisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telotristat ethyl"
]
],
[
[
"Alpelisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isotretinoin"
],
... | Alpelisib may cause a moderate interaction that could exacerbate diseases when taken with Isotretinoin and Isotretinoin may cause a moderate interaction that could exacerbate diseases when taken with Telotristat ethyl
Alpelisib may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib and Gilteritinib may cause a moderate interaction that could exacerbate diseases when taken with Telotristat ethyl
Alpelisib may lead to a major life threatening interaction when taken with Enzalutamide and Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Telotristat ethyl
Alpelisib may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a moderate interaction that could exacerbate diseases when taken with Telotristat ethyl
Alpelisib may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib and Brigatinib may lead to a major life threatening interaction when taken with Telotristat ethyl
Alpelisib may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib and Glasdegib may lead to a major life threatening interaction when taken with Telotristat ethyl
Alpelisib may cause a moderate interaction that could exacerbate diseases when taken with Isotretinoin and Isotretinoin may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Telotristat ethyl
Alpelisib may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Telotristat ethyl
Alpelisib may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib and Vemurafenib may lead to a major life threatening interaction when taken with Sorafenib and Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Telotristat ethyl |
DB01035 | DB11817 | 1,401 | 1,259 | [
"DDInter1524",
"DDInter165"
] | Procainamide | Baricitinib | A derivative of procaine with less CNS action. | Baricitinib is a Janus kinase (JAK) inhibitor. JAKs are tyrosine protein kinases that play an important role in pro-inflammatory signaling pathways. Overactive JAKs have been implicated in autoimmune disorders, such as rheumatoid arthritis. By inhibiting the actions of JAK1 and JAK2, baricitinib attenuates JAK-mediated inflammation and immune responses. Baricitinib was first approved by the European Commission (EC) in February 2017 for the treatment of rheumatoid arthritis in adults and was later approved by the FDA in 2018. The EC later approved baricitinib for the treatment of atopic dermatitis, making it the first JAK inhibitor used for this indication in Europe. While baricitinib was granted emergency use as a treatment for COVID-19 in combination with [remdesivir] under the Emergency Use Authorization (EUA) in November 2020, the FDA fully approved the use of baricitinib for the treatment of COVID-19 in May 2022. | Major | 2 | [
[
[
1401,
25,
1259
]
],
[
[
1401,
25,
927
],
[
927,
24,
1259
]
],
[
[
1401,
25,
1619
],
[
1619,
64,
1259
]
],
[
[
1401,
25,
36
],
[
36,
... | [
[
[
"Procainamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Baricitinib"
]
],
[
[
"Procainamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Encorafenib"
],
[
"Encorafenib",
... | Procainamide may lead to a major life threatening interaction when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Baricitinib
Procainamide may lead to a major life threatening interaction when taken with Rucaparib and Rucaparib may lead to a major life threatening interaction when taken with Baricitinib
Procainamide may lead to a major life threatening interaction when taken with Eribulin and Eribulin may lead to a major life threatening interaction when taken with Baricitinib
Procainamide may lead to a major life threatening interaction when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Baricitinib
Procainamide may cause a moderate interaction that could exacerbate diseases when taken with Infliximab and Infliximab may lead to a major life threatening interaction when taken with Baricitinib
Procainamide may cause a moderate interaction that could exacerbate diseases when taken with Guselkumab and Guselkumab may lead to a major life threatening interaction when taken with Baricitinib
Procainamide may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept and Rilonacept may lead to a major life threatening interaction when taken with Baricitinib
Procainamide (Compound) resembles Probenecid (Compound) and Probenecid may lead to a major life threatening interaction when taken with Baricitinib
Procainamide may lead to a major life threatening interaction when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Oxycodone and Oxycodone may cause a moderate interaction that could exacerbate diseases when taken with Baricitinib |
DB01069 | DB01166 | 401 | 477 | [
"DDInter1533",
"DDInter379"
] | Promethazine | Cilostazol | Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946. Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.[A189907,A190153,A190159,A190150,A190171] Promethazine was granted FDA approval before 29 March 1951.[A190177,L4000] | Cilostazol is a quinolinone derivative and antiplatelet agent with vasodilating properties that has been used in the symptomatic treatment of intermittent claudication in patients with peripheral ischaemia. It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both primary and secondary aggregation and reducing calcium-induced contractions. | Moderate | 1 | [
[
[
401,
24,
477
]
],
[
[
401,
6,
12523
],
[
12523,
45,
477
]
],
[
[
401,
21,
28642
],
[
28642,
60,
477
]
],
[
[
401,
24,
801
],
[
801,
... | [
[
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cilostazol"
]
],
[
[
"Promethazine",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compoun... | Promethazine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Cilostazol (Compound)
Promethazine (Compound) causes Shock (Side Effect) and Shock (Side Effect) is caused by Cilostazol (Compound)
Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Brivaracetam and Brivaracetam may cause a minor interaction that can limit clinical effects when taken with Cilostazol
Promethazine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Cilostazol
Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Adenosine and Adenosine may cause a moderate interaction that could exacerbate diseases when taken with Cilostazol
Promethazine (Compound) resembles Chlorpromazine (Compound) and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpromazine and Chlorpromazine may cause a moderate interaction that could exacerbate diseases when taken with Cilostazol
Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Cilostazol
Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Halothane and Halothane may cause a moderate interaction that could exacerbate diseases when taken with Cilostazol
Promethazine may lead to a major life threatening interaction when taken with Deutetrabenazine and Deutetrabenazine may cause a moderate interaction that could exacerbate diseases when taken with Cilostazol |
DB08815 | DB08912 | 154 | 1,040 | [
"DDInter1104",
"DDInter462"
] | Lurasidone | Dabrafenib | Lurasidone is an atypical antipsychotic developed by Dainippon Sumitomo Pharma. It was approved by the U.S. Food and Drug Administration (FDA) for treatment of schizophrenia on October 29, 2010 and is currently pending approval for the treatment of bipolar disorder in the United States. | Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation. It was also used for metastatic non-small cell lung cancer with the same mutation. In May 2018, Tafinlar (dabrafenib), in combination with Mekinist (), was approved to treat anaplastic thyroid cancer caused by an abnormal BRAF V600E gene. | Moderate | 1 | [
[
[
154,
24,
1040
]
],
[
[
154,
6,
8374
],
[
8374,
45,
1040
]
],
[
[
154,
21,
28900
],
[
28900,
60,
1040
]
],
[
[
154,
63,
1101
],
[
1101,... | [
[
[
"Lurasidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
]
],
[
[
"Lurasidone",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",... | Lurasidone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Dabrafenib (Compound)
Lurasidone (Compound) causes Abdominal pain (Side Effect) and Abdominal pain (Side Effect) is caused by Dabrafenib (Compound)
Lurasidone may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Dabrafenib
Lurasidone may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib
Lurasidone may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib
Lurasidone may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor and Ivacaftor may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib
Lurasidone may lead to a major life threatening interaction when taken with Enzalutamide and Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib
Lurasidone may lead to a major life threatening interaction when taken with Imatinib and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib
Lurasidone may lead to a major life threatening interaction when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib |
DB00867 | DB01087 | 1,052 | 1,520 | [
"DDInter1606",
"DDInter1520"
] | Ritodrine | Primaquine | Adrenergic beta-agonist used to control premature labor. | An aminoquinoline that is given by mouth to produce a radical cure and prevent relapse of vivax and ovale malarias following treatment with a blood schizontocide. It has also been used to prevent transmission of falciparum malaria by those returning to areas where there is a potential for re-introduction of malaria. Adverse effects include anemias and GI disturbances. (From Martindale, The Extra Pharmacopeia, 30th ed, p404) | Moderate | 1 | [
[
[
1052,
24,
1520
]
],
[
[
1052,
24,
1487
],
[
1487,
64,
1520
]
],
[
[
1052,
24,
1342
],
[
1342,
63,
1520
]
],
[
[
1052,
24,
1133
],
[
11... | [
[
[
"Ritodrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Primaquine"
]
],
[
[
"Ritodrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxychloroquine"
],
... | Ritodrine may cause a moderate interaction that could exacerbate diseases when taken with Hydroxychloroquine and Hydroxychloroquine may lead to a major life threatening interaction when taken with Primaquine
Ritodrine may cause a moderate interaction that could exacerbate diseases when taken with Romidepsin and Romidepsin may cause a moderate interaction that could exacerbate diseases when taken with Primaquine
Ritodrine may cause a moderate interaction that could exacerbate diseases when taken with Granisetron and Granisetron may cause a moderate interaction that could exacerbate diseases when taken with Primaquine
Ritodrine may cause a moderate interaction that could exacerbate diseases when taken with Tamoxifen and Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Primaquine
Ritodrine (Compound) resembles Formoterol (Compound) and Ritodrine may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Primaquine
Ritodrine may lead to a major life threatening interaction when taken with Dolasetron and Dolasetron may lead to a major life threatening interaction when taken with Primaquine
Ritodrine may lead to a major life threatening interaction when taken with Arsenic trioxide and Arsenic trioxide may lead to a major life threatening interaction when taken with Primaquine
Ritodrine may cause a moderate interaction that could exacerbate diseases when taken with Hydroxychloroquine and Hydroxychloroquine (Compound) resembles Chloroquine (Compound) and Chloroquine (Compound) resembles Primaquine (Compound)
Ritodrine may cause a moderate interaction that could exacerbate diseases when taken with Romidepsin and Romidepsin may lead to a major life threatening interaction when taken with Hydroxychloroquine and Hydroxychloroquine may lead to a major life threatening interaction when taken with Primaquine |
DB00995 | DB01098 | 1,112 | 14 | [
"DDInter139",
"DDInter1622"
] | Auranofin | Rosuvastatin | Auranofin is a gold salt that is capable of eliciting pharmacologic actions that suppress inflammation and stimulate cell-mediated immunity. It has subsequently been listed by the World Health Organization as a member of the antirheumatic agent category. Auranofin appears to induce heme oxygenase 1 (HO-1) mRNA. Heme oxygenase 1 is an inducible heme-degrading enzyme with anti-inflammatory properties. | Rosuvastatin, also known as the brand name product Crestor, is a lipid-lowering drug that belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage elevated lipid levels by inhibiting the endogenous production of cholesterol in the liver. More specifically, statin medications competitively inhibit the enzyme hydroxymethylglutaryl-coenzyme A (HMG-CoA) Reductase, which catalyzes the conversion of HMG-CoA to mevalonic acid and is the third step in a sequence of metabolic reactions involved in the production of several compounds involved in lipid metabolism and transport including cholesterol, low-density lipoprotein (LDL) (sometimes referred to as "bad cholesterol"), and very low-density lipoprotein (VLDL). Prescribing of statin medications is considered standard practice following any cardiovascular events and for people with a moderate to high risk of development of CVD, such as those with Type 2 Diabetes. The clear evidence of the benefit of statin use coupled with very minimal side effects or long term effects has resulted in this class becoming one of the most widely prescribed medications in North America.[A181087, A181406] Rosuvastatin and other drugs from the statin class of medications including [atorvastatin], [pravastatin], [simvastatin], [fluvastatin], and [lovastatin] are considered first-line options for the treatment of dyslipidemia.[A181087, A181406] This is largely due to the fact that cardiovascular disease (CVD), which includes heart attack, atherosclerosis, angina, peripheral artery disease, and stroke, has become a leading cause of death in high-income countries and a major cause of morbidity around the world. Elevated cholesterol levels, and in particular, elevated low-density lipoprotein (LDL) levels, are an important risk factor for the development of CVD.[A181087,A181553] Use of statins to target and reduce LDL levels has been shown in a number of landmark studies to significantly reduce the risk of development of CVD and all-cause mortality.[A181090,A181093,A181096,A181427,A181475,A181538] Statins are considered a cost-effective treatment option for CVD due to their evidence of reducing all-cause mortality including fatal and non-fatal CVD as well as the need for surgical revascularization or angioplasty following a heart attack.[A181087, A181406] Evidence has shown that even for low-risk individuals (with <10% risk of a major vascular event occurring within 5 years) statins cause a 20%-22% relative reduction in major cardiovascular events (heart attack, stroke, coronary revascularization, and coronary death) for every 1 mmol/L reduction in LDL without any significant side effects or risks.[A181397, A181403] While all statin medications are considered equally effective from a clinical standpoint, rosuvastatin is considered the most potent; doses of 10 to 40mg rosuvastatin per day were found in clinical studies to result in a 45.8% to 54.6% decreases in LDL cholesterol levels, which is about three-fold more potent than [atorvastatin]'s effects on LDL cholesterol.[A181409,A1793] However, the results of the SATURN trial concluded that despite this difference in potency, there was no difference in their effect on the progression of coronary atherosclerosis. Rosuvastatin is also a unique member of the class of statins due to its high hydrophilicity which increases hepatic uptake at the site of action, low bioavailability, and minimal metabolism via the Cytochrome P450 system. This last point results in less risk of drug-drug interactions compared to [atorvastatin], [lovastatin], and [simvastatin], which are all extensively metabolized by Cytochrome P450 (CYP) 3A4, an enzyme involved in the metabolism of many commonly used drugs. Drugs such as [ciclosporin], [gemfibrozil], and some antiretrovirals are more likely to interact with this statin through antagonism of OATP1B1 organic anion transporter protein 1B1-mediated hepatic uptake of rosuvastatin.[F4649, F4652] | Moderate | 1 | [
[
[
1112,
24,
14
]
],
[
[
1112,
6,
1829
],
[
1829,
45,
14
]
],
[
[
1112,
18,
11048
],
[
11048,
46,
14
]
],
[
[
1112,
18,
2900
],
[
2900,
... | [
[
[
"Auranofin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rosuvastatin"
]
],
[
[
"Auranofin",
"{u} (Compound) binds {v} (Gene)",
"ALB"
],
[
"ALB",
"{u} (Gene) is bound by {v} (Compound)",
... | Auranofin (Compound) binds ALB (Gene) and ALB (Gene) is bound by Rosuvastatin (Compound)
Auranofin (Compound) downregulates VAT1 (Gene) and VAT1 (Gene) is upregulated by Rosuvastatin (Compound)
Auranofin (Compound) downregulates NFKBIA (Gene) and NFKBIA (Gene) is downregulated by Rosuvastatin (Compound)
Auranofin (Compound) causes Constipation (Side Effect) and Constipation (Side Effect) is caused by Rosuvastatin (Compound)
Auranofin may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon alfa-2b and Peginterferon alfa-2b may cause a moderate interaction that could exacerbate diseases when taken with Rosuvastatin
Auranofin may lead to a major life threatening interaction when taken with Hydroxychloroquine and Hydroxychloroquine may cause a moderate interaction that could exacerbate diseases when taken with Rosuvastatin
Auranofin may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Rosuvastatin
Auranofin may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Rosuvastatin
Auranofin may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Rosuvastatin |
DB00059 | DB01048 | 1,560 | 764 | [
"DDInter1404",
"DDInter1"
] | Pegaspargase | Abacavir | Pegaspargase is a conjugate of monomethoxypolyethylene glycol (mPEG) and L-asparaginase (L-asparagine amidohydrolase), an asparagine-specific enzyme that converts L-asparagine into aspartic acid and ammonia. Asparagine is an amino acid that is vital for cell survival. In humans, most normal tissues can produce asparagine through the action of asparagine synthetase. However, leukemia cells have low levels of this enzyme and depend on exogenous sources. Therefore, the use of pegaspargase results in leukemic cell death.[A103,A255912,L44667] Pegaspargase has the same mechanism of action as [L-asparaginase] derived from _Escherichia coli_, a previously developed enzyme used for the treatment of acute lymphoblastic leukemia (ALL). However, using L-asparaginase derived from _Escherich | Abacavir (ABC) is a powerful nucleoside analog reverse transcriptase inhibitor (NRTI) used to treat HIV and AIDS. Chemically, it is a synthetic carbocyclic nucleoside and is the enantiomer with 1S, 4R absolute configuration on the cyclopentene ring. In vivo, abacavir sulfate dissociates to its free base, abacavir. | Moderate | 1 | [
[
[
1560,
24,
764
]
],
[
[
1560,
24,
912
],
[
912,
24,
764
]
],
[
[
1560,
24,
1142
],
[
1142,
63,
764
]
],
[
[
1560,
25,
1510
],
[
1510,
... | [
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abacavir"
]
],
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Interferon beta-1a"
]... | Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Interferon beta-1a and Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Abacavir
Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Orlistat and Orlistat may cause a moderate interaction that could exacerbate diseases when taken with Abacavir
Pegaspargase may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Abacavir
Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Interferon beta-1a and Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Cladribine and Cladribine may cause a moderate interaction that could exacerbate diseases when taken with Abacavir
Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Clofarabine and Clofarabine (Compound) resembles Nelarabine (Compound) and Nelarabine (Compound) resembles Abacavir (Compound)
Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Orlistat and Orlistat (Compound) causes Urticaria (Side Effect) and Urticaria (Side Effect) is caused by Abacavir (Compound)
Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a and Peginterferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Cladribine and Cladribine may cause a moderate interaction that could exacerbate diseases when taken with Abacavir
Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin and Brentuximab vedotin may lead to a major life threatening interaction when taken with Cladribine and Cladribine may cause a moderate interaction that could exacerbate diseases when taken with Abacavir
Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone and Naltrexone (Compound) binds UGT1A1 (Gene) and UGT1A1 (Gene) is bound by Abacavir (Compound) |
DB00490 | DB08820 | 946 | 1,478 | [
"DDInter254",
"DDInter997"
] | Buspirone | Ivacaftor | Buspirone is a novel anxiolytic agent with a unique structure and a pharmacological profile. Belonging to the azaspirodecanedione drug class, buspirone is a serotonin 5-HT<sub>1A</sub> receptor agonist that is not chemically or pharmacologically related to benzodiazepines, barbiturates, and other sedative/anxiolytic drugs. Unlike many drugs used to treat anxiety, buspirone does not exhibit anticonvulsant, sedative, hypnotic, and muscle-relaxant properties. Due to these characteristics, buspirone been termed 'anxioselective'. First synthesized in 1968 then patented in 1975, it is commonly marketed under the brand name Buspar®. Buspirone was first approved in 1986 by the FDA and has been used to treat anxiety disorders, such as generalized anxiety disorder (GAD), and relieve symptoms of anxiety | Ivacaftor (also known as Kalydeco or VX-770) is a drug used for the management of Cystic Fibrosis (CF). It is manufactured and distributed by Vertex Pharmaceuticals. It was approved by the Food and Drug Administration on January 31, 2012, and by Health Canada in late 2012. Ivacaftor is administered as a monotherapy and also administered in combination with other drugs for the management of CF.[L6814,L6979,L6847] Cystic Fibrosis is an autosomal recessive disorder caused by one of several different mutations in the gene for the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein, an ion channel involved in the transport of chloride and sodium ions across cell membranes. CFTR is active in epithelial cells of organs such as of the lungs, pancreas, liver, digestive system, and reproductive tract. Alterations in the CFTR gene result in altered production, misfolding, or function of the protein and consequently abnormal fluid and ion transport across cell membranes.[A20298, A20299] As a result, CF patients produce thick, sticky mucus that clogs the ducts of organs where it is produced making patients more susceptible to complications such as infections, lung damage, pancreatic insufficiency, and malnutrition. Prior to the development of ivacaftor, management of CF primarily involved therapies for the control of infections, nutritional support, clearance of mucus, and management of symptoms rather than improvements in the underlying disease process or lung function (FEV1). Notably, ivacaftor was the first medication approved for the management of the underlying causes of CF (abnormalities in CFTR protein function) rather than control of symptoms. | Moderate | 1 | [
[
[
946,
24,
1478
]
],
[
[
946,
6,
8374
],
[
8374,
45,
1478
]
],
[
[
946,
21,
28762
],
[
28762,
60,
1478
]
],
[
[
946,
24,
1040
],
[
1040,... | [
[
[
"Buspirone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivacaftor"
]
],
[
[
"Buspirone",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Buspirone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ivacaftor (Compound)
Buspirone (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Ivacaftor (Compound)
Buspirone may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib and Dabrafenib may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor
Buspirone may cause a moderate interaction that could exacerbate diseases when taken with Aminoglutethimide and Aminoglutethimide may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor
Buspirone may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor
Buspirone may lead to a major life threatening interaction when taken with Granisetron and Granisetron may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor
Buspirone may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may lead to a major life threatening interaction when taken with Ivacaftor
Buspirone may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may lead to a major life threatening interaction when taken with Ivacaftor
Buspirone may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Ribociclib may lead to a major life threatening interaction when taken with Ivacaftor |
DB00722 | DB01088 | 743 | 714 | [
"DDInter1079",
"DDInter908"
] | Lisinopril | Iloprost | Lisinopril is an angiotensin converting enzyme inhibitor (ACEI) used to treat hypertension, heart failure, and myocardial infarction.[L8384,L8387,L8390] Lisinopril and [captopril] are the only ACEIs that are not prodrugs. It functions by inhibition of angiotensin converting enzyme as well as the renin angiotensin aldosterone system.[A184781,A184808,A184817] ACEIs are commonly used as a first line therapy in the treatment of hypertension, along with thiazide diuretics or beta blockers. Lisinopril was granted FDA approval on 29 December 1987. | Iloprost is a mimetic of prostacyclin (PGI2; epoprostenol). Iloprost consists of a mixture of the 4R and 4S diastereoisomers at a ratio of approximately 53:47. It is a potent vasodilator with reported anti-thrombotic properties. | Moderate | 1 | [
[
[
743,
24,
714
]
],
[
[
743,
40,
1638
],
[
1638,
24,
714
]
],
[
[
743,
24,
1479
],
[
1479,
24,
714
]
],
[
[
743,
63,
1648
],
[
1648,
... | [
[
[
"Lisinopril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iloprost"
]
],
[
[
"Lisinopril",
"{u} (Compound) resembles {v} (Compound)",
"Trandolapril"
],
[
"Trandolapril",
"{u} may cause a moder... | Lisinopril (Compound) resembles Trandolapril (Compound) and Trandolapril may cause a moderate interaction that could exacerbate diseases when taken with Iloprost
Lisinopril may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Iloprost
Lisinopril may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Iloprost
Lisinopril (Compound) resembles Enalapril (Compound) and Enalapril may cause a moderate interaction that could exacerbate diseases when taken with Iloprost
Lisinopril may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin and Empagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Iloprost
Lisinopril may cause a moderate interaction that could exacerbate diseases when taken with Dalteparin and Dalteparin may lead to a major life threatening interaction when taken with Iloprost
Lisinopril (Compound) resembles Trandolapril (Compound) and Trandolapril may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Iloprost
Lisinopril may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a minor interaction that can limit clinical effects when taken with Capsicum and Capsicum may cause a minor interaction that can limit clinical effects when taken with Iloprost
Lisinopril may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Trandolapril and Trandolapril may cause a moderate interaction that could exacerbate diseases when taken with Iloprost |
DB00315 | DB01168 | 767 | 1,053 | [
"DDInter1969",
"DDInter1526"
] | Zolmitriptan | Procarbazine | Zolmitriptan is a member of the triptan class of 5-hydroxytryptamine(5-HT)<sub>1B/1D/(1F)</sub> receptor agonists used to treat acute migraine.[A462, L12978] [Sumatriptan] was the first triptan to be developed, but had poor oral bioavailability and lipophilicity. This led to the development of second-generation triptans, including [almotriptan], [eletriptan], [frovatriptan], [naratriptan], [rizatriptan], and zolmitriptan. Triptans can be administered alone or in combination with an NSAID like [naproxen], and represent the current "gold standard" for acute migraine treatment. Zolmitriptan was first approved by the FDA for sale by Zeneca Pharmaceuticals under the trade name Zomig® on November | An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease. | Major | 2 | [
[
[
767,
25,
1053
]
],
[
[
767,
21,
28762
],
[
28762,
60,
1053
]
],
[
[
767,
24,
1362
],
[
1362,
63,
1053
]
],
[
[
767,
25,
1039
],
[
1039... | [
[
[
"Zolmitriptan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Procarbazine"
]
],
[
[
"Zolmitriptan",
"{u} (Compound) causes {v} (Side Effect)",
"Headache"
],
[
"Headache",
"{u} (Side Effect) is caused by {v} (... | Zolmitriptan (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Procarbazine (Compound)
Zolmitriptan may cause a moderate interaction that could exacerbate diseases when taken with Olaparib and Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Procarbazine
Zolmitriptan may lead to a major life threatening interaction when taken with Dexfenfluramine and Dexfenfluramine may lead to a major life threatening interaction when taken with Procarbazine
Zolmitriptan may lead to a major life threatening interaction when taken with Palonosetron and Palonosetron may lead to a major life threatening interaction when taken with Procarbazine
Zolmitriptan (Compound) resembles Almotriptan (Compound) and Almotriptan may lead to a major life threatening interaction when taken with Procarbazine
Zolmitriptan may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may lead to a major life threatening interaction when taken with Procarbazine
Zolmitriptan may cause a moderate interaction that could exacerbate diseases when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Procarbazine
Zolmitriptan (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Atenolol (Compound) and Atenolol (Compound) resembles Procarbazine (Compound)
Zolmitriptan (Compound) causes Neuropathy (Side Effect) and Neuropathy (Side Effect) is caused by Ofloxacin (Compound) and Ofloxacin may cause a minor interaction that can limit clinical effects when taken with Procarbazine |
DB00563 | DB00951 | 663 | 1,072 | [
"DDInter1174",
"DDInter986"
] | Methotrexate | Isoniazid | Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division in neoplastic diseases such as breast cancer and non-Hodgkin's lymphoma.[A180322,L7144,L7147,L7150,L7180] Due to the toxic effects of methotrexate, it is indicated for treatment of some forms of arthritis and severe psoriasis only if first line treatment has failed or patients are intolerant of those treatments. Methotrexate was granted FDA approval on 7 December 1953. | Antibacterial agent used primarily as a tuberculostatic. It remains the treatment of choice for tuberculosis. | Moderate | 1 | [
[
[
663,
24,
1072
]
],
[
[
663,
21,
28722
],
[
28722,
60,
1072
]
],
[
[
663,
24,
1486
],
[
1486,
62,
1072
]
],
[
[
663,
24,
870
],
[
870,
... | [
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoniazid"
]
],
[
[
"Methotrexate",
"{u} (Compound) causes {v} (Side Effect)",
"Nausea"
],
[
"Nausea",
"{u} (Side Effect) is caused ... | Methotrexate (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Isoniazid (Compound)
Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Methylprednisolone and Methylprednisolone may cause a minor interaction that can limit clinical effects when taken with Isoniazid
Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone may cause a minor interaction that can limit clinical effects when taken with Isoniazid
Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Betamethasone and Betamethasone may cause a minor interaction that can limit clinical effects when taken with Isoniazid
Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Pioglitazone and Pioglitazone may cause a moderate interaction that could exacerbate diseases when taken with Isoniazid
Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Theophylline and Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Isoniazid
Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Etoposide and Etoposide may cause a moderate interaction that could exacerbate diseases when taken with Isoniazid
Methotrexate may lead to a major life threatening interaction when taken with Etanercept and Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Isoniazid
Methotrexate may lead to a major life threatening interaction when taken with Golimumab and Golimumab may cause a moderate interaction that could exacerbate diseases when taken with Isoniazid |
DB00701 | DB09272 | 1,091 | 412 | [
"DDInter90",
"DDInter632"
] | Amprenavir | Eluxadoline | Amprenavir is a protease inhibitor used to treat HIV infection. | Eluxadoline is a mixed mu-opioid receptor agonist, kappa-opioid receptor agonist, and a-delta opioid receptor antagonist indicated for use in diarrhea-predominant irritable bowel syndrome (IBS-D). The mu-, kappa-, and delta-opioid receptors mediate endogenous and exogenous opioid response in the central nervous system and peripherally in the gastrointestinal system. Agonism of peripheral mu-opioid receptors results in reduced colonic motility, while antagonism of central delta-opioid receptors results in improved analgesia, making eluxadoline usable for the symptoms of both pain and diarrhea characteristic of IBS-D. Marketed under the tradename Viberzi (FDA), eluxadoline is an antimotility agent that decreases bowel contractions, inhibits colonic transit, and reduces fluid/ion secretion resulting in improved symptoms of abdominal pain and reductions in the Bristol Stool Scale. | Moderate | 1 | [
[
[
1091,
24,
412
]
],
[
[
1091,
25,
543
],
[
543,
24,
412
]
],
[
[
1091,
64,
467
],
[
467,
24,
412
]
],
[
[
1091,
23,
1374
],
[
1374,
... | [
[
[
"Amprenavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eluxadoline"
]
],
[
[
"Amprenavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Loperamide"
],
[
"Loperamid... | Amprenavir may lead to a major life threatening interaction when taken with Loperamide and Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Eluxadoline
Amprenavir may lead to a major life threatening interaction when taken with Simvastatin and Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Eluxadoline
Amprenavir may cause a minor interaction that can limit clinical effects when taken with Abiraterone and Abiraterone may cause a moderate interaction that could exacerbate diseases when taken with Eluxadoline
Amprenavir may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Eluxadoline
Amprenavir (Compound) resembles Fosamprenavir (Compound) and Fos
Amprenavir may cause a minor interaction that can limit clinical effects when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Eluxadoline
Amprenavir may cause a minor interaction that can limit clinical effects when taken with Darolutamide and Darolutamide may lead to a major life threatening interaction when taken with Eluxadoline
Amprenavir may lead to a major life threatening interaction when taken with Lapatinib and Lapatinib may lead to a major life threatening interaction when taken with Eluxadoline
Amprenavir may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may lead to a major life threatening interaction when taken with Eluxadoline |
DB01098 | DB09115 | 14 | 505 | [
"DDInter1622",
"DDInter559"
] | Rosuvastatin | Diiodohydroxyquinoline | Rosuvastatin, also known as the brand name product Crestor, is a lipid-lowering drug that belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage elevated lipid levels by inhibiting the endogenous production of cholesterol in the liver. More specifically, statin medications competitively inhibit the enzyme hydroxymethylglutaryl-coenzyme A (HMG-CoA) Reductase, which catalyzes the conversion of HMG-CoA to mevalonic acid and is the third step in a sequence of metabolic reactions involved in the production of several compounds involved in lipid metabolism and transport including cholesterol, low-density lipoprotein (LDL) (sometimes referred to as "bad cholesterol"), and very low-density lipoprotein (VLDL). Prescribing of statin medications is considered standard practice following any cardiovascular events and for people with a moderate to high risk of development of CVD, such as those with Type 2 | Diiodohydroxyquinoline, also known as uidoquinol and iodoquinol, is a quinoline derivative that can be used in the treatment of amoebiasis. The exact mechanism of action is unknown. Iodoquinol is not currently available in any FDA-approved products. | Moderate | 1 | [
[
[
14,
24,
505
]
],
[
[
14,
24,
1593
],
[
1593,
24,
505
]
],
[
[
14,
63,
467
],
[
467,
24,
505
]
],
[
[
14,
25,
1510
],
[
1510,
24,... | [
[
[
"Rosuvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diiodohydroxyquinoline"
]
],
[
[
"Rosuvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"... | Rosuvastatin may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Diiodohydroxyquinoline
Rosuvastatin may cause a moderate interaction that could exacerbate diseases when taken with Simvastatin and Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Diiodohydroxyquinoline
Rosuvastatin may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may cause a moderate interaction that could exacerbate diseases when taken with Diiodohydroxyquinoline
Rosuvastatin may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may cause a moderate interaction that could exacerbate diseases when taken with Diiodohydroxyquinoline
Rosuvastatin may cause a moderate interaction that could exacerbate diseases when taken with Benznidazole and Benznidazole may cause a moderate interaction that could exacerbate diseases when taken with Diiodohydroxyquinoline
Rosuvastatin may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Simvastatin and Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Diiodohydroxyquinoline
Rosuvastatin may cause a moderate interaction that could exacerbate diseases when taken with Simvastatin and Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Diiodohydroxyquinoline
Rosuvastatin may cause a moderate interaction that could exacerbate diseases when taken with Golimumab and Golimumab may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Diiodohydroxyquinoline
Rosuvastatin may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Diiodohydroxyquinoline |
DB00054 | DB01125 | 1,432 | 279 | [
"DDInter6",
"DDInter98"
] | Abciximab | Anisindione | Abciximab is a Fab fragment of the chimeric human-murine monoclonal antibody 7E3. Abciximab binds to the glycoprotein (GP) IIb/IIIa receptor of human platelets and inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor, and other adhesive molecules. It also binds to vitronectin (αvβ3) receptor found on platelets and vessel wall endothelial and smooth muscle cells. | Anisindione is a synthetic anticoagulant and an indanedione derivative. Its anticoagulant action is mediated through the inhibition of the vitamin K-mediated gamma-carboxylation of precursor proteins that are critical in forming the formation of active procoagulation factors II, VII, IX, and X, as well as the anticoagulant proteins C and S, in the liver. | Major | 2 | [
[
[
1432,
25,
279
]
],
[
[
1432,
63,
1595
],
[
1595,
24,
279
]
],
[
[
1432,
24,
557
],
[
557,
63,
279
]
],
[
[
1432,
24,
222
],
[
222,
... | [
[
[
"Abciximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Anisindione"
]
],
[
[
"Abciximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Collagenase clostridium histolyticum"
]... | Abciximab may cause a moderate interaction that could exacerbate diseases when taken with Collagenase clostridium histolyticum and Collagenase clostridium histolyticum may cause a moderate interaction that could exacerbate diseases when taken with Anisindione
Abciximab may cause a moderate interaction that could exacerbate diseases when taken with Deoxycholic acid and Deoxycholic acid may cause a moderate interaction that could exacerbate diseases when taken with Anisindione
Abciximab may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Anisindione
Abciximab may lead to a major life threatening interaction when taken with Dipyridamole and Dipyridamole may cause a moderate interaction that could exacerbate diseases when taken with Anisindione
Abciximab may lead to a major life threatening interaction when taken with Defibrotide and Defibrotide may lead to a major life threatening interaction when taken with Anisindione
Abciximab may lead to a major life threatening interaction when taken with Lepirudin and Lepirudin may lead to a major life threatening interaction when taken with Anisindione
Abciximab may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicylic acid and Acetylsalicylic acid may lead to a major life threatening interaction when taken with Anisindione
Abciximab may cause a moderate interaction that could exacerbate diseases when taken with Bivalirudin and Bivalirudin may lead to a major life threatening interaction when taken with Anisindione
Abciximab may lead to a major life threatening interaction when taken with Drotrecogin alfa and Drotrecogin alfa may lead to a major life threatening interaction when taken with Anisindione |
DB00063 | DB14357 | 366 | 944 | [
"DDInter659",
"DDInter347"
] | Eptifibatide | Chamomile | Synthetic cyclic hexapeptide that binds to platelet receptor glycoprotein and inhibits platelet aggregation. Derived from venom of the Southeastern pygmy rattlesnake (Sistrurus miliarus barbouri), eptifibatide is a cyclic heptapeptide that belongs to the class of arginin-glycin-aspartat-mimetics. | Chamomile is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug. | Minor | 0 | [
[
[
366,
23,
944
]
],
[
[
366,
25,
256
],
[
256,
23,
944
]
],
[
[
366,
64,
582
],
[
582,
23,
944
]
],
[
[
366,
24,
1061
],
[
1061,
2... | [
[
[
"Eptifibatide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Chamomile"
]
],
[
[
"Eptifibatide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Prasugrel"
],
[
"Prasugrel"... | Eptifibatide may lead to a major life threatening interaction when taken with Prasugrel and Prasugrel may cause a minor interaction that can limit clinical effects when taken with Chamomile
Eptifibatide may lead to a major life threatening interaction when taken with Reteplase and Reteplase may cause a minor interaction that can limit clinical effects when taken with Chamomile
Eptifibatide may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil may cause a minor interaction that can limit clinical effects when taken with Chamomile
Eptifibatide may cause a moderate interaction that could exacerbate diseases when taken with Bivalirudin and Bivalirudin may cause a minor interaction that can limit clinical effects when taken with Chamomile
Eptifibatide may lead to a major life threatening interaction when taken with Prasugrel and Prasugrel may lead to a major life threatening interaction when taken with Reteplase and Reteplase may cause a minor interaction that can limit clinical effects when taken with Chamomile
Eptifibatide may lead to a major life threatening interaction when taken with Reteplase and Reteplase may lead to a major life threatening interaction when taken with Prasugrel and Prasugrel may cause a minor interaction that can limit clinical effects when taken with Chamomile
Eptifibatide may lead to a major life threatening interaction when taken with Warfarin and Warfarin may lead to a major life threatening interaction when taken with Prasugrel and Prasugrel may cause a minor interaction that can limit clinical effects when taken with Chamomile
Eptifibatide may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Prasugrel and Prasugrel may cause a minor interaction that can limit clinical effects when taken with Chamomile
Eptifibatide may cause a moderate interaction that could exacerbate diseases when taken with Bivalirudin and Bivalirudin may lead to a major life threatening interaction when taken with Prasugrel and Prasugrel may cause a minor interaction that can limit clinical effects when taken with Chamomile |
DB08903 | DB11110 | 996 | 603 | [
"DDInter170",
"DDInter1115"
] | Bedaquiline | Magnesium citrate | Bedaquiline is a bactericidal antimycobacterial drug belonging to the class of diarylquinoline. The quinolinic central heterocyclic nucleus with alcohol and amine side chains is responsible for bedaquiline-mediated antimycobacterial activity. Although it is closely related to fluoroquinolones, bedaquiline does not affect DNA gyrase; instead, bedaquiline inhibits the c subunit of ATP synthase responsible for synthesizing ATP. Consequently, bedaquiline can be used to treat mycobacterial infection, particularly tuberculosis (TB). Although the current standard of TB treatment of anti-TB drugs for 2 months, including 2 key drugs [isoniazid] and [rifampin], is highly effective, the emergence of multidrug-resistant TB (MDR-TB) to [isoniazid] and [rifampin] has substantially worsened patients outcome. Bedaquiline was approved by the FDA on December 28, | Magnesium citrate is a low volume and osmotic cathartic agent. The cathartic action works primarily through the high osmolarity of the solution which draws large amounts of fluid into space where is used. Magnesium citrate is considered by the FDA as an approved inactive ingredient for approved drug products under the specifications of oral administration of a maximum concentration of 237 mg. It is also considered as an active ingredient in over-the-counter products. | Moderate | 1 | [
[
[
996,
24,
603
]
],
[
[
996,
64,
57
],
[
57,
24,
603
]
],
[
[
996,
25,
484
],
[
484,
63,
603
]
],
[
[
996,
25,
1228
],
[
1228,
24,... | [
[
[
"Bedaquiline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium citrate"
]
],
[
[
"Bedaquiline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Arsenic trioxide"
],
[
... | Bedaquiline may lead to a major life threatening interaction when taken with Arsenic trioxide and Arsenic trioxide may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate
Bedaquiline may lead to a major life threatening interaction when taken with Entrectinib and Entrectinib may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate
Bedaquiline may lead to a major life threatening interaction when taken with Lenvatinib and Lenvatinib may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate
Bedaquiline may cause a moderate interaction that could exacerbate diseases when taken with Oxytetracycline and Oxytetracycline may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate
Bedaquiline (Compound) resembles Toremifene (Compound) and Bedaquiline may lead to a major life threatening interaction when taken with Toremifene and Toremifene may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate
Bedaquiline may lead to a major life threatening interaction when taken with Arsenic trioxide and Arsenic trioxide may lead to a major life threatening interaction when taken with Foscarnet and Foscarnet may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate
Bedaquiline may lead to a major life threatening interaction when taken with Entrectinib and Entrectinib may lead to a major life threatening interaction when taken with Arsenic trioxide and Arsenic trioxide may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate
Bedaquiline may lead to a major life threatening interaction when taken with Cilostazol and Cilostazol may lead to a major life threatening interaction when taken with Arsenic trioxide and Arsenic trioxide may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate
Bedaquiline may cause a moderate interaction that could exacerbate diseases when taken with Oxytetracycline and Oxytetracycline may cause a minor interaction that can limit clinical effects when taken with Amiloride and Amiloride may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate |
DB05812 | DB08820 | 1,374 | 1,478 | [
"DDInter8",
"DDInter997"
] | Abiraterone | Ivacaftor | Abiraterone is a potent, irreversible, and selective inhibitor of 17 αhydroxylase/C17,20-lyase (CYP17), an enzyme expressed in testicular, adrenal, and prostatic tumour tissues, to regulate androgen biosynthesis.[A3811, A260880, L40968] Abiraterone was first approved by the FDA and EMA on April, July, and September 2011, respectively. It is used to treat metastatic castration-resistant prostate cancer and hormone-sensitive high-risk metastatic prostate cancer.[L40968, L40193, L47740, L47745] As abiraterone has poor oral bioavailability and is susceptible to hydrolysis by esterases, abiraterone acetate was developed as an orally bioavailable prodrug with enhanced stability and absorption.[A3811, A260835] | Ivacaftor (also known as Kalydeco or VX-770) is a drug used for the management of Cystic Fibrosis (CF). It is manufactured and distributed by Vertex Pharmaceuticals. It was approved by the Food and Drug Administration on January 31, 2012, and by Health Canada in late 2012. Ivacaftor is administered as a monotherapy and also administered in combination with other drugs for the management of CF.[L6814,L6979,L6847] Cystic Fibrosis is an autosomal recessive disorder caused by one of several different mutations in the gene for the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein, an ion channel involved in the transport of chloride and sodium ions across cell membranes. CFTR is active in epithelial cells of organs such as of the lungs, pancreas, liver, digestive system, and reproductive tract. Alterations in the CFTR gene result in altered production, misfolding, or function of the protein and consequently abnormal fluid and ion transport across cell membranes.[A20298, A20299] As a result, CF patients produce thick, sticky mucus that clogs the ducts of organs where it is produced making patients more susceptible to complications such as infections, lung damage, pancreatic insufficiency, and malnutrition. Prior to the development of ivacaftor, management of CF primarily involved therapies for the control of infections, nutritional support, clearance of mucus, and management of symptoms rather than improvements in the underlying disease process or lung function (FEV1). Notably, ivacaftor was the first medication approved for the management of the underlying causes of CF (abnormalities in CFTR protein function) rather than control of symptoms. | Moderate | 1 | [
[
[
1374,
24,
1478
]
],
[
[
1374,
6,
8374
],
[
8374,
45,
1478
]
],
[
[
1374,
21,
29221
],
[
29221,
60,
1478
]
],
[
[
1374,
23,
907
],
[
90... | [
[
[
"Abiraterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivacaftor"
]
],
[
[
"Abiraterone",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)"... | Abiraterone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ivacaftor (Compound)
Abiraterone (Compound) causes Infestation (Side Effect) and Infestation (Side Effect) is caused by Ivacaftor (Compound)
Abiraterone may cause a minor interaction that can limit clinical effects when taken with Doravirine and Doravirine may cause a minor interaction that can limit clinical effects when taken with Ivacaftor
Abiraterone may lead to a major life threatening interaction when taken with Escitalopram and Escitalopram may cause a minor interaction that can limit clinical effects when taken with Ivacaftor
Abiraterone may cause a minor interaction that can limit clinical effects when taken with Donepezil and Donepezil may cause a minor interaction that can limit clinical effects when taken with Ivacaftor
Abiraterone may lead to a major life threatening interaction when taken with Loperamide and Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor
Abiraterone may cause a moderate interaction that could exacerbate diseases when taken with Avapritinib and Avapritinib may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor
Abiraterone may lead to a major life threatening interaction when taken with Osimertinib and Osimertinib may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor
Abiraterone may cause a moderate interaction that could exacerbate diseases when taken with Flibanserin and Flibanserin may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor |
DB01030 | DB08899 | 869 | 129 | [
"DDInter1835",
"DDInter649"
] | Topotecan | Enzalutamide | An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA topoisomerases, type I. | Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line treatment of prostate cancer and remission can be achieved, arising resistance is inevitable, becoming castration-resistant prostate cancer. Until recently, docetaxel is the only treatment available for metastatic CRPC; however, AR inhibitors have been developed for more targeted therapy, although first-generation AR inhibitors like bicalutamide did not substantially increase the survival rate. Second-generation such as enzalutamide is more efficacious due to a higher affinity to AR and no partial agonist activity compared to bicalutamide.[A252667,A252642] Due to a favorable pharmacological profile, a phase 1 study of enzalutamide was initiated in July 2007. Compared to the average time of 10 to 15 years for a drug to go from pre-clinical to clinical studies, enzalutamide was developed relatively rapidly. | Moderate | 1 | [
[
[
869,
24,
129
]
],
[
[
869,
6,
8374
],
[
8374,
45,
129
]
],
[
[
869,
21,
28703
],
[
28703,
60,
129
]
],
[
[
869,
24,
110
],
[
110,
... | [
[
[
"Topotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
]
],
[
[
"Topotecan",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",... | Topotecan (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Enzalutamide (Compound)
Topotecan (Compound) causes Pruritus (Side Effect) and Pruritus (Side Effect) is caused by Enzalutamide (Compound)
Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Polatuzumab vedotin and Polatuzumab vedotin may cause a minor interaction that can limit clinical effects when taken with Enzalutamide
Topotecan may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide
Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Sorafenib and Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide
Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Elagolix and Elagolix may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide
Topotecan may cause a minor interaction that can limit clinical effects when taken with Ofloxacin and Ofloxacin may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide
Topotecan may cause a minor interaction that can limit clinical effects when taken with Lomefloxacin and Lomefloxacin may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide
Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide and Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide |
DB06595 | DB08860 | 1,491 | 788 | [
"DDInter1214",
"DDInter1479"
] | Midostaurin | Pitavastatin | Midostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3. It was initially characterized as a potential broad-spectrum antineoplastic agent, with activity toward diverse solid and hematopoietic tumors. It was approved on April 28, 2017 and has shown to increase the overall survival rate in patients with AML as an adjunct therapy along with chemotherapeutic agents. | Pitavastatin, also known as the brand name product Livalo, is a lipid-lowering drug belonging to the statin class of medications. By inhibiting the endogenous production of cholesterol within the liver, statins lower abnormal cholesterol and lipid levels and ultimately reduce the risk of cardiovascular disease. More specifically, statin medications competitively inhibit the enzyme hydroxymethylglutaryl-coenzyme A (HMG-CoA) Reductase, which catalyzes the conversion of HMG-CoA to mevalonic acid. This is the third step in a sequence of metabolic reactions involved in the production of several compounds involved in lipid metabolism and transport including cholesterol, low-density lipoprotein (LDL) (sometimes referred to as "bad cholesterol"), and very low-density lipoprotein (VLDL). Prescribing of statin medications is considered standard practice following any cardiovascular events and for people with a moderate to high risk of development of CVD, such as those with Type 2 Diabetes. The clear evidence of the benefit of statin use coupled with very minimal side effects or long term effects has resulted in this class becoming one of the most widely prescribed medications in North America.[A181087, A181406] Pitavastatin and other drugs from the statin class of medications including [atorvastatin], [pravastatin], [rosuvastatin], [fluvastatin], and [lovastatin] are considered first-line options for the treatment of dyslipidemia.[A181087, A181406] Increasing use of the statin class of drugs is largely due to the fact that cardiovascular disease (CVD), which includes heart attack, atherosclerosis, angina, peripheral artery disease, and stroke, has become a leading cause of death in high-income countries and a major cause of morbidity around the world. Elevated cholesterol levels, and in particular, elevated low-density lipoprotein (LDL) levels, are an important risk factor for the development of CVD.[A181087,A181553] Use of statins to target and reduce LDL levels has been shown in a number of landmark studies to significantly reduce the risk of development of CVD and all-cause mortality.[A181090,A181093,A181096,A181427,A181475,A181538] Statins are considered a cost-effective treatment option for CVD due to their evidence of reducing all-cause mortality including fatal and non-fatal CVD as well as the need for surgical revascularization or angioplasty following a heart attack.[A181087, A181406] Evidence has shown that even for low-risk individuals (with <10% risk of a major vascular event occurring within 5 years) statins cause a 20%-22% relative reduction in major cardiovascular events (heart attack, stroke, coronary revascularization, and coronary death) for every 1 mmol/L reduction in LDL without any significant side effects or risks.[A181397, A181403] While all statin medications are considered equally effective from a clinical standpoint, [rosuvastatin] is considered the most potent; doses of 10 to 40mg [rosuvastatin] per day were found in clinical studies to result in a 45.8% to 54.6% decrease in LDL cholesterol levels.[A181409,A181535,A181538,A1793] Study data has confirmed that pitavastatin's potency in lowering LDL-C is comparable to that of other statins but also has increased efficacy in increasing HDL-C (also known as "good cholesterol").[A182000,A182003,A182006] Despite these differences in potency, several trials have demonstrated only minimal differences in terms of clinical outcomes between statins.[A181538, A181427] | Moderate | 1 | [
[
[
1491,
24,
788
]
],
[
[
1491,
63,
671
],
[
671,
1,
788
]
],
[
[
1491,
63,
700
],
[
700,
40,
788
]
],
[
[
1491,
24,
850
],
[
850,
... | [
[
[
"Midostaurin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitavastatin"
]
],
[
[
"Midostaurin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluvastatin"
],
... | Midostaurin may cause a moderate interaction that could exacerbate diseases when taken with Fluvastatin and Fluvastatin (Compound) resembles Pitavastatin (Compound)
Midostaurin may cause a moderate interaction that could exacerbate diseases when taken with Atorvastatin and Atorvastatin (Compound) resembles Pitavastatin (Compound)
Midostaurin may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin and Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Pitavastatin
Midostaurin may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Pitavastatin
Midostaurin may lead to a major life threatening interaction when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Pitavastatin
Midostaurin may lead to a major life threatening interaction when taken with Infliximab and Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Pitavastatin
Midostaurin may lead to a major life threatening interaction when taken with Golimumab and Golimumab may cause a moderate interaction that could exacerbate diseases when taken with Pitavastatin
Midostaurin may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Pitavastatin
Midostaurin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a moderate interaction that could exacerbate diseases when taken with Pitavastatin |
DB00022 | DB01004 | 268 | 563 | [
"DDInter1408",
"DDInter806"
] | Peginterferon alfa-2b | Ganciclovir | Peginterferon alfa-2b is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, and affecting 72% of all chronic HCV patients. Treatment options for chronic Hepatitis C have advanced significantly since 2011, with the development of Direct Acting Antivirals (DAAs) resulting in less use of Peginterferon alfa-2b. Peginterferon alfa-2b is derived from the alfa-2b moeity of recombinant human interferon and acts by binding to human type 1 interferon receptors. Activation and dimerization of this receptor induces the body's innate antiviral response by activating the janus kinase | An acyclovir analog that is a potent inhibitor of the Herpesvirus family including cytomegalovirus. Ganciclovir is used to treat complications from AIDS-associated cytomegalovirus infections. | Moderate | 1 | [
[
[
268,
24,
563
]
],
[
[
268,
24,
248
],
[
248,
40,
563
]
],
[
[
268,
24,
36
],
[
36,
63,
563
]
],
[
[
268,
25,
1101
],
[
1101,
24,... | [
[
[
"Peginterferon alfa-2b",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ganciclovir"
]
],
[
[
"Peginterferon alfa-2b",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valg... | Peginterferon alfa-2b may cause a moderate interaction that could exacerbate diseases when taken with Valganciclovir and Valganciclovir (Compound) resembles Ganciclovir (Compound)
Peginterferon alfa-2b may cause a moderate interaction that could exacerbate diseases when taken with Eribulin and Eribulin may cause a moderate interaction that could exacerbate diseases when taken with Ganciclovir
Peginterferon alfa-2b may lead to a major life threatening interaction when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Ganciclovir
Peginterferon alfa-2b may cause a moderate interaction that could exacerbate diseases when taken with Interferon alfacon-1 and Interferon alfacon-1 may cause a moderate interaction that could exacerbate diseases when taken with Ganciclovir
Peginterferon alfa-2b may lead to a major life threatening interaction when taken with Baricitinib and Baricitinib may cause a moderate interaction that could exacerbate diseases when taken with Ganciclovir
Peginterferon alfa-2b may cause a moderate interaction that could exacerbate diseases when taken with Interferon alfa-n1 and Interferon alfa-n1 may cause a moderate interaction that could exacerbate diseases when taken with Ganciclovir
Peginterferon alfa-2b may cause a minor interaction that can limit clinical effects when taken with Cyclophosphamide and Cyclophosphamide may cause a moderate interaction that could exacerbate diseases when taken with Ganciclovir
Peginterferon alfa-2b may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol and Certolizumab pegol may lead to a major life threatening interaction when taken with Ganciclovir
Peginterferon alfa-2b may lead to a major life threatening interaction when taken with Deferiprone and Deferiprone may lead to a major life threatening interaction when taken with Ganciclovir |
DB00009 | DB00861 | 1,271 | 914 | [
"DDInter56",
"DDInter551"
] | Alteplase | Diflunisal | Alteplase is a recombinant tissue plasminogen activator (rt-PA) used as a thrombolytic agent. It cleaves plasminogen to form plasmin, an enzyme involved in the degradation of fibrin clots. In the absence of fibrin, the alteplase-mediated conversion of plasminogen is limited, thanks to the high affinity between alteplase and fibrin.[A252330,L43125] Alteplase is a purified glycoprotein of 527 amino acids expressed in Chinese hamster ovary (CHO) cells.[A252345,L43125] It was first approved by the FDA in 1987 for the management of thromboembolic disease, including acute myocardial infarction (AMI). The use of alteplase to manage AMI has decreased thanks to the availability of safer treatments such as angioplasty and stenting. However, its use for the treatment of acute ischem | Diflunisal, a salicylate derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with pharmacologic actions similar to other prototypical NSAIAs. Diflunisal possesses anti-inflammatory, analgesic and antipyretic activity. Though its mechanism of action has not been clearly established, most of its actions appear to be associated with inhibition of prostaglandin synthesis via the arachidonic acid pathway. Diflunisal is used to relieve pain accompanied with inflammation and in the symptomatic treatment of rheumatoid arthritis and osteoarthritis. | Moderate | 1 | [
[
[
1271,
24,
914
]
],
[
[
1271,
25,
1564
],
[
1564,
63,
914
]
],
[
[
1271,
24,
1061
],
[
1061,
24,
914
]
],
[
[
1271,
25,
366
],
[
366,
... | [
[
[
"Alteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diflunisal"
]
],
[
[
"Alteplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Defibrotide"
],
[
"Defibrotide... | Alteplase may lead to a major life threatening interaction when taken with Defibrotide and Defibrotide may cause a moderate interaction that could exacerbate diseases when taken with Diflunisal
Alteplase may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Diflunisal
Alteplase may lead to a major life threatening interaction when taken with Eptifibatide and Eptifibatide may cause a moderate interaction that could exacerbate diseases when taken with Diflunisal
Alteplase may cause a moderate interaction that could exacerbate diseases when taken with Dexfenfluramine and Dexfenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Diflunisal
Alteplase may lead to a major life threatening interaction when taken with Bivalirudin and Bivalirudin may cause a moderate interaction that could exacerbate diseases when taken with Diflunisal
Alteplase may lead to a major life threatening interaction when taken with Panobinostat and Panobinostat may lead to a major life threatening interaction when taken with Diflunisal
Alteplase may lead to a major life threatening interaction when taken with Fondaparinux and Fondaparinux may lead to a major life threatening interaction when taken with Diflunisal
Alteplase may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Flurbiprofen (Compound) resembles Diflunisal (Compound) and Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Diflunisal
Alteplase may lead to a major life threatening interaction when taken with Defibrotide and Defibrotide may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Diflunisal |
DB00008 | DB09115 | 491 | 505 | [
"DDInter1407",
"DDInter559"
] | Peginterferon alfa-2a | Diiodohydroxyquinoline | Peginterferon alfa-2a is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, and affecting 72% of all chronic HCV patients. Treatment options for chronic Hepatitis C have advanced significantly since 2011, with the development of Direct Acting Antivirals (DAAs) resulting in less use of Peginterferon alfa-2a. Peginterferon alfa-2a is derived from the alfa-2a moeity of recombinant human interferon and acts by binding to human type 1 interferon receptors. Activation and dimerization of this receptor induces the body's innate antiviral response by activating the janus kinase | Diiodohydroxyquinoline, also known as uidoquinol and iodoquinol, is a quinoline derivative that can be used in the treatment of amoebiasis. The exact mechanism of action is unknown. Iodoquinol is not currently available in any FDA-approved products. | Moderate | 1 | [
[
[
491,
24,
505
]
],
[
[
491,
24,
1593
],
[
1593,
24,
505
]
],
[
[
491,
25,
1510
],
[
1510,
24,
505
]
],
[
[
491,
24,
1434
],
[
1434,
... | [
[
[
"Peginterferon alfa-2a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diiodohydroxyquinoline"
]
],
[
[
"Peginterferon alfa-2a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
... | Peginterferon alfa-2a may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Diiodohydroxyquinoline
Peginterferon alfa-2a may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may cause a moderate interaction that could exacerbate diseases when taken with Diiodohydroxyquinoline
Peginterferon alfa-2a may cause a moderate interaction that could exacerbate diseases when taken with Benznidazole and Benznidazole may cause a moderate interaction that could exacerbate diseases when taken with Diiodohydroxyquinoline
Peginterferon alfa-2a may cause a moderate interaction that could exacerbate diseases when taken with Etanercept and Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Diiodohydroxyquinoline
Peginterferon alfa-2a may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Simvastatin and Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Diiodohydroxyquinoline
Peginterferon alfa-2a may cause a moderate interaction that could exacerbate diseases when taken with Simvastatin and Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Diiodohydroxyquinoline
Peginterferon alfa-2a may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Diiodohydroxyquinoline
Peginterferon alfa-2a may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Diiodohydroxyquinoline
Peginterferon alfa-2a may cause a moderate interaction that could exacerbate diseases when taken with Hydroxychloroquine and Hydroxychloroquine may lead to a major life threatening interaction when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Diiodohydroxyquinoline |
DB00470 | DB00612 | 530 | 1,121 | [
"DDInter601",
"DDInter216"
] | Dronabinol | Bisoprolol | Dronabinol (marketed as Marinol) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). THC demonstrates its effects through weak partial agonist activity at Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R) receptors, which results in the well-known effects of smoking cannabis such as increased appetite, reduced pain, and changes in emotional and cognitive processes. Due to its evidence as an appetite stimulant and an anti-nauseant, Dronabinol is approved for use in anorexia associated with weight loss in patients with AIDS and for the treatment of nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments [FDA Label]. Tetrahydrocannabinol (THC) and cannabidiol (CBD) are the two most abundant cannabinoids found naturally in | Bisoprolol is a cardioselective β1-adrenergic blocking agent used to treat high blood pressure.[A180472,L7219] It is considered a potent drug with a long-half life that can be used once daily to reduce the need for multiple doses of antihypertensive drugs. Bisoprolol is generally well tolerated, likely due to its β1-adrenergic receptor selectivity and is a useful alternative to non-selective β-blocker drugs in the treatment of hypertension such as [Carvedilol] and [Labetalol]. It may be used alone or in combination with other drugs to manage hypertension and can be useful in patients with chronic obstructive pulmonary disease (COPD) due to its receptor selectivity. | Moderate | 1 | [
[
[
530,
24,
1121
]
],
[
[
530,
24,
819
],
[
819,
40,
1121
]
],
[
[
530,
63,
88
],
[
88,
40,
1121
]
],
[
[
530,
6,
8374
],
[
8374,
4... | [
[
[
"Dronabinol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bisoprolol"
]
],
[
[
"Dronabinol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acebutolol"
],
[
... | Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Acebutolol and Acebutolol (Compound) resembles Bisoprolol (Compound)
Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Metoprolol and Metoprolol (Compound) resembles Bisoprolol (Compound)
Dronabinol (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Bisoprolol (Compound)
Dronabinol (Compound) causes Ill-defined disorder (Side Effect) and Ill-defined disorder (Side Effect) is caused by Bisoprolol (Compound)
Dronabinol may lead to a major life threatening interaction when taken with Iohexol and Iohexol may cause a moderate interaction that could exacerbate diseases when taken with Bisoprolol
Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazine and Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Bisoprolol
Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Bisoprolol
Dronabinol (Compound) resembles Nabilone (Compound) and Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Bisoprolol
Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Acebutolol and Acebutolol (Compound) resembles Esmolol (Compound) and Esmolol (Compound) resembles Bisoprolol (Compound) |
DB00860 | DB15699 | 891 | 652 | [
"DDInter1513",
"DDInter232"
] | Prednisolone | Brexucabtagene autoleucel | Prednisolone is a glucocorticoid similar to [cortisol] used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects. Prednisolone was granted FDA approval on 21 June 1955. | Mantle cell lymphoma is a heterogeneous sub-category of non-Hodgkin's lymphoma that can be classified as either an aggressive nodal or an indolent leukemic non-nodal variant. Despite the introduction of Bruton's tyrosine kinase (BTK) inhibitors such as [ibrutinib] and [acalabrutinib], the prognosis for MCL patients remains poor and those that relapse following BTK inhibitor therapy have few treatment options.[A216153, A216158] More recently, chimeric antigen receptor (CAR) T cell therapies have been developed that modify a patient's own T cells using viral transduction to bind to and destroy cancerous cells. These therapies differ in manufacturing methodology, viral vector, chimeric antigen choice, and the internal co-stimulatory domains of the chimeric antigen. Similar to [axicabtagene ciloleucel], brexucabtagene autoleucel employs a murine anti-CD19 single-chain variable fragment (scFv) linked to internal CD28- and CD3ζ-derived co-stimulatory domains.[A216148, A216163, L15148] However, the preparation of brexucabtagene autoleucel, previously referred to as KTE-X19, uses a method of T cell enrichment that decreases the prevalence of CD19-expressing tumour cells in the CAR T cell preparation. Brexucabtagene autoleucel was granted accelerated approval for the treatment of relapsed and refractory MCL by the FDA on July 24, 2020, and is currently available through Kite Pharma Inc. under the tradename TECARTUS. | Major | 2 | [
[
[
891,
25,
652
]
],
[
[
891,
24,
259
],
[
259,
24,
652
]
],
[
[
891,
63,
1184
],
[
1184,
24,
652
]
],
[
[
891,
25,
976
],
[
976,
2... | [
[
[
"Prednisolone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Brexucabtagene autoleucel"
]
],
[
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilonacept"
],
... | Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept and Rilonacept may cause a moderate interaction that could exacerbate diseases when taken with Brexucabtagene autoleucel
Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Anakinra and Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Brexucabtagene autoleucel
Prednisolone may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may lead to a major life threatening interaction when taken with Brexucabtagene autoleucel
Prednisolone (Compound) resembles Budesonide (Compound) and Budesonide may lead to a major life threatening interaction when taken with Brexucabtagene autoleucel
Prednisolone (Compound) resembles Fludrocortisone (Compound) and Fludrocortisone may lead to a major life threatening interaction when taken with Brexucabtagene autoleucel
Prednisolone may lead to a major life threatening interaction when taken with Infliximab and Infliximab may lead to a major life threatening interaction when taken with Brexucabtagene autoleucel
Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept and Rilonacept may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T and Sipuleucel-T may cause a moderate interaction that could exacerbate diseases when taken with Brexucabtagene autoleucel
Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T and Sipuleucel-T may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept and Rilonacept may cause a moderate interaction that could exacerbate diseases when taken with Brexucabtagene autoleucel
Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Anakinra and Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept and Rilonacept may cause a moderate interaction that could exacerbate diseases when taken with Brexucabtagene autoleucel |
DB06210 | DB09061 | 72 | 1,627 | [
"DDInter631",
"DDInter284"
] | Eltrombopag | Cannabidiol | Eltrombopag is used to treat low blood platelet counts in adults with chronic immune (idiopathic) thrombocytopenia (ITP), when certain other medicines, or surgery to remove the spleen, have not worked well enough. ITP is a condition that may cause unusual bruising or bleeding due to an abnormally low number of platelets in the blood. Eltrombopag has also been recently approved (late 2012) for the treatment of thrombocytopenia (low blood platelet counts) in patients with chronic hepatitis C to allow them to initiate and maintain interferon-based therapy. | Cannabidiol, or CBD, is one of at least 85 active cannabinoids identified within the Cannabis plant. It is a major phytocannabinoid, accounting for up to 40% of the Cannabis plant's extract, that binds to a wide variety of physiological targets of the endocannabinoid system within the body. Although the exact medical implications are currently being investigated, CBD has shown promise as a therapeutic and pharmaceutical drug target. In particular, CBD has shown promise as an analgesic, anticonvulsant, muscle relaxant, anxiolytic, antipsychotic and has shown neuroprotective, anti-inflammatory, and antioxidant activity, among other currently investigated uses [A32477, A32469]. CBD's exact place within medical practice is still currently hotly debated, however as the body of evidence grows and legislation changes to reflect its wide-spread use, public and medical opinion have changed significantly with regards to its usefulness in a number of medical conditions ranging from anxiety to epilepsy. From a pharmacological perspective, Cannabis' (and CBD's) diverse receptor profile explains its potential application for such a wide variety of medical conditions. Cannabis contains more than 400 different chemical compounds, of which 61 are considered cannabinoids, a class of compounds that act upon endogenous cannabinoid receptors of the body . Cannabinoid receptors are utilized endogenously by the body through the endocannabinoid system, which includes a group of lipid proteins, enzymes, and receptors that are involved in many physiological processes. Through its modulation of neurotransmitter release, the endocannabinoid system regulates cognition, pain sensation, appetite, memory, sleep, immune function, and mood among many other bodily systems. These effects are largely mediated through two members of the G-protein coupled receptor family, cannabinoid receptors 1 and 2 (CB1 and CB2)[A32585,A32824]. CB1 receptors are found in both the central and peripheral nervous systems, with the majority of receptors localized to the hippocampus and amygdala of the brain. Physiological effects of using cannabis make sense in the context of its receptor activity as the hippocampus and amygdala are primarily involved with regulation of memory, fear, and emotion. In contrast, CB2 receptors are mainly found peripherally in immune cells, lymphoid tissue, and peripheral nerve terminals . Tetrahydrocannabinol (THC) and cannabidiol (CBD) are two types of cannabinoids found naturally in the resin of the marijuana plant, both of which interact with the cannabinoid receptors that are found throughout the body. Although THC and CBD have been the most studied cannabinoids, there are many others identified to date including cannabinol (CBN), cannabigerol (CBG), (CBDV), and (THCV) that can be found within the medical cannabis . While both CBD and THC are used for medicinal purposes, they have different receptor activity, function, and physiological effects. If not provided in their activated form (such as through synthetic forms of THC like or ), THC and CBD are obtained through conversion from their precursors, tetrahydrocannabinolic acid-A (THCA-A) and cannabidiolic acid (CBDA), through decarboxylation reactions. This can be achieved through heating, smoking, vaporization, or baking of dried unfertilized female cannabis flowers. The primary psychoactive component of Cannabis, delta 9-tetrahydrocannabinol (Δ9-THC), demonstrates its effects through weak partial agonist activity at Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R) receptors. This activity results in the well-known effects of smoking cannabis such as increased appetite, reduced pain, and changes in emotional and cognitive processes. In contrast to THC's weak agonist activity, CBD has been shown to act as a negative allosteric modulator of the cannabinoid CB1 receptor, the most abundant G-Protein Coupled Receptor (GPCR) in the body . Allosteric regulation is achieved through the modulation of receptor activity on a functionally distinct site from the agonist or antagonist binding site which is clinically significant as direct agonists (such as THC) are limited by their psychomimetic effects such as changes to mood, memory, and anxiety. In addition to the well-known activity on CB1 and CB2 receptors, there is further evidence that CBD also activates 5-HT1A/2A/3A serotonergic and TRPV1–2 vanilloid receptors, antagonizes alpha-1 adrenergic and µ-opioid receptors, inhibits synaptosomal uptake of noradrenaline, dopamine, serotonin and gamma-aminobutyric acid (GABA), and cellular uptake of anandamide, acts on mitochondria Ca2+ stores, blocks low-voltage-activated (T-type) Ca2+ channels, stimulates activity of the inhibitory glycine-receptor, and inhibits activity of fatty amide hydrolase (FAAH) [A31555, A31574]. CBD is currently available in Canada within a 1:1 formulation with tetrahydrocannbinol (THC) (as the formulation known as "nabiximols") as the brand name product Sativex. It is approved for use as adjunctive treatment for symptomatic relief of spasticity in adult patients with multiple sclerosis (MS). Sativex was also given a conditional Notice of Compliance (NOC/c) for use as adjunctive treatment for the symptomatic relief of neuropathic pain in adult patients with multiple sclerosis and as adjunctive analgesic treatment for moderate to severe pain in adult patients with advanced cancer . In April 2018, a Food and Drug Administration advisory panel unanimously recommended approval of Epidiolex (cannabidiol oral solution) for the treatment of two rare forms of epilepsy - Lennox-Gastaut syndrome and Dravet syndrome, which are among the two most difficult types of epilepsy to treat [L2721, L2719]. Epidiolex was granted Orphan Drug designation as well as Fast Track Approval from the FDA for further study in these hard to treat conditions. Notably, phase 3 clinical trials of Epidiolex have demonstrated clinically significant improvement in Lennox-Gastaut syndrome and Dravet syndrome . On June 25th, 2018, Epidiolex was approved by the FDA to be the first CBD-based product available on the US market. | Moderate | 1 | [
[
[
72,
24,
1627
]
],
[
[
72,
24,
384
],
[
384,
23,
1627
]
],
[
[
72,
24,
351
],
[
351,
62,
1627
]
],
[
[
72,
63,
1419
],
[
1419,
23... | [
[
[
"Eltrombopag",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cannabidiol"
]
],
[
[
"Eltrombopag",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
],
[... | Eltrombopag may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may cause a minor interaction that can limit clinical effects when taken with Cannabidiol
Eltrombopag may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Ribociclib may cause a minor interaction that can limit clinical effects when taken with Cannabidiol
Eltrombopag may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may cause a minor interaction that can limit clinical effects when taken with Cannabidiol
Eltrombopag may cause a moderate interaction that could exacerbate diseases when taken with Simvastatin and Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Cannabidiol
Eltrombopag may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a and Peginterferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Cannabidiol
Eltrombopag may lead to a major life threatening interaction when taken with Peginterferon alfa-2a and Peginterferon alfa-2a may cause a moderate interaction that could exacerbate diseases when taken with Cannabidiol
Eltrombopag may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin and Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Cannabidiol
Eltrombopag may lead to a major life threatening interaction when taken with Carfilzomib and Carfilzomib may cause a moderate interaction that could exacerbate diseases when taken with Cannabidiol
Eltrombopag may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Cannabidiol |
DB00365 | DB06699 | 839 | 774 | [
"DDInter842",
"DDInter493"
] | Grepafloxacin | Degarelix | Grepafloxacin is an oral broad-spectrum quinoline antibacterial agent used to treat bacterial infections. Due to the QTc-prolonging potential, as indicated by the changes in the QT interval on the electrocardiogram, and the risk for cardiovascular adverse events, grepafloxacin was withdrawn in the United States. | Degarelix is used for the treatment of advanced prostate cancer. Degarelix is a synthetic peptide derivative drug which binds to gonadotropin-releasing hormone (GnRH) receptors in the pituitary gland and blocks interaction with GnRH. This antagonism reduces luteinising hormone (LH) and follicle-stimulating hormone (FSH) which ultimately causes testosterone suppression. Reduction in testosterone is important in treating men with advanced prostate cancer. Chemically, it is a synthetic linear decapeptide amide with seven unnatural amino acids, five of which are D-amino acids. FDA approved on December 24, 2008. | Major | 2 | [
[
[
839,
25,
774
]
],
[
[
839,
64,
521
],
[
521,
1,
774
]
],
[
[
839,
23,
112
],
[
112,
23,
774
]
],
[
[
839,
25,
888
],
[
888,
24,
... | [
[
[
"Grepafloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Degarelix"
]
],
[
[
"Grepafloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Goserelin"
],
[
"Goserelin",
"{u... | Grepafloxacin may lead to a major life threatening interaction when taken with Goserelin and Goserelin (Compound) resembles Degarelix (Compound)
Grepafloxacin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Degarelix
Grepafloxacin may lead to a major life threatening interaction when taken with Tamoxifen and Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Degarelix
Grepafloxacin may lead to a major life threatening interaction when taken with Entrectinib and Entrectinib may cause a moderate interaction that could exacerbate diseases when taken with Degarelix
Grepafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol and Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Degarelix
Grepafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Castor oil and Castor oil may cause a moderate interaction that could exacerbate diseases when taken with Degarelix
Grepafloxacin may lead to a major life threatening interaction when taken with Mefloquine and Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Degarelix
Grepafloxacin may lead to a major life threatening interaction when taken with Macimorelin and Macimorelin may lead to a major life threatening interaction when taken with Degarelix
Grepafloxacin may lead to a major life threatening interaction when taken with Toremifene and Toremifene may lead to a major life threatening interaction when taken with Degarelix |
DB00046 | DB00252 | 1,179 | 362 | [
"DDInter940",
"DDInter1460"
] | Insulin lispro | Phenytoin | Insulin lispro is a rapid-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promotes glucose metabolism. Insulin is released from the pancreas following a meal to promote the uptake of glucose from the blood into internal organs and tissues such as the liver, fat cells, and skeletal muscle. Absorption of glucose into cells allows for its transformation into glycogen or fat for storage. Insulin also inhibits hepatic glucose production, enhances protein synthesis, and inhibits lipolysis and proteolysis among many other functions. Insulin is an important treatment in the management of Type 1 Diabetes (T1D) which is caused by an autoimmune reaction that destroys the beta cells of the pancreas, resulting in the body not being able to | Phenytoin is classified as a hydantoin derivative and despite its narrow therapeutic index, it is one of the most commonly used anticonvulsants.[A33595,A188832,A189219] Since it's introduction about 80 years ago, phenytoin has not only been established as an effective anti-epileptic, but has also been investigated for several other indications such as bipolar disorder, retina protection, and wound healing.[A188826,A188832] Clinicians are advised to initiate therapeutic drug monitoring in patients who require phenytoin since even small deviations from the recommended therapeutic range can lead to suboptimal treatment, or adverse effects.[A189219,A35884] Both parenteral and oral formulations of phenytoin are available on the market. | Moderate | 1 | [
[
[
1179,
24,
362
]
],
[
[
1179,
24,
651
],
[
651,
40,
362
]
],
[
[
1179,
24,
1101
],
[
1101,
62,
362
]
],
[
[
1179,
24,
167
],
[
167,
... | [
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenytoin"
]
],
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosphenytoin"
],... | Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Fosphenytoin and Fosphenytoin (Compound) resembles Phenytoin (Compound)
Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Phenytoin
Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin
Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone and Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin
Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli and Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin
Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin and Midostaurin may lead to a major life threatening interaction when taken with Phenytoin
Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may lead to a major life threatening interaction when taken with Phenytoin
Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Fosphenytoin and Fosphenytoin (Compound) resembles Benzyl Benzoate (Compound) and Benzyl Benzoate (Compound) resembles Phenytoin (Compound)
Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Benzphetamine and Benzphetamine (Compound) resembles Benzyl Benzoate (Compound) and Benzyl Benzoate (Compound) resembles Phenytoin (Compound) |
DB10343 | DB12267 | 962 | 1,476 | [
"DDInter160",
"DDInter233"
] | Bacillus calmette-guerin substrain tice live antigen | Brigatinib | Bacillus calmette-guerin substrain tice live antigen is a vaccine containing attenuated live culture preparation of the Bacillus of Calmette and Guerin (BCG) strain of *Mycobacterium bovis* for percutaneous use. It is administered to prevent the development of tuberculosis. | Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the EML4-ALK fusion gene, which is a pivotal player in the transformation of susceptible lung parenchyma. Brigatinib was developed by Ariad Pharmaceuticals, a subsidiary of Takeda Pharmaceutical Company Limited, and FDA-approved on April 28, 2017. | Major | 2 | [
[
[
962,
25,
1476
]
],
[
[
962,
64,
168
],
[
168,
23,
1476
]
],
[
[
962,
64,
629
],
[
629,
24,
1476
]
],
[
[
962,
25,
1456
],
[
1456,
... | [
[
[
"Bacillus calmette-guerin substrain tice live antigen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Brigatinib"
]
],
[
[
"Bacillus calmette-guerin substrain tice live antigen",
"{u} may lead to a major life threatening interaction wh... | Bacillus calmette-guerin substrain tice live antigen may lead to a major life threatening interaction when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Brigatinib
Bacillus calmette-guerin substrain tice live antigen may lead to a major life threatening interaction when taken with Sirolimus and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Bacillus calmette-guerin substrain tice live antigen may lead to a major life threatening interaction when taken with Venetoclax and Venetoclax may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Bacillus calmette-guerin substrain tice live antigen may lead to a major life threatening interaction when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Bacillus calmette-guerin substrain tice live antigen may lead to a major life threatening interaction when taken with Etanercept and Etanercept may lead to a major life threatening interaction when taken with Brigatinib
Bacillus calmette-guerin substrain tice live antigen may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may lead to a major life threatening interaction when taken with Brigatinib
Bacillus calmette-guerin substrain tice live antigen may lead to a major life threatening interaction when taken with Baricitinib and Baricitinib may lead to a major life threatening interaction when taken with Brigatinib
Bacillus calmette-guerin substrain tice live antigen may lead to a major life threatening interaction when taken with Bortezomib and Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Anakinra and Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Bacillus calmette-guerin substrain tice live antigen may lead to a major life threatening interaction when taken with Sirolimus and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Gemfibrozil and Gemfibrozil may cause a minor interaction that can limit clinical effects when taken with Brigatinib |
DB00059 | DB00559 | 1,560 | 152 | [
"DDInter1404",
"DDInter223"
] | Pegaspargase | Bosentan | Pegaspargase is a conjugate of monomethoxypolyethylene glycol (mPEG) and L-asparaginase (L-asparagine amidohydrolase), an asparagine-specific enzyme that converts L-asparagine into aspartic acid and ammonia. Asparagine is an amino acid that is vital for cell survival. In humans, most normal tissues can produce asparagine through the action of asparagine synthetase. However, leukemia cells have low levels of this enzyme and depend on exogenous sources. Therefore, the use of pegaspargase results in leukemic cell death.[A103,A255912,L44667] Pegaspargase has the same mechanism of action as [L-asparaginase] derived from _Escherichia coli_, a previously developed enzyme used for the treatment of acute lymphoblastic leukemia (ALL). However, using L-asparaginase derived from _Escherich | Bosentan is a dual endothelin receptor antagonist marketed under the trade name Tracleer by Actelion Pharmaceuticals. Bosentan is used to treat pulmonary hypertension by blocking the action of endothelin molecules that would otherwise promote narrowing of the blood vessels and lead to high blood pressure. | Moderate | 1 | [
[
[
1560,
24,
152
]
],
[
[
1560,
24,
168
],
[
168,
23,
152
]
],
[
[
1560,
25,
1101
],
[
1101,
23,
152
]
],
[
[
1560,
24,
1613
],
[
1613,
... | [
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bosentan"
]
],
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
[
... | Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Bosentan
Pegaspargase may lead to a major life threatening interaction when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Bosentan
Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a and Peginterferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Bosentan
Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Acetohexamide and Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Bosentan
Pegaspargase may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may cause a moderate interaction that could exacerbate diseases when taken with Bosentan
Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib and Bosutinib may lead to a major life threatening interaction when taken with Bosentan
Pegaspargase may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Bosentan
Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Bosentan (Compound)
Pegaspargase may lead to a major life threatening interaction when taken with Bexarotene and Bexarotene (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Bosentan (Compound) |
DB00907 | DB09241 | 290 | 1,629 | [
"DDInter427",
"DDInter1186"
] | Cocaine (topical) | Methylene blue | Cocaine can cause developmental toxicity and female reproductive toxicity according to an independent committee of scientific and health experts. | Methylene blue is an oxidation-reduction agent. The intravenous form of methylene blue is approved by the FDA for the treatment of pediatric and adult patients with acquired methemoglobinemia. Historically, it has been widely used in Africa to treat malaria, but now it disappeared when chloroquine (CQ) and other drugs entered the market. Its use as an urinary tract antiseptic has also been investigated. Methylthioninium chloride (INN, or methylene blue, proposed trade name Rember) is an investigational drug being developed by the University of Aberdeen and TauRx Therapeutics that has been shown in early clinical trials to be an inhibitor of Tau protein aggregation. The drug is of potential interest for the treatment of patients with Alzheimer's disease. | Major | 2 | [
[
[
290,
25,
1629
]
],
[
[
290,
64,
1052
],
[
1052,
24,
1629
]
],
[
[
290,
25,
1148
],
[
1148,
24,
1629
]
],
[
[
290,
24,
697
],
[
697,
... | [
[
[
"Cocaine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methylene blue"
]
],
[
[
"Cocaine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ritodrine"
],
[
"Ritodrine",
"{u} may c... | Cocaine may lead to a major life threatening interaction when taken with Methylene blue
Cocaine may lead to a major life threatening interaction when taken with Ritodrine and Ritodrine may cause a moderate interaction that could exacerbate diseases when taken with Methylene blue
Cocaine may lead to a major life threatening interaction when taken with Isoprenaline and Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Methylene blue
Cocaine may cause a moderate interaction that could exacerbate diseases when taken with Phenobarbital and Phenobarbital may cause a moderate interaction that could exacerbate diseases when taken with Methylene blue
Cocaine may lead to a major life threatening interaction when taken with Levosalbutamol and Levosalbutamol may cause a moderate interaction that could exacerbate diseases when taken with Methylene blue
Cocaine may cause a moderate interaction that could exacerbate diseases when taken with Nefazodone and Nefazodone may lead to a major life threatening interaction when taken with Methylene blue
Cocaine may lead to a major life threatening interaction when taken with Methylphenidate and Methylphenidate may lead to a major life threatening interaction when taken with Methylene blue
Cocaine may lead to a major life threatening interaction when taken with Dextroamphetamine and Dextroamphetamine may lead to a major life threatening interaction when taken with Methylene blue
Cocaine may cause a moderate interaction that could exacerbate diseases when taken with Oxcarbazepine and Oxcarbazepine may lead to a major life threatening interaction when taken with Methylene blue
Cocaine may cause a moderate interaction that could exacerbate diseases when taken with Iobenguane and Cocaine may lead to a major life threatening interaction when taken with Iobenguane and Iobenguane may lead to a major life threatening interaction when taken with Methylene blue |
DB01404 | DB09030 | 757 | 840 | [
"DDInter820",
"DDInter1945"
] | Ginseng | Vorapaxar | Ginseng is promoted as an adaptogen (a product that increases the body's resistance to stress), one which can to a certain extent be supported with reference to its anticarcinogenic and antioxidant properties. Ginseng is also known to contain phytoestrogens. | Vorapaxar is a tricyclic himbacine-derived selective inhibitor of protease activated receptor (PAR-1) indicated for reducing the incidence of thrombotic cardiovascular events in patients with a history of myocardial infarction (MI) or with peripheral arterial disease (PAD). By inhibiting PAR-1, a thrombin receptor expressed on platelets, vorapaxar prevents thrombin-related platelet aggregation. | Moderate | 1 | [
[
[
757,
24,
840
]
],
[
[
757,
24,
578
],
[
578,
24,
840
]
],
[
[
757,
63,
500
],
[
500,
25,
840
]
],
[
[
757,
24,
1409
],
[
1409,
2... | [
[
[
"Ginseng",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vorapaxar"
]
],
[
[
"Ginseng",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
],
[
"Ti... | Ginseng may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Vorapaxar
Ginseng may cause a moderate interaction that could exacerbate diseases when taken with Enoxaparin and Enoxaparin may lead to a major life threatening interaction when taken with Vorapaxar
Ginseng may cause a moderate interaction that could exacerbate diseases when taken with Apixaban and Apixaban may lead to a major life threatening interaction when taken with Vorapaxar
Ginseng may cause a moderate interaction that could exacerbate diseases when taken with Edoxaban and Edoxaban may lead to a major life threatening interaction when taken with Vorapaxar
Ginseng may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticagrelor may cause a minor interaction that can limit clinical effects when taken with Chamomile and Chamomile may cause a minor interaction that can limit clinical effects when taken with Vorapaxar
Ginseng may cause a moderate interaction that could exacerbate diseases when taken with Enoxaparin and Enoxaparin may cause a minor interaction that can limit clinical effects when taken with Chamomile and Chamomile may cause a minor interaction that can limit clinical effects when taken with Vorapaxar
Ginseng may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Fosamprenavir and Fosamprenavir may lead to a major life threatening interaction when taken with Vorapaxar
Ginseng may cause a moderate interaction that could exacerbate diseases when taken with Betrixaban and Betrixaban may cause a minor interaction that can limit clinical effects when taken with Capsicum and Capsicum may cause a minor interaction that can limit clinical effects when taken with Vorapaxar
Ginseng may cause a moderate interaction that could exacerbate diseases when taken with Acetohexamide and Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Vorapaxar |
DB00771 | DB06077 | 262 | 879 | [
"DDInter397",
"DDInter1102"
] | Clidinium | Lumateperone | Clidinium is a synthetic anticholinergic agent which has been shown in experimental and clinical studies to have a pronounced antispasmodic and antisecretory effect on the gastrointestinal tract. It inhibits muscarinic actions of acetylcholine at postganglionic parasympathetic neuroeffector sites. It is used for the treatment of peptic ulcer disease and also to help relieve abdominal or stomach spasms or cramps due to colicky abdominal pain, diverticulitis, and irritable bowel syndrome. | Schizophrenia is a complex mental illness and impacts approximately 1% of the population. Although there are several antipsychotics including [aripiprazole], [paliperidone] and [clozapine] available for clinical use, they are generally accompanied by significant metabolic and/or neurological adverse effects. Lumateperone is a newly approved 2nd generation antipsychotic currently indicated for the treatment of schizophrenia. It has a unique receptor binding profile and differs from other antipsychotics in that it modulates glutamate, serotonin and dopamine, which are all neurotransmitters that contribute to the pathophysiology of schizophrenia.[A189093,A189174] The data so far indicates that lumateperone can alleviate both positive and negative symptoms of schizophrenia. Further, not only is the new antipsychotic selective for dopamine (D2) receptors in the mesolimbic and mesocortical brain regions, but it also has minimal off-target activity. Both characteristics lend to a more favourable adverse effect profile and ultimately safer drug.[A189093,L10908] | Moderate | 1 | [
[
[
262,
24,
879
]
],
[
[
262,
24,
407
],
[
407,
63,
879
]
],
[
[
262,
24,
1511
],
[
1511,
24,
879
]
],
[
[
262,
63,
999
],
[
999,
2... | [
[
[
"Clidinium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lumateperone"
]
],
[
[
"Clidinium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
],
[
"... | Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium may cause a moderate interaction that could exacerbate diseases when taken with Lumateperone
Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate and Mepenzolate may cause a moderate interaction that could exacerbate diseases when taken with Lumateperone
Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazine and Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Lumateperone
Clidinium (Compound) resembles Trospium (Compound) and Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Trospium and Trospium may cause a moderate interaction that could exacerbate diseases when taken with Lumateperone
Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may lead to a major life threatening interaction when taken with Lumateperone
Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Metoclopramide and Metoclopramide may lead to a major life threatening interaction when taken with Lumateperone
Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate and Mepenzolate may cause a moderate interaction that could exacerbate diseases when taken with Lumateperone
Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate and Mepenzolate may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium may cause a moderate interaction that could exacerbate diseases when taken with Lumateperone
Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazine and Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Linagliptin and Linagliptin may cause a moderate interaction that could exacerbate diseases when taken with Lumateperone |
DB00934 | DB08899 | 413 | 129 | [
"DDInter1124",
"DDInter649"
] | Maprotiline | Enzalutamide | Maprotiline is a tetracyclic antidepressant with similar pharmacological properties to tricyclic antidepressants (TCAs). Similar to TCAs, maprotiline inhibits neuronal norepinephrine reuptake, possesses some anticholinergic activity, and does not affect monoamine oxidase activity. It differs from TCAs in that it does not appear to block serotonin reuptake. Maprotiline may be used to treat depressive affective disorders, including dysthymic disorder (depressive neurosis) and major depressive disorder. Maprotiline is effective at reducing symptoms of anxiety associated with depression. | Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line treatment of prostate cancer and remission can be achieved, arising resistance is inevitable, becoming castration-resistant prostate cancer. Until recently, docetaxel is the only treatment available for metastatic CRPC; however, AR inhibitors have been developed for more targeted therapy, although first-generation AR inhibitors like bicalutamide did not substantially increase the survival rate. Second-generation such as enzalutamide is more efficacious due to a higher affinity to AR and no partial agonist activity compared to bicalutamide.[A252667,A252642] Due to a favorable pharmacological profile, a phase 1 study of enzalutamide was initiated in July 2007. Compared to the average time of 10 to 15 years for a drug to go from pre-clinical to clinical studies, enzalutamide was developed relatively rapidly. | Moderate | 1 | [
[
[
413,
24,
129
]
],
[
[
413,
24,
918
],
[
918,
1,
129
]
],
[
[
413,
6,
12523
],
[
12523,
45,
129
]
],
[
[
413,
21,
28703
],
[
28703,
... | [
[
[
"Maprotiline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
]
],
[
[
"Maprotiline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bicalutamide"
],
... | Maprotiline may cause a moderate interaction that could exacerbate diseases when taken with Bicalutamide and Bicalutamide (Compound) resembles Enzalutamide (Compound)
Maprotiline (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Enzalutamide (Compound)
Maprotiline (Compound) causes Pruritus (Side Effect) and Pruritus (Side Effect) is caused by Enzalutamide (Compound)
Maprotiline may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Enzalutamide
Maprotiline may cause a moderate interaction that could exacerbate diseases when taken with Sorafenib and Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide
Maprotiline may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline and Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide
Maprotiline may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol and Vilanterol may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide
Maprotiline may lead to a major life threatening interaction when taken with Granisetron and Granisetron may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide
Maprotiline may lead to a major life threatening interaction when taken with Hydroxychloroquine and Hydroxychloroquine may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide |
DB10316 | DB12498 | 334 | 76 | [
"DDInter1248",
"DDInter1238"
] | Mumps virus strain B level jeryl lynn live antigen | Mogamulizumab | Mumps virus strain B level jeryl lynn live antigen is a live attenuated virus vaccine for subcutenous injection. It is an active immunization against mumps, which is a common childhood disease. | Mogamulizumab is a humanized monoclonal antibody (mAb) directed against CC chemokine receptor 4 (CCR4) for the treatment of Mycosis Fungoides (MF) and Sézary Syndrome (SS), the most common subtypes of cutaneous T-cell lymphoma. Cutaneous T-cell lymphomas occur when certain white blood cells, called T cells, become cancerous; these cancers typically affect the skin, causing various types of skin lesions. On August 8 2018, the U.S. Food and Drug Administration (FDA) approved mogamulizumab injection (also known as _Poteligeo_) for intravenous use for the treatment of adult patients with relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS) after at least one prior systemic therapy. It was approved for the same indications in Canada in June 2022. Mogamulizumab is derived from Kyowa Hakko Kirin's POTELLIGENT (®) technology, which produces antibodies with enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) activity. Approval in Japan was granted on April 30 2012 by the Japanese Ministry of Health, Labour and Welfare for patients with relapsed or refractory CCR4-positive adult T-cell leukemia-lymphoma. | Major | 2 | [
[
[
334,
25,
76
]
],
[
[
334,
64,
1531
],
[
1531,
24,
76
]
],
[
[
334,
25,
738
],
[
738,
24,
76
]
],
[
[
334,
25,
676
],
[
676,
64,
... | [
[
[
"Mumps virus strain B level jeryl lynn live antigen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mogamulizumab"
]
],
[
[
"Mumps virus strain B level jeryl lynn live antigen",
"{u} may lead to a major life threatening interaction whe... | Mumps virus strain B level jeryl lynn live antigen may lead to a major life threatening interaction when taken with Canakinumab and Canakinumab may cause a moderate interaction that could exacerbate diseases when taken with Mogamulizumab
Mumps virus strain B level jeryl lynn live antigen may lead to a major life threatening interaction when taken with Niraparib and Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Mogamulizumab
Mumps virus strain B level jeryl lynn live antigen may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may lead to a major life threatening interaction when taken with Mogamulizumab
Mumps virus strain B level jeryl lynn live antigen may lead to a major life threatening interaction when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Mogamulizumab
Mumps virus strain B level jeryl lynn live antigen may lead to a major life threatening interaction when taken with Baricitinib and Baricitinib may lead to a major life threatening interaction when taken with Mogamulizumab
Mumps virus strain B level jeryl lynn live antigen may lead to a major life threatening interaction when taken with Canakinumab and Canakinumab may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Mogamulizumab
Mumps virus strain B level jeryl lynn live antigen may lead to a major life threatening interaction when taken with Alefacept and Alefacept may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Mogamulizumab
Mumps virus strain B level jeryl lynn live antigen may lead to a major life threatening interaction when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab and Canakinumab may cause a moderate interaction that could exacerbate diseases when taken with Mogamulizumab
Mumps virus strain B level jeryl lynn live antigen may lead to a major life threatening interaction when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab and Canakinumab may cause a moderate interaction that could exacerbate diseases when taken with Mogamulizumab |
DB01244 | DB01254 | 762 | 1,213 | [
"DDInter192",
"DDInter484"
] | Bepridil | Dasatinib | A long-acting, non selective, calcium channel blocker with significant anti-anginal activity. The drug produces significant coronary vasodilation and modest peripheral effects. It has antihypertensive and selective anti-arrhythmia activities and acts as a calmodulin antagonist. It is no longer marketed in the United States, as it has been implicated in causing ventricular arrhythmias (ie. Torsade de pointes). | Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.[A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the breakpoint cluster region (BCR) gene transcribe the chimeric protein BCR-ABL. BCR-ABL is associated with the uncontrolled activity of the ABL tyrosine kinase and is involved in the pathogenesis of CML and 15-30% of ALL cases.[A11377,A33432] Dasatinib also inhibits a spectrum of kinases involved in cancer, including several SRC-family kinases. Unlike [imatinib], another tyrosine kinase used for the treatment of CML and Ph-positive ALL, dasatinib inhibits the active and inactive conformations of the ABL kinase domain.[A2226,A11377] Also, mutations in the kinase domain of BCR-ABL may lead to relapse during imatinib treatment. Since dasatinib does not interact with some of the residues involved in those mutations, the use of this drug represents a therapeutic alternative for patients with cancers that have developed imatinib-resistance. The use of dasatinib was first approved by the FDA in 2006.[L45171,L45186] | Major | 2 | [
[
[
762,
25,
1213
]
],
[
[
762,
6,
4973
],
[
4973,
45,
1213
]
],
[
[
762,
21,
28882
],
[
28882,
60,
1213
]
],
[
[
762,
62,
112
],
[
112,
... | [
[
[
"Bepridil",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dasatinib"
]
],
[
[
"Bepridil",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Dasatinib"
... | Bepridil (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Dasatinib (Compound)
Bepridil (Compound) causes Body temperature increased (Side Effect) and Body temperature increased (Side Effect) is caused by Dasatinib (Compound)
Bepridil may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Dasatinib
Bepridil may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Dasatinib
Bepridil may cause a moderate interaction that could exacerbate diseases when taken with Niraparib and Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib
Bepridil may lead to a major life threatening interaction when taken with Granisetron and Granisetron may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib
Bepridil may lead to a major life threatening interaction when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib
Bepridil may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol and Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib
Bepridil (Compound) resembles Dextropropoxyphene (Compound) and Dextropropoxyphene may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib |
DB00059 | DB09122 | 1,560 | 1,613 | [
"DDInter1404",
"DDInter1409"
] | Pegaspargase | Peginterferon beta-1a | Pegaspargase is a conjugate of monomethoxypolyethylene glycol (mPEG) and L-asparaginase (L-asparagine amidohydrolase), an asparagine-specific enzyme that converts L-asparagine into aspartic acid and ammonia. Asparagine is an amino acid that is vital for cell survival. In humans, most normal tissues can produce asparagine through the action of asparagine synthetase. However, leukemia cells have low levels of this enzyme and depend on exogenous sources. Therefore, the use of pegaspargase results in leukemic cell death.[A103,A255912,L44667] Pegaspargase has the same mechanism of action as [L-asparaginase] derived from _Escherichia coli_, a previously developed enzyme used for the treatment of acute lymphoblastic leukemia (ALL). However, using L-asparaginase derived from _Escherich | Multiple Sclerosis (MS) is a chronic and inflammatory autoimmune disease of the central nervous system, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792] Peginterferon beta-1a is an interferon therapy used for the management of relapsing forms of MS. It was originally approved by the FDA in 2014 for subcutaneous use, and was approved for intramuscular use in January 2021. Currently, it is the only approved pegylated interferon for the management of MS with an proven ability to reduce relapses and delay the progression of disability resulting from MS. | Moderate | 1 | [
[
[
1560,
24,
1613
]
],
[
[
1560,
24,
671
],
[
671,
24,
1613
]
],
[
[
1560,
24,
975
],
[
975,
63,
1613
]
],
[
[
1560,
63,
816
],
[
816,
... | [
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon beta-1a"
]
],
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluvastatin"... | Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Fluvastatin and Fluvastatin may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Lurbinectedin and Lurbinectedin may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Gemtuzumab ozogamicin and Gemtuzumab ozogamicin may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Pegaspargase may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Pegaspargase may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Peginterferon beta-1a
Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Zidovudine and Zidovudine may lead to a major life threatening interaction when taken with Peginterferon beta-1a
Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Fluvastatin and Fluvastatin may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Cannabidiol and Cannabidiol may cause a minor interaction that can limit clinical effects when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Lurbinectedin and Lurbinectedin may lead to a major life threatening interaction when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a |
DB00446 | DB01005 | 597 | 995 | [
"DDInter351",
"DDInter894"
] | Chloramphenicol | Hydroxyurea | An antibiotic first isolated from cultures of _Streptomyces venezuelae_ in 1947 but now produced synthetically. It has a relatively simple structure and was the first broad-spectrum antibiotic to be discovered. It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic. (From Martindale, The Extra Pharmacopoeia, 29th ed, p106) The FDA has withdrawn all oral drug products containing chloramphenicol, due to the high risk of fatal aplastic anemia associated with this specific route of administration.[L43942,L44022] | Hydroxyurea is a non-alkylating antineoplastic agent that was first synthesized in 1869 but was not characterized biologically until 1928. It was first approved by the FDA in 1998 for the treatment of sickle cell anemia in adults. Although clinical evidence on the efficacy of hydroxyurea in certain conditions exists, hydroxyurea is used sparingly in clinical settings, largely due to lack of knowledge and adherence, the need for therapeutic monitoring, and serious side effects of secondary cancer and birth defects. | Moderate | 1 | [
[
[
597,
24,
995
]
],
[
[
597,
21,
28883
],
[
28883,
60,
995
]
],
[
[
597,
24,
1238
],
[
1238,
24,
995
]
],
[
[
597,
24,
869
],
[
869,
... | [
[
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxyurea"
]
],
[
[
"Chloramphenicol",
"{u} (Compound) causes {v} (Side Effect)",
"Skin disorder"
],
[
"Skin disorder",
"{u} (S... | Chloramphenicol (Compound) causes Skin disorder (Side Effect) and Skin disorder (Side Effect) is caused by Hydroxyurea (Compound)
Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Pentostatin and Pentostatin may cause a moderate interaction that could exacerbate diseases when taken with Hydroxyurea
Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Topotecan and Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Hydroxyurea
Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Mitomycin and Mitomycin may cause a moderate interaction that could exacerbate diseases when taken with Hydroxyurea
Chloramphenicol may cause a minor interaction that can limit clinical effects when taken with Cyclophosphamide and Cyclophosphamide may cause a moderate interaction that could exacerbate diseases when taken with Hydroxyurea
Chloramphenicol may lead to a major life threatening interaction when taken with Lurbinectedin and Lurbinectedin may cause a moderate interaction that could exacerbate diseases when taken with Hydroxyurea
Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Hydroxyurea
Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Didanosine and Didanosine may lead to a major life threatening interaction when taken with Hydroxyurea
Chloramphenicol may lead to a major life threatening interaction when taken with Clozapine and Clozapine may lead to a major life threatening interaction when taken with Hydroxyurea |
DB00850 | DB11130 | 1,630 | 407 | [
"DDInter1432",
"DDInter1344"
] | Perphenazine | Opium | An antipsychotic phenothiazine derivative with actions and uses similar to those of chlorpromazine. | Opium is the first substance of the diverse group of the opiates. It has been known for a long time, and the first evidence of a poppy culture dates from 5 thousand years by the Sumerians. During the years, opium was used as a sedative and hypnotic, but it was determined to be addictive. Opium is extracted from _Papaver somniferum_, which is more known as poppies. This plant is an integrant of the Papaveraceae family, and it is characterized by solitary leaves and capsulated fruits. Therefore, opium is a sticky brown resin obtained by collecting and drying the latex that exudes from the poppy pods. Once extracted, opium contains two main groups of alkaloids; the psychoactive constituents which are in the category of phenanthrenes and alkaloids that have no central nervous system effect in the category of isoquinolines. Morphine is the most prevalent and principal alkaloid in opium, and it is responsible for most of the harmful effects of opium. Opium has gradually been superseded by a variety of synthetic opioids and general anesthetics. Some of the isolated derivatives of opium are morphine, noscapine, strychnine, veratrine, colchicine, codeine, and quinine. Opium is a prohibited drug of abuse in most countries, but the illegal production of this drug and its derivatives keeps being registered. There is some legal production of opium in different countries for the obtention of alkaloids by extraction. | Moderate | 1 | [
[
[
1630,
24,
407
]
],
[
[
1630,
63,
662
],
[
662,
24,
407
]
],
[
[
1630,
35,
104
],
[
104,
24,
407
]
],
[
[
1630,
24,
849
],
[
849,
... | [
[
[
"Perphenazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
]
],
[
[
"Perphenazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
],
[
... | Perphenazine may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Opium
Perphenazine (Compound) resembles Methdilazine (Compound) and Perphenazine may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Opium
Perphenazine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Opium
Perphenazine (Compound) resembles Methotrimeprazine (Compound) and Methotrimeprazine may cause a moderate interaction that could exacerbate diseases when taken with Opium
Perphenazine may lead to a major life threatening interaction when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Opium
Perphenazine may lead to a major life threatening interaction when taken with Metoclopramide and Metoclopramide may cause a moderate interaction that could exacerbate diseases when taken with Opium
Perphenazine may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine and Pentoxyverine may cause a moderate interaction that could exacerbate diseases when taken with Opium
Perphenazine may cause a moderate interaction that could exacerbate diseases when taken with Procarbazine and Procarbazine may lead to a major life threatening interaction when taken with Opium
Perphenazine may lead to a major life threatening interaction when taken with Iohexol and Iohexol may lead to a major life threatening interaction when taken with Opium |
DB06605 | DB08896 | 1,409 | 292 | [
"DDInter108",
"DDInter1576"
] | Apixaban | Regorafenib | Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseases[Label,A6897]. It is marketed under the name Eliquis[Label,L6043]. Apixaban was approved by the FDA on December 28, 2012. | Regorafenib is an orally-administered inhibitor of multiple kinases. It is used for the treatment of metastatic colorectal cancer, advanced gastrointestinal stromal tumours, and hepatocellular carcinoma. FDA approved on September 27, 2012. Approved use of Regorafenib was expanded to treat Hepatocellular Carcinoma in April 2017. | Major | 2 | [
[
[
1409,
25,
292
]
],
[
[
1409,
63,
79
],
[
79,
1,
292
]
],
[
[
1409,
6,
6017
],
[
6017,
45,
292
]
],
[
[
1409,
21,
29122
],
[
29122,
... | [
[
[
"Apixaban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Regorafenib"
]
],
[
[
"Apixaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sorafenib"
],
[
"Sorafenib",
... | Apixaban may cause a moderate interaction that could exacerbate diseases when taken with Sorafenib and Sorafenib (Compound) resembles Regorafenib (Compound)
Apixaban (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Regorafenib (Compound)
Apixaban (Compound) causes Mediastinal disorder (Side Effect) and Mediastinal disorder (Side Effect) is caused by Regorafenib (Compound)
Apixaban may cause a moderate interaction that could exacerbate diseases when taken with Desvenlafaxine and Desvenlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Regorafenib
Apixaban may cause a moderate interaction that could exacerbate diseases when taken with Pegaspargase and Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Regorafenib
Apixaban may lead to a major life threatening interaction when taken with Lumacaftor and Lumacaftor may cause a moderate interaction that could exacerbate diseases when taken with Regorafenib
Apixaban may lead to a major life threatening interaction when taken with Phenytoin and Phenytoin may cause a moderate interaction that could exacerbate diseases when taken with Regorafenib
Apixaban may cause a moderate interaction that could exacerbate diseases when taken with Lefamulin and Lefamulin may cause a moderate interaction that could exacerbate diseases when taken with Regorafenib
Apixaban may lead to a major life threatening interaction when taken with Boceprevir and Boceprevir may cause a moderate interaction that could exacerbate diseases when taken with Regorafenib |
DB00757 | DB08903 | 1,166 | 996 | [
"DDInter581",
"DDInter170"
] | Dolasetron | Bedaquiline | Dolasetron is an antinauseant and antiemetic agent indicated for the prevention of nausea and vomiting associated with moderately-emetogenic cancer chemotherapy and for the prevention of postoperative nausea and vomiting. Dolasetron is a highly specific and selective serotonin 5-HT3 receptor antagonist. This drug is not shown to have activity at other known serotonin receptors, and has low affinity for dopamine receptors. | Bedaquiline is a bactericidal antimycobacterial drug belonging to the class of diarylquinoline. The quinolinic central heterocyclic nucleus with alcohol and amine side chains is responsible for bedaquiline-mediated antimycobacterial activity. Although it is closely related to fluoroquinolones, bedaquiline does not affect DNA gyrase; instead, bedaquiline inhibits the c subunit of ATP synthase responsible for synthesizing ATP. Consequently, bedaquiline can be used to treat mycobacterial infection, particularly tuberculosis (TB). Although the current standard of TB treatment of anti-TB drugs for 2 months, including 2 key drugs [isoniazid] and [rifampin], is highly effective, the emergence of multidrug-resistant TB (MDR-TB) to [isoniazid] and [rifampin] has substantially worsened patients outcome. Bedaquiline was approved by the FDA on December 28, 2012, to treat pulmonary MDR-TB, following favorable results in multiple pre-clinical and clinical studies.[A261856,A261861] It is the first drug that was approved in the last 40 years by the FDA for TB unresponsive to current treatments on the market. Currently, bedaquiline is the last-line anti-TB drug and must only be used in an appropriate combination regimen.[L48506,A261866] | Major | 2 | [
[
[
1166,
25,
996
]
],
[
[
1166,
6,
8374
],
[
8374,
45,
996
]
],
[
[
1166,
21,
29282
],
[
29282,
60,
996
]
],
[
[
1166,
23,
112
],
[
112,
... | [
[
[
"Dolasetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bedaquiline"
]
],
[
[
"Dolasetron",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Bedaqu... | Dolasetron (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Bedaquiline (Compound)
Dolasetron (Compound) causes Arrhythmia (Side Effect) and Arrhythmia (Side Effect) is caused by Bedaquiline (Compound)
Dolasetron may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Bedaquiline
Dolasetron may lead to a major life threatening interaction when taken with Bupropion and Bupropion may cause a moderate interaction that could exacerbate diseases when taken with Bedaquiline
Dolasetron may cause a moderate interaction that could exacerbate diseases when taken with Lactulose and Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Bedaquiline
Dolasetron may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol and Olodaterol may cause a moderate interaction that could exacerbate diseases when taken with Bedaquiline
Dolasetron may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol and Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Bedaquiline
Dolasetron may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin may lead to a major life threatening interaction when taken with Bedaquiline
Dolasetron may lead to a major life threatening interaction when taken with Glasdegib and Glasdegib may lead to a major life threatening interaction when taken with Bedaquiline |
DB00445 | DB00740 | 322 | 424 | [
"DDInter655",
"DDInter1596"
] | Epirubicin | Riluzole | An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA. | A glutamate antagonist (receptors, glutamate) used as an anticonvulsant (anticonvulsants) and to prolong the survival of patients with amyotrophic lateral sclerosis. Riluzole is marketed as Rilutek by Sanofi. | Moderate | 1 | [
[
[
322,
24,
424
]
],
[
[
322,
7,
2602
],
[
2602,
46,
424
]
],
[
[
322,
7,
19748
],
[
19748,
57,
424
]
],
[
[
322,
18,
8914
],
[
8914,
... | [
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Riluzole"
]
],
[
[
"Epirubicin",
"{u} (Compound) upregulates {v} (Gene)",
"PTK2B"
],
[
"PTK2B",
"{u} (Gene) is upregulated by {v} (Com... | Epirubicin (Compound) upregulates PTK2B (Gene) and PTK2B (Gene) is upregulated by Riluzole (Compound)
Epirubicin (Compound) upregulates PRAF2 (Gene) and PRAF2 (Gene) is downregulated by Riluzole (Compound)
Epirubicin (Compound) downregulates NUP85 (Gene) and NUP85 (Gene) is downregulated by Riluzole (Compound)
Epirubicin (Compound) causes Eczema (Side Effect) and Eczema (Side Effect) is caused by Riluzole (Compound)
Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli and Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Riluzole
Epirubicin may lead to a major life threatening interaction when taken with Osimertinib and Osimertinib may cause a moderate interaction that could exacerbate diseases when taken with Riluzole
Epirubicin may lead to a major life threatening interaction when taken with Anagrelide and Anagrelide may cause a moderate interaction that could exacerbate diseases when taken with Riluzole
Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat and Osilodrostat may cause a moderate interaction that could exacerbate diseases when taken with Riluzole
Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone and Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Riluzole |
DB00400 | DB06414 | 353 | 655 | [
"DDInter843",
"DDInter703"
] | Griseofulvin | Etravirine | An antifungal antibiotic. Griseofulvin may be given by mouth in the treatment of tinea infections. | Etravirine is an antiretroviral agent more specifically classified as a Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI). Etraverine is used clinically for the treatment of human immunodeficiency virus type 1 (HIV-1) infection. On January 18, 2007, the FDA granted accelerated approved for the use of etravirine 100mg tablets in the treatment of adult HIV-1 infection documented to be resistant to therapy with other NNRTIs and antiretroviral agents. On March 26, 2012, approval was extended for use in treatment-experienced pediatric patients 6 to 18 years of age, weighing at least 16 kg. Etravarine must always be used in combination with other antiretroviral drugs. Etravirine exerts its effects via direct inhibition of the reverse transcriptase enzyme of human immunodeficiency virus type 1 (HIV-1), and consequently blocks DNA-dependent and RNA-dependent polymerase activity. Etravirine does not inhibit human DNA polymerase alpha, beta or gamma. Common side effects of use include mild to moderate rash within the first 6 weeks of therapy, nausea, diarrhea and peripheral neuropathy. Patients are advised to immediately contact their healthcare provider if a rash develops. In 2009, postmarketing case reports of Stevens-Johnson Syndrome, toxic epidermal necrolysis, erythema multiforme, and other hypersensitivity reactions lead to a revision of etravirine's "Warnings and Precautions," as well as notification of health care providers. In 2013, reports of Autoimmune disorders (such as Graves’ disease, polymyositis, and Guillain-Barré syndrome) in the setting of immune reconstitution, as well as more in depth information about the development of rashes in patients taking etravirine, lead to a modification of etravirine's monograph. | Moderate | 1 | [
[
[
353,
24,
655
]
],
[
[
353,
24,
786
],
[
786,
40,
655
]
],
[
[
353,
6,
8374
],
[
8374,
45,
655
]
],
[
[
353,
21,
28680
],
[
28680,
... | [
[
[
"Griseofulvin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etravirine"
]
],
[
[
"Griseofulvin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilpivirine"
],
... | Griseofulvin may cause a moderate interaction that could exacerbate diseases when taken with Rilpivirine and Rilpivirine (Compound) resembles Etravirine (Compound)
Griseofulvin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Etravirine (Compound)
Griseofulvin (Compound) causes Rash (Side Effect) and Rash (Side Effect) is caused by Etravirine (Compound)
Griseofulvin may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Etravirine
Griseofulvin may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib and Sunitinib may cause a moderate interaction that could exacerbate diseases when taken with Etravirine
Griseofulvin may cause a moderate interaction that could exacerbate diseases when taken with Apixaban and Apixaban may cause a moderate interaction that could exacerbate diseases when taken with Etravirine
Griseofulvin may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine and Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Etravirine
Griseofulvin may lead to a major life threatening interaction when taken with Medroxyprogesterone acetate and Medroxyprogesterone acetate may cause a moderate interaction that could exacerbate diseases when taken with Etravirine
Griseofulvin may cause a minor interaction that can limit clinical effects when taken with Lidocaine and Lidocaine may cause a moderate interaction that could exacerbate diseases when taken with Etravirine |
DB00655 | DB01254 | 559 | 1,213 | [
"DDInter682",
"DDInter484"
] | Estrone | Dasatinib | Estrone, one of the major mammalian estrogens, is an aromatized C18 steroid with a 3-hydroxyl group and a 17-ketone. It is produced in vivo from androstenedione or from testosterone via estradiol. It is produced primarily in the ovaries, placenta, and in peripheral tissues (especially adipose tissue) through conversion of adrostenedione. Estrone may be further metabolized to 16-alpha-hydroxyestrone, which may be reduced to estriol by estradiol dehydrogenase. | Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.[A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the breakpoint cluster region (BCR) gene transcribe the chimeric protein BCR-ABL. BCR-ABL is associated with the uncontrolled activity of the ABL tyrosine kinase and is involved in the pathogenesis of CML and 15-30% of ALL cases.[A11377,A33432] Dasatinib also inhibits a spectrum of kinases involved in cancer, including several SRC-family kinases. Unlike [imatinib], another tyrosine kinase used for the treatment of CML and Ph-positive ALL, dasatinib inhibits the active and inactive conformations of the ABL kinase domain.[A2226,A11377] Also, mutations in the kinase domain of BCR-ABL may lead to relapse during imatinib treatment. Since dasatinib does not interact with some of the residues involved in those mutations, the use of this drug represents a therapeutic alternative for patients with cancers that have developed imatinib-resistance. The use of dasatinib was first approved by the FDA in 2006.[L45171,L45186] | Moderate | 1 | [
[
[
559,
24,
1213
]
],
[
[
559,
6,
17404
],
[
17404,
45,
1213
]
],
[
[
559,
18,
10375
],
[
10375,
57,
1213
]
],
[
[
559,
21,
28845
],
[
28... | [
[
[
"Estrone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dasatinib"
]
],
[
[
"Estrone",
"{u} (Compound) binds {v} (Gene)",
"ABCG2"
],
[
"ABCG2",
"{u} (Gene) is bound by {v} (Compound)",
"D... | Estrone (Compound) binds ABCG2 (Gene) and ABCG2 (Gene) is bound by Dasatinib (Compound)
Estrone (Compound) downregulates RPS4Y1 (Gene) and RPS4Y1 (Gene) is downregulated by Dasatinib (Compound)
Estrone (Compound) causes Oedema (Side Effect) and Oedema (Side Effect) is caused by Dasatinib (Compound)
Estrone may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib
Estrone may cause a moderate interaction that could exacerbate diseases when taken with Griseofulvin and Griseofulvin may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib
Estrone may cause a moderate interaction that could exacerbate diseases when taken with Prednisolone and Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib
Estrone (Compound) resembles Estrone sulfate (Compound) and Estrone sulfate may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib
Estrone (Compound) resembles Testosterone (Compound) and Testosterone may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib
Estrone may cause a minor interaction that can limit clinical effects when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib |
DB01035 | DB01128 | 1,401 | 918 | [
"DDInter1524",
"DDInter204"
] | Procainamide | Bicalutamide | A derivative of procaine with less CNS action. | Bicalutamide is an oral non-steroidal anti-androgen for prostate cancer. It is comprised of a racemic mixture that is a 50:50 composition of the (R)-bicalutamide and (S)-bicalutamide enantionmers. Bicalutamide binds to the androgen receptor. | Major | 2 | [
[
[
1401,
25,
918
]
],
[
[
1401,
25,
129
],
[
129,
40,
918
]
],
[
[
1401,
6,
12523
],
[
12523,
45,
918
]
],
[
[
1401,
21,
28642
],
[
28642... | [
[
[
"Procainamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bicalutamide"
]
],
[
[
"Procainamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
... | Procainamide may lead to a major life threatening interaction when taken with Enzalutamide and Enzalutamide (Compound) resembles Bicalutamide (Compound)
Procainamide (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Bicalutamide (Compound)
Procainamide (Compound) causes Shock (Side Effect) and Shock (Side Effect) is caused by Bicalutamide (Compound)
Procainamide may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Bicalutamide
Procainamide may lead to a major life threatening interaction when taken with Lapatinib and Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Bicalutamide
Procainamide may lead to a major life threatening interaction when taken with Pentamidine and Pentamidine may cause a moderate interaction that could exacerbate diseases when taken with Bicalutamide
Procainamide may cause a moderate interaction that could exacerbate diseases when taken with Loperamide and Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Bicalutamide
Procainamide may lead to a major life threatening interaction when taken with Primaquine and Primaquine may cause a moderate interaction that could exacerbate diseases when taken with Bicalutamide
Procainamide may cause a moderate interaction that could exacerbate diseases when taken with Mineral oil and Mineral oil may cause a moderate interaction that could exacerbate diseases when taken with Bicalutamide |
DB01211 | DB15035 | 609 | 503 | [
"DDInter393",
"DDInter1959"
] | Clarithromycin | Zanubrutinib | Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarithromycin may be bacteriostatic or bactericidal depending on the organism and drug concentration. | Zanubrutinib is a novel Bruton's tyrosine kinase (BTK) inhibitor used for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. Mantle cell lymphoma is an aggressive mature B-cell non-Hodgkin lymphoma associated with early relapse, poor clinical outcomes, and long-term survival. BTK is an enzyme that plays a role in oncogenic signalling pathways, promoting the survival and proliferation of malignant B cells. Compared to the first-generation BTK inhibitor [ibrutinib], zanubrutinib displays higher potency and selectivity for BTK with fewer off-target effects. Due to this enhanced selectivity towards BTK, zanubrutinib belongs to the second-generation BTK inhibitor drug group that also includes [acalabrutinib], which was approved by the FDA in 2017. Zanubrutinib was granted accelerated approval by the FDA in November 2019 based on clinical trial results that demonstrated an 84% overall response rate from zanubrutinib therapy in patients with MCL, which measures the proportion of patients in a trial whose tumour is entirely or partially destroyed by a drug. It is currently marketed under the trade name BRUKINSA™ and is available as oral capsules. In August 2021, the FDA granted accelerated approval to zanubrutinib for the treatment of adults with Waldenström’s macroglobulinemia. This indication is valid in the US, Europe, and Canada. In September 2021, zanubrutinib was granted another accelerated approval for the treatment of relapsed or refractory marginal zone lymphoma who have received at least one anti-CD20-based regimen. In October 2022, the EMA's Committee for Medicinal Products for Human Use (CHMP) recommended zanubrutinib be granted marketing authorization for the treatment of chronic lymphocytic leukemia. | Major | 2 | [
[
[
609,
25,
503
]
],
[
[
609,
25,
982
],
[
982,
24,
503
]
],
[
[
609,
62,
222
],
[
222,
24,
503
]
],
[
[
609,
63,
1324
],
[
1324,
2... | [
[
[
"Clarithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Zanubrutinib"
]
],
[
[
"Clarithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivosidenib"
],
[
"Ivosidenib",
... | Clarithromycin may lead to a major life threatening interaction when taken with Ivosidenib and Ivosidenib may cause a moderate interaction that could exacerbate diseases when taken with Zanubrutinib
Clarithromycin may cause a minor interaction that can limit clinical effects when taken with Sibutramine and Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Zanubrutinib
Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone and Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Zanubrutinib
Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Somatrem and Somatrem may cause a moderate interaction that could exacerbate diseases when taken with Zanubrutinib
Clarithromycin may lead to a major life threatening interaction when taken with Panobinostat and Panobinostat may lead to a major life threatening interaction when taken with Zanubrutinib
Clarithromycin may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may lead to a major life threatening interaction when taken with Zanubrutinib
Clarithromycin may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Zanubrutinib
Clarithromycin may cause a minor interaction that can limit clinical effects when taken with Fluconazole and Fluconazole may lead to a major life threatening interaction when taken with Zanubrutinib
Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may lead to a major life threatening interaction when taken with Zanubrutinib |
DB00635 | DB00876 | 1,573 | 1,414 | [
"DDInter1515",
"DDInter658"
] | Prednisone | Eprosartan | A synthetic anti-inflammatory glucocorticoid derived from [cortisone]. It is biologically inert and converted to [prednisolone] in the liver. Prednisone was granted FDA approval on 21 February 1955. | Eprosartan is an angiotensin II receptor antagonist used to treat hypertension. It performs 2 actions on the renin angiotensin system. By preventing the binding of angiotensin II to AT1, vascular smooth muscle relaxes and vasodilation occurs. By inhibiting norepinephrine production, blood pressure is further reduced. | Moderate | 1 | [
[
[
1573,
24,
1414
]
],
[
[
1573,
24,
240
],
[
240,
40,
1414
]
],
[
[
1573,
21,
28957
],
[
28957,
60,
1414
]
],
[
[
1573,
63,
176
],
[
176... | [
[
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eprosartan"
]
],
[
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Losartan"
],
[
... | Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Losartan and Losartan (Compound) resembles Eprosartan (Compound)
Prednisone (Compound) causes Arthralgia (Side Effect) and Arthralgia (Side Effect) is caused by Eprosartan (Compound)
Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Insulin glargine and Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Eprosartan
Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Eprosartan
Prednisone (Compound) resembles Triamcinolone (Compound) and Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Eprosartan
Prednisone (Compound) resembles Budesonide (Compound) and Budesonide may cause a moderate interaction that could exacerbate diseases when taken with Eprosartan
Prednisone (Compound) resembles Fludrocortisone (Compound) and Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Eprosartan
Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Eprosartan
Prednisone may lead to a major life threatening interaction when taken with Bupropion and Bupropion may cause a moderate interaction that could exacerbate diseases when taken with Eprosartan |
DB00816 | DB01177 | 1,674 | 77 | [
"DDInter1346",
"DDInter904"
] | Orciprenaline | Idarubicin | A beta-adrenergic agonist used in the treatment of asthma and bronchospasms. [PubChem] | An orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity. | Moderate | 1 | [
[
[
1674,
24,
77
]
],
[
[
1674,
7,
1917
],
[
1917,
57,
77
]
],
[
[
1674,
21,
28987
],
[
28987,
60,
77
]
],
[
[
1674,
24,
739
],
[
739,
... | [
[
[
"Orciprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idarubicin"
]
],
[
[
"Orciprenaline",
"{u} (Compound) upregulates {v} (Gene)",
"CDC25B"
],
[
"CDC25B",
"{u} (Gene) is downregulated... | Orciprenaline (Compound) upregulates CDC25B (Gene) and CDC25B (Gene) is downregulated by Idarubicin (Compound)
Orciprenaline (Compound) causes Chills (Side Effect) and Chills (Side Effect) is caused by Idarubicin (Compound)
Orciprenaline may cause a moderate interaction that could exacerbate diseases when taken with Lomefloxacin and Lomefloxacin may cause a minor interaction that can limit clinical effects when taken with Idarubicin
Orciprenaline may cause a moderate interaction that could exacerbate diseases when taken with Triclabendazole and Triclabendazole may cause a moderate interaction that could exacerbate diseases when taken with Idarubicin
Orciprenaline may cause a moderate interaction that could exacerbate diseases when taken with Bicalutamide and Bicalutamide may cause a moderate interaction that could exacerbate diseases when taken with Idarubicin
Orciprenaline may cause a moderate interaction that could exacerbate diseases when taken with Tramadol and Tramadol may cause a moderate interaction that could exacerbate diseases when taken with Idarubicin
Orciprenaline (Compound) resembles Isoprenaline (Compound) and Orciprenaline may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline and Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Idarubicin
Orciprenaline may lead to a major life threatening interaction when taken with Gatifloxacin and Gatifloxacin may lead to a major life threatening interaction when taken with Idarubicin
Orciprenaline may lead to a major life threatening interaction when taken with Saquinavir and Saquinavir may lead to a major life threatening interaction when taken with Idarubicin |
DB00289 | DB08865 | 847 | 1,593 | [
"DDInter132",
"DDInter448"
] | Atomoxetine | Crizotinib | Atomoxetine is a selective norepinephrine (NE) reuptake inhibitor used for the treatment of attention deficit hyperactivity disorder (ADHD). Also known as the marketed product Strattera, atomoxetine is used with other treatment modalities (psychological, educational, cognitive behaviour therapy, etc) to improve developmentally inappropriate symptoms associated with ADHD including distractibility, short attention span, hyperactivity, emotional lability, and impulsivity. Although the underlying pathophysiology that causes ADHD remains unclear, evidence suggests that dysregulation in noradrenergic and dopaminergic pathways plays a critical role in suboptimal executive functioning within prefrontal regions of the brain, which are involved in attention and memory. Atomoxetine has been shown to specifically increase NA and DA within the prefrontal cortex, but not in the nucleus accumbens (NA) or striatum. This is beneficial in the treatment of ADHD as DA activation in the subcortical NA and stri | Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-associated protein-like 4 (EML4)-ALK fusion protein, crizotinib offers robust effectiveness in treating NSCLC in patients with this type of rearrangement. Crizotinib was the first-in-class drug used to treat ALK-positive tumors. Second- and third-generation ALK-tyrosine kinase-inhibitors have overcome many of the pharmacodynamic and genetic resistance mechanisms crizotinib is prone to. Crizotinib was approved by the FDA in 2011, and its use is accompanied by FDA-approved tests used to detect ALK and ROS1 rearrangements. | Major | 2 | [
[
[
847,
25,
1593
]
],
[
[
847,
6,
8374
],
[
8374,
45,
1593
]
],
[
[
847,
18,
1903
],
[
1903,
57,
1593
]
],
[
[
847,
21,
29093
],
[
29093,... | [
[
[
"Atomoxetine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Crizotinib"
]
],
[
[
"Atomoxetine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Crizo... | Atomoxetine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Crizotinib (Compound)
Atomoxetine (Compound) downregulates FABP5 (Gene) and FABP5 (Gene) is downregulated by Crizotinib (Compound)
Atomoxetine (Compound) causes Fatigue (Side Effect) and Fatigue (Side Effect) is caused by Crizotinib (Compound)
Atomoxetine (Compound) resembles Modafinil (Compound) and Modafinil may cause a minor interaction that can limit clinical effects when taken with Crizotinib
Atomoxetine may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib may cause a minor interaction that can limit clinical effects when taken with Crizotinib
Atomoxetine may cause a moderate interaction that could exacerbate diseases when taken with Gefitinib and Gefitinib may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib
Atomoxetine may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide and Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib
Atomoxetine may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli and Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib
Atomoxetine (Compound) resembles Tolterodine (Compound) and Tolterodine may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib |
DB00978 | DB01268 | 739 | 1,151 | [
"DDInter1084",
"DDInter1731"
] | Lomefloxacin | Sunitinib | Lomefloxacin is a fluoroquinolone antibiotic, used to treat bacterial infections including bronchitis and urinary tract infections (UTIs). Additionally, it has been employed for the prophylaxis of UTIs prior to surgery as well. | Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally available as an orally administered formulation. Sunitinib inhibits cellular signaling by targeting multiple RTKs. These include all platelet-derived growth factor receptors (PDGF-R) and vascular endothelial growth factor receptors (VEGF-R). Sunitinib also inhibits KIT (CD117), the RTK that drives the majority of GISTs. In addition, sunitinib inhibits other RTKs including RET, CSF-1R, and flt3. | Moderate | 1 | [
[
[
739,
24,
1151
]
],
[
[
739,
6,
5912
],
[
5912,
45,
1151
]
],
[
[
739,
21,
29662
],
[
29662,
60,
1151
]
],
[
[
739,
62,
112
],
[
112,
... | [
[
[
"Lomefloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sunitinib"
]
],
[
[
"Lomefloxacin",
"{u} (Compound) binds {v} (Gene)",
"ABCC2"
],
[
"ABCC2",
"{u} (Gene) is bound by {v} (Compound)"... | Lomefloxacin (Compound) binds ABCC2 (Gene) and ABCC2 (Gene) is bound by Sunitinib (Compound)
Lomefloxacin (Compound) causes Candida infection (Side Effect) and Candida infection (Side Effect) is caused by Sunitinib (Compound)
Lomefloxacin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Sunitinib
Lomefloxacin may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline and Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib
Lomefloxacin may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib and Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib
Lomefloxacin may lead to a major life threatening interaction when taken with Insulin degludec and Insulin degludec may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib
Lomefloxacin may cause a minor interaction that can limit clinical effects when taken with Tioguanine and Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib
Lomefloxacin may lead to a major life threatening interaction when taken with Insulin lispro and Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib
Lomefloxacin may cause a moderate interaction that could exacerbate diseases when taken with Quinine and Quinine may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib |
DB01142 | DB15982 | 1,264 | 1,339 | [
"DDInter593",
"DDInter193"
] | Doxepin | Berotralstat | Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepressant but it is commonly associated with the class since it shares a lot of properties with members of the drug family including [amitriptyline], [clomipramine], [desipramine], [imipramine], [nortriptyline], [protriptyline] and [trimipramine]. Doxepin was developed by Pfizer and FDA approved in 1969 as an antidepressant. However, in 2010 it was approved for the treatment of insomnia. The latter | Berotralstat is a selective inhibitor of plasma kallikrein used in the prophylaxis of attacks of hereditary angioedema (HAE). It works by blocking the enzymatic activity of plasma kallikrein in releasing bradykinin, the major biologic peptide that promotes swelling and pain associated with attacks of HAE. Berotralstat is strictly used to prevent, but not treat, these attacks. Developed by BioCryst Pharmaceuticals, berotralstat is marketed under the name Orladeyo as oral capsules. Berotralstat was first approved by the FDA on December 3, 2020, as the first once-daily oral therapy to prevent angioedema attacks of HAE in adults and pediatric patients 12 years and older. Berotralstat was approved by the European Commission on April 30, 2021 and by Health Canada on June 06, 2022. | Moderate | 1 | [
[
[
1264,
24,
1339
]
],
[
[
1264,
64,
222
],
[
222,
23,
1339
]
],
[
[
1264,
24,
283
],
[
283,
23,
1339
]
],
[
[
1264,
24,
1213
],
[
1213,
... | [
[
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Berotralstat"
]
],
[
[
"Doxepin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sibutramine"
],
[
"Sibutramine",... | Doxepin may lead to a major life threatening interaction when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Berotralstat
Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib may cause a minor interaction that can limit clinical effects when taken with Berotralstat
Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Berotralstat
Doxepin may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Berotralstat
Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Daunorubicin and Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Berotralstat
Doxepin may lead to a major life threatening interaction when taken with Granisetron and Granisetron may cause a moderate interaction that could exacerbate diseases when taken with Berotralstat
Doxepin (Compound) resembles Diphenhydramine (Compound) and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Berotralstat
Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Cobicistat and Cobicistat may lead to a major life threatening interaction when taken with Berotralstat
Doxepin may lead to a major life threatening interaction when taken with Vemurafenib and Vemurafenib may lead to a major life threatening interaction when taken with Berotralstat |
DB00041 | DB08904 | 1,648 | 375 | [
"DDInter38",
"DDInter342"
] | Aldesleukin | Certolizumab pegol | Aldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression clone encodes a modified human interleukin-2. This recombinant form differs from native interleukin-2 in the following ways: a) Aldesleukin is not glycosylated because it is derived from E. coli; b) the molecule has no N-terminal alanine; the codon for this amino acid was deleted during the genetic engineering procedure; c) the molecule has serine substituted for cysteine at amino acid position 125. | Certolizumab pegol is a pegylated monoclonal antibody against the tumor necrosis factor-alpha (TNF-alpha). It is formed with a humanized Fab fragment of 50 kDa, from an IgG 1 isotype, fused to a 40 kDa polyethylene glycol moiety replacing the Fc antibody region. The absence of the Fc region was ideated to prevent complement fixation and antibody-mediated cytotoxicity as well as to markedly increase its half-life. Certolizumab does not require glycosylation for active function and hence, its production is significantly more affordable when compared to other existing TNF-alpha therapies as it can be done directly in bacterial hosts such as _E. coli_. It was developed and manufactured by UCB Pharma, first FDA approved in 2008 and updated for a new indication on March 28, 2019. | Major | 2 | [
[
[
1648,
25,
375
]
],
[
[
1648,
24,
704
],
[
704,
24,
375
]
],
[
[
1648,
24,
200
],
[
200,
63,
375
]
],
[
[
1648,
25,
367
],
[
367,
... | [
[
[
"Aldesleukin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fentanyl"
],
[
"Fe... | Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Fentanyl and Fentanyl may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans and Candida albicans may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol
Aldesleukin may lead to a major life threatening interaction when taken with Interferon alfacon-1 and Interferon alfacon-1 may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol
Aldesleukin may lead to a major life threatening interaction when taken with Interferon alfa-n1 and Interferon alfa-n1 may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol
Aldesleukin may lead to a major life threatening interaction when taken with Natalizumab and Natalizumab may lead to a major life threatening interaction when taken with Certolizumab pegol
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Carmustine and Carmustine may lead to a major life threatening interaction when taken with Certolizumab pegol
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Naxitamab and Naxitamab may lead to a major life threatening interaction when taken with Certolizumab pegol
Aldesleukin may lead to a major life threatening interaction when taken with Rotavirus vaccine and Rotavirus vaccine may lead to a major life threatening interaction when taken with Certolizumab pegol
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli and Asparaginase Escherichia coli may lead to a major life threatening interaction when taken with Certolizumab pegol |
DB00398 | DB06402 | 79 | 1,079 | [
"DDInter1702",
"DDInter1756"
] | Sorafenib | Telavancin | Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular carcinoma, sorafenib is also indicated to treat renal carcinoma and differentiated thyroid carcinoma. | Telavancin is a semi-synthetic derivative of vanocymycin that has bactericidal activity against Methicillin-resistant Staphylococcus aureus (MRSA) and other gram-positive bacteria. MRSA is an important pathogen capable of causing hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), and skin and subcutaneous tissue infections among others. | Moderate | 1 | [
[
[
79,
24,
1079
]
],
[
[
79,
24,
968
],
[
968,
40,
1079
]
],
[
[
79,
21,
28750
],
[
28750,
60,
1079
]
],
[
[
79,
23,
112
],
[
112,
... | [
[
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telavancin"
]
],
[
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oritavancin"
],
[
... | Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Oritavancin and Oritavancin (Compound) resembles Telavancin (Compound)
Sorafenib (Compound) causes Abdominal discomfort (Side Effect) and Abdominal discomfort (Side Effect) is caused by Telavancin (Compound)
Sorafenib may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Telavancin
Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Castor oil and Castor oil may cause a moderate interaction that could exacerbate diseases when taken with Telavancin
Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Loperamide and Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Telavancin
Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Terfenadine and Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Telavancin
Sorafenib may lead to a major life threatening interaction when taken with Vemurafenib and Vemurafenib may lead to a major life threatening interaction when taken with Telavancin
Sorafenib may lead to a major life threatening interaction when taken with Dolasetron and Dolasetron may lead to a major life threatening interaction when taken with Telavancin
Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus may lead to a major life threatening interaction when taken with Telavancin |
DB00976 | DB05812 | 1,056 | 1,374 | [
"DDInter1758",
"DDInter8"
] | Telithromycin | Abiraterone | Telithromycin, a semi-synthetic erythromycin derivative, belongs to a new chemical class of antibiotics called ketolides. Ketolides have been recently added to the macrolide-lincosamide-streptogramin class of antibiotics. Similar to the macrolide antibiotics, telithromycin prevents bacterial growth by interfering with bacterial protein synthesis. Telithromycin binds to the 50S subunit of the 70S bacterial ribosome and blocks further peptide elongation. Binding occurs simultaneously at to two domains of 23S RNA of the 50S ribosomal subunit, domain II and V, where older macrolides bind only to one. It is used to treat mild to moderate respiratory infections. | Abiraterone is a potent, irreversible, and selective inhibitor of 17 αhydroxylase/C17,20-lyase (CYP17), an enzyme expressed in testicular, adrenal, and prostatic tumour tissues, to regulate androgen biosynthesis.[A3811, A260880, L40968] Abiraterone was first approved by the FDA and EMA on April, July, and September 2011, respectively. It is used to treat metastatic castration-resistant prostate cancer and hormone-sensitive high-risk metastatic prostate cancer.[L40968, L40193, L47740, L47745] As abiraterone has poor oral bioavailability and is susceptible to hydrolysis by esterases, abiraterone acetate was developed as an orally bioavailable prodrug with enhanced stability and absorption.[A3811, A260835] | Moderate | 1 | [
[
[
1056,
24,
1374
]
],
[
[
1056,
6,
12523
],
[
12523,
45,
1374
]
],
[
[
1056,
21,
29113
],
[
29113,
60,
1374
]
],
[
[
1056,
24,
466
],
[
... | [
[
[
"Telithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abiraterone"
]
],
[
[
"Telithromycin",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Comp... | Telithromycin (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Abiraterone (Compound)
Telithromycin (Compound) causes Hypokalaemia (Side Effect) and Hypokalaemia (Side Effect) is caused by Abiraterone (Compound)
Telithromycin may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Abiraterone
Telithromycin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Abiraterone
Telithromycin may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Abiraterone
Telithromycin may lead to a major life threatening interaction when taken with Apixaban and Apixaban may cause a moderate interaction that could exacerbate diseases when taken with Abiraterone
Telithromycin may cause a moderate interaction that could exacerbate diseases when taken with Palonosetron and Palonosetron may cause a moderate interaction that could exacerbate diseases when taken with Abiraterone
Telithromycin may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Abiraterone
Telithromycin may lead to a major life threatening interaction when taken with Quinine and Quinine may cause a moderate interaction that could exacerbate diseases when taken with Abiraterone |
DB00367 | DB00414 | 566 | 590 | [
"DDInter1061",
"DDInter16"
] | Levonorgestrel | Acetohexamide | Levonorgestrel (LNG) is a synthetic progestogen similar to [Progesterone] used in contraception and hormone therapy.[A181988,T659] Also known as Plan B, it is used as a single agent in emergency contraception, and as a hormonal contraceptive released from an intrauterine device, commonly referred to as an IUD. Some of these devices are known as Jaydess, Kyleena, and Mirena. A subdermal implant of levonorgestrel that slowly releases the hormone over a long-term period is also available. In addition to the above uses, levonorgestrel is used as a component of long-term combination contraceptives.[A181991,L7760,L7778] Globally, levonorgestrel is the most commonly used emergency contraceptive. It was initially granted FDA approval in 1982 and was the first emergency contraceptive containing only progesterone, showing high levels of efficacy and a lack of estrogen | A sulfonylurea hypoglycemic agent that is metabolized in the liver to 1-hydrohexamide. Acetohexamide has been discontinued in the US market. | Moderate | 1 | [
[
[
566,
24,
590
]
],
[
[
566,
24,
1017
],
[
1017,
63,
590
]
],
[
[
566,
40,
989
],
[
989,
24,
590
]
],
[
[
566,
40,
1197
],
[
1197,
... | [
[
[
"Levonorgestrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetohexamide"
]
],
[
[
"Levonorgestrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
... | Levonorgestrel may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Acetohexamide
Levonorgestrel (Compound) resembles Progesterone (Compound) and Progesterone may cause a moderate interaction that could exacerbate diseases when taken with Acetohexamide
Levonorgestrel (Compound) resembles Norethisterone (Compound) and Norethisterone may cause a moderate interaction that could exacerbate diseases when taken with Acetohexamide
Levonorgestrel may cause a moderate interaction that could exacerbate diseases when taken with Insulin glargine and Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Acetohexamide
Levonorgestrel (Compound) resembles Danazol (Compound) and Danazol may cause a moderate interaction that could exacerbate diseases when taken with Acetohexamide
Levonorgestrel may lead to a major life threatening interaction when taken with Lumacaftor and Lumacaftor may cause a moderate interaction that could exacerbate diseases when taken with Acetohexamide
Levonorgestrel may lead to a major life threatening interaction when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Acetohexamide
Levonorgestrel (Compound) resembles Etonogestrel (Compound) and Etonogestrel may cause a moderate interaction that could exacerbate diseases when taken with Acetohexamide
Levonorgestrel may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may lead to a major life threatening interaction when taken with Acetohexamide |
DB00697 | DB01259 | 876 | 392 | [
"DDInter1821",
"DDInter1024"
] | Tizanidine | Lapatinib | Tizanidine is a fast-acting drug used for the management of muscle spasm, which may result from the effects of multiple sclerosis, stroke, an acquired brain injury, or a spinal cord injury. It may also be caused by musculoskeletal injury. Regardless of the cause, muscle spasticity can be an extremely painful and debilitating condition. Initially approved by the FDA in 1996, tizanidine is an Alpha-2 adrenergic receptor agonist reducing spasticity by the presynaptic inhibition of excitatory neurotransmitters that cause firing of neurons promoting muscle spasm [FDA label]. | Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a human epidermal growth factor receptor type 2 (HER2/ERBB2) and epidermal growth factor receptor (HER1/EGFR/ERBB1) tyrosine kinases inhibitor. It binds to the intracellular phosphorylation domain to prevent receptor autophosphorylation upon ligand binding. | Moderate | 1 | [
[
[
876,
24,
392
]
],
[
[
876,
18,
10780
],
[
10780,
46,
392
]
],
[
[
876,
21,
29539
],
[
29539,
60,
392
]
],
[
[
876,
23,
112
],
[
112,
... | [
[
[
"Tizanidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapatinib"
]
],
[
[
"Tizanidine",
"{u} (Compound) downregulates {v} (Gene)",
"CCNB2"
],
[
"CCNB2",
"{u} (Gene) is upregulated by {v} (... | Tizanidine (Compound) downregulates CCNB2 (Gene) and CCNB2 (Gene) is upregulated by Lapatinib (Compound)
Tizanidine (Compound) causes Hepatotoxicity (Side Effect) and Hepatotoxicity (Side Effect) is caused by Lapatinib (Compound)
Tizanidine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Lapatinib
Tizanidine may cause a moderate interaction that could exacerbate diseases when taken with Bicalutamide and Bicalutamide may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib
Tizanidine may cause a moderate interaction that could exacerbate diseases when taken with Mefloquine and Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib
Tizanidine may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib and Sunitinib may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib
Tizanidine may lead to a major life threatening interaction when taken with Cimetidine and Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib
Tizanidine may lead to a major life threatening interaction when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib
Tizanidine may lead to a major life threatening interaction when taken with Primaquine and Primaquine may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib |
DB01045 | DB11837 | 463 | 1,297 | [
"DDInter1590",
"DDInter1351"
] | Rifampicin | Osilodrostat | A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160) | Osilodrostat is an inhibitor of 11β-hydroxylase (also referred to as CYP11B1), the enzyme that catalyzes the final step in the biosynthesis of endogenous cortisol. It is used to lower circulating cortisol levels in the treatment of Cushing's disease, a disorder in which cortisol levels are chronically and supraphysiologically elevated. Cushing's disease is often the result of ACTH hypersecretion secondary to a pituitary tumor, and surgical resection of the tumour is generally the treatment of choice. As an orally bioavailable drug therapy, osilodrostat provides a novel treatment option for patients in whom removal of the causative tumor is not an option or for whom previous pituitary surgery has not been curative. Osilodrostat is manufactured by Novartis under the brand name Isturisa. It has undergone phase II clinical trials for the treatment of solid tumours, hypertension, and heart failure, but development for these indications was discontinued by Novartis in January 2013. Osilodrostat was approved for use in the EU in January 2020 for the treatment of endogenous Cushing's syndrome (i.e. Cushing's disease), and was granted FDA approval and Orphan Drug designation in the US in March 2020 for the same indication. | Major | 2 | [
[
[
463,
25,
1297
]
],
[
[
463,
25,
1135
],
[
1135,
23,
1297
]
],
[
[
463,
63,
112
],
[
112,
23,
1297
]
],
[
[
463,
25,
466
],
[
466,
... | [
[
[
"Rifampicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osilodrostat"
]
],
[
[
"Rifampicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{u} m... | Rifampicin may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Osilodrostat
Rifampicin may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Osilodrostat
Rifampicin may lead to a major life threatening interaction when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Osilodrostat
Rifampicin may lead to a major life threatening interaction when taken with Elagolix and Elagolix may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat
Rifampicin may lead to a major life threatening interaction when taken with Ticagrelor and Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat
Rifampicin may lead to a major life threatening interaction when taken with Quinine and Quinine may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat
Rifampicin may cause a moderate interaction that could exacerbate diseases when taken with Pantoprazole and Pantoprazole may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat
Rifampicin may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide and Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat
Rifampicin may cause a minor interaction that can limit clinical effects when taken with Lidocaine and Lidocaine may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat |
DB09272 | DB11130 | 412 | 407 | [
"DDInter632",
"DDInter1344"
] | Eluxadoline | Opium | Eluxadoline is a mixed mu-opioid receptor agonist, kappa-opioid receptor agonist, and a-delta opioid receptor antagonist indicated for use in diarrhea-predominant irritable bowel syndrome (IBS-D). The mu-, kappa-, and delta-opioid receptors mediate endogenous and exogenous opioid response in the central nervous system and peripherally in the gastrointestinal system. Agonism of peripheral mu-opioid receptors results in reduced colonic motility, while antagonism of central delta-opioid receptors results in improved analgesia, making eluxadoline usable for the symptoms of both pain and diarrhea characteristic of IBS-D. Marketed under the tradename Viberzi (FDA), eluxadoline is an antimotility agent that decreases bowel contractions, inhibits colonic transit, and reduces fluid/ion secretion resulting in improved symptoms of abdominal pain and reductions in the Bristol Stool Scale. | Opium is the first substance of the diverse group of the opiates. It has been known for a long time, and the first evidence of a poppy culture dates from 5 thousand years by the Sumerians. During the years, opium was used as a sedative and hypnotic, but it was determined to be addictive. Opium is extracted from _Papaver somniferum_, which is more known as poppies. This plant is an integrant of the Papaveraceae family, and it is characterized by solitary leaves and capsulated fruits. Therefore, opium is a sticky brown resin obtained by collecting and drying the latex that exudes from the poppy pods. Once extracted, opium contains two main groups of alkaloids; the psychoactive constituents which are in the category of phenanthrenes and alkaloids that have no central nervous system effect in the category of isoquinolines. Morphine is the most prevalent and principal alkaloid in opium, and it is responsible for most of the harmful effects of opium. Opium has gradually been superseded by a variety of synthetic opioids and general anesthetics. Some of the isolated derivatives of opium are morphine, noscapine, strychnine, veratrine, colchicine, codeine, and quinine. Opium is a prohibited drug of abuse in most countries, but the illegal production of this drug and its derivatives keeps being registered. There is some legal production of opium in different countries for the obtention of alkaloids by extraction. | Moderate | 1 | [
[
[
412,
24,
407
]
],
[
[
412,
63,
662
],
[
662,
24,
407
]
],
[
[
412,
24,
1536
],
[
1536,
63,
407
]
],
[
[
412,
63,
314
],
[
314,
2... | [
[
[
"Eluxadoline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
]
],
[
[
"Eluxadoline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
],
[
... | Eluxadoline may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Opium
Eluxadoline may cause a moderate interaction that could exacerbate diseases when taken with Belladonna and Belladonna may cause a moderate interaction that could exacerbate diseases when taken with Opium
Eluxadoline may cause a moderate interaction that could exacerbate diseases when taken with Nalbuphine and Nalbuphine may lead to a major life threatening interaction when taken with Opium
Eluxadoline may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Zolpidem and Zolpidem may cause a moderate interaction that could exacerbate diseases when taken with Opium
Eluxadoline may cause a moderate interaction that could exacerbate diseases when taken with Fluvoxamine and Fluvoxamine may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Opium
Eluxadoline may cause a moderate interaction that could exacerbate diseases when taken with Clopidogrel and Clopidogrel may lead to a major life threatening interaction when taken with Fluvoxamine and Fluvoxamine may cause a moderate interaction that could exacerbate diseases when taken with Opium
Eluxadoline may cause a moderate interaction that could exacerbate diseases when taken with Clomipramine and Clomipramine (Compound) resembles Carbinoxamine (Compound) and Clomipramine may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Opium
Eluxadoline may cause a moderate interaction that could exacerbate diseases when taken with Belladonna and Belladonna may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Opium
Eluxadoline may cause a moderate interaction that could exacerbate diseases when taken with Nifedipine and Nifedipine (Compound) resembles Felodipine (Compound) and Felodipine may cause a moderate interaction that could exacerbate diseases when taken with Opium |
DB06589 | DB08827 | 1,250 | 990 | [
"DDInter1400",
"DDInter1085"
] | Pazopanib | Lomitapide | Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009. | Lomitapide is a microsomal triglyceride transfer protein (MTP) inhibitor used in homozygous familial hypercholesterolemia (HoFH) patients. It is marketed under the name Juxtapid (R). | Major | 2 | [
[
[
1250,
25,
990
]
],
[
[
1250,
64,
1080
],
[
1080,
1,
990
]
],
[
[
1250,
6,
8374
],
[
8374,
45,
990
]
],
[
[
1250,
54,
19146
],
[
19146,... | [
[
[
"Pazopanib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lomitapide"
]
],
[
[
"Pazopanib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Conivaptan"
],
[
"Conivaptan",
"{u} (Co... | Pazopanib may lead to a major life threatening interaction when taken with Conivaptan and Conivaptan (Compound) resembles Lomitapide (Compound)
Pazopanib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Lomitapide (Compound)
Pazopanib (Compound) is included by Cytochrome P450 3A4 Inhibitors (Pharmacologic Class) and Cytochrome P450 3A4 Inhibitors (Pharmacologic Class) includes Lomitapide (Compound)
Pazopanib (Compound) causes Dry skin (Side Effect) and Dry skin (Side Effect) is caused by Lomitapide (Compound)
Pazopanib may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Lomitapide
Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel and Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Lomitapide
Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Olaparib and Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Lomitapide
Pazopanib may lead to a major life threatening interaction when taken with Cimetidine and Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Lomitapide
Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin and Midostaurin may cause a moderate interaction that could exacerbate diseases when taken with Lomitapide |
DB00651 | DB00683 | 746 | 1,382 | [
"DDInter613",
"DDInter1212"
] | Dyphylline | Midazolam | Dyphylline is a theophylline derivative with broncho- and vasodilator properties. It is typically used in the management of asthma, cardiac dyspnea, and bronchitis. | Midazolam is a short-acting hypnotic-sedative drug with anxiolytic, muscle relaxant, anticonvulsant, sedative, hypnotic, and amnesic properties. It belongs to a class of drugs called _benzodiazepines_. This drug is unique from others in this class due to its rapid onset of effects and short duration of action. Midazolam is available by oral, rectal, intranasal, intramuscular (IM), and intravenous (IV) routes and has been used in various biomedical applications, including dentistry, cardiac surgery, and endoscopic procedures as pre-anesthetic medication, and as an adjunct to local anesthesia. This drug was initially approved by the US FDA in 1985, and has been approved for various indications since. In late 2018, the intramuscular preparation was approved by the FDA for the treatment of status epilepticus in adults. In May 2019, the nasal spray of midazolam was approved for the acute treatment of distinctive intermittent, stereotypic seizure episodes in patients 12 years of age and older. Midazolam is considered a schedule IV drug in the United States due to the low potential for abuse and low risk of dependence. | Minor | 0 | [
[
[
746,
23,
1382
]
],
[
[
746,
23,
1216
],
[
1216,
40,
1382
]
],
[
[
746,
62,
902
],
[
902,
40,
1382
]
],
[
[
746,
21,
28762
],
[
28762,
... | [
[
[
"Dyphylline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Midazolam"
]
],
[
[
"Dyphylline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Flurazepam"
],
[
"... | Dyphylline may cause a minor interaction that can limit clinical effects when taken with Flurazepam and Flurazepam (Compound) resembles Midazolam (Compound)
Dyphylline may cause a minor interaction that can limit clinical effects when taken with Clobazam and Clobazam (Compound) resembles Midazolam (Compound)
Dyphylline (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Midazolam (Compound)
Dyphylline (Compound) resembles Theophylline (Compound) and Theophylline may cause a minor interaction that can limit clinical effects when taken with Midazolam
Dyphylline may cause a minor interaction that can limit clinical effects when taken with Flurazepam and Flurazepam (Compound) resembles Fludiazepam (Compound) and Fludiazepam (Compound) resembles Midazolam (Compound)
Dyphylline may cause a minor interaction that can limit clinical effects when taken with Clobazam and Clobazam (Compound) resembles Fludiazepam (Compound) and Fludiazepam (Compound) resembles Midazolam (Compound)
Dyphylline (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Flurazepam (Compound) and Flurazepam (Compound) resembles Midazolam (Compound)
Dyphylline (Compound) causes Extrasystoles (Side Effect) and Extrasystoles (Side Effect) is caused by Theophylline (Compound) and Theophylline may cause a minor interaction that can limit clinical effects when taken with Midazolam
Dyphylline (Compound) resembles Theobromine (Compound) and Theobromine (Compound) resembles Theophylline (Compound) and Theophylline may cause a minor interaction that can limit clinical effects when taken with Midazolam |
DB08896 | DB15035 | 292 | 503 | [
"DDInter1576",
"DDInter1959"
] | Regorafenib | Zanubrutinib | Regorafenib is an orally-administered inhibitor of multiple kinases. It is used for the treatment of metastatic colorectal cancer, advanced gastrointestinal stromal tumours, and hepatocellular carcinoma. FDA approved on September 27, 2012. Approved use of Regorafenib was expanded to treat Hepatocellular Carcinoma in April 2017. | Zanubrutinib is a novel Bruton's tyrosine kinase (BTK) inhibitor used for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. Mantle cell lymphoma is an aggressive mature B-cell non-Hodgkin lymphoma associated with early relapse, poor clinical outcomes, and long-term survival. BTK is an enzyme that plays a role in oncogenic signalling pathways, promoting the survival and proliferation of malignant B cells. Compared to the first-generation BTK inhibitor [ibrutinib], zanubrutinib displays higher potency and selectivity for BTK with fewer off-target effects. Due to this enhanced selectivity towards BTK, zanubrutinib belongs to the second-generation BTK inhibitor drug group that also includes [acalabrutinib], which was approved by the FDA in 2017. Zanubrutinib was granted accelerated approval by the FDA in November 2019 based on clinical trial results that demonstrated an 84% overall response rate from zanubrutinib therapy in patients with MCL, which measures the proportion of patients in a trial whose tumour is entirely or partially destroyed by a drug. It is currently marketed under the trade name BRUKINSA™ and is available as oral capsules. In August 2021, the FDA granted accelerated approval to zanubrutinib for the treatment of adults with Waldenström’s macroglobulinemia. This indication is valid in the US, Europe, and Canada. In September 2021, zanubrutinib was granted another accelerated approval for the treatment of relapsed or refractory marginal zone lymphoma who have received at least one anti-CD20-based regimen. In October 2022, the EMA's Committee for Medicinal Products for Human Use (CHMP) recommended zanubrutinib be granted marketing authorization for the treatment of chronic lymphocytic leukemia. | Major | 2 | [
[
[
292,
25,
503
]
],
[
[
292,
63,
222
],
[
222,
24,
503
]
],
[
[
292,
24,
98
],
[
98,
24,
503
]
],
[
[
292,
64,
39
],
[
39,
25,
... | [
[
[
"Regorafenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Zanubrutinib"
]
],
[
[
"Regorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
"Sibut... | Regorafenib may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Zanubrutinib
Regorafenib may cause a moderate interaction that could exacerbate diseases when taken with Somatrem and Somatrem may cause a moderate interaction that could exacerbate diseases when taken with Zanubrutinib
Regorafenib may lead to a major life threatening interaction when taken with Panobinostat and Panobinostat may lead to a major life threatening interaction when taken with Zanubrutinib
Regorafenib may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlatinib may lead to a major life threatening interaction when taken with Zanubrutinib
Regorafenib may lead to a major life threatening interaction when taken with Desirudin and Desirudin may lead to a major life threatening interaction when taken with Zanubrutinib
Regorafenib may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may lead to a major life threatening interaction when taken with Zanubrutinib
Regorafenib may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Regorafenib may lead to a major life threatening interaction when taken with Flurbiprofen and Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Zanubrutinib and Flurbiprofen may lead to a major life threatening interaction when taken with Zanubrutinib
Regorafenib may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone and Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Zanubrutinib
Regorafenib may cause a moderate interaction that could exacerbate diseases when taken with Somatrem and Somatrem may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Zanubrutinib |
DB00584 | DB01069 | 610 | 401 | [
"DDInter638",
"DDInter1533"
] | Enalapril | Promethazine | Enalapril is a prodrug belonging to the angiotensin-converting enzyme (ACE) inhibitor drug class that works on the renin-angiotensin-aldosterone system, which is responsible for the regulation of blood pressure and fluid and electrolyte homeostasis. Enalapril is an orally-active and long-acting nonsulphydryl antihypertensive agent that suppresses the renin-angiotensin-aldosterone system to lower blood pressure. It was developed from a targeted research programmed using molecular modelling. Being a prodrug, enalapril is rapidly biotransformed into its active metabolite, [enalaprilat], which is responsible for the pharmacological actions of enalapril. The active metabolite of enalapril competitively inhibits the ACE to hinder the production of angiotensin II, a key component of the renin-angiotensin-aldosterone system that promotes v | Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946. Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.[A189907,A190153,A190159,A190150,A190171] Promethazine was granted FDA approval before 29 March 1951.[A190177,L4000] | Moderate | 1 | [
[
[
610,
24,
401
]
],
[
[
610,
24,
1264
],
[
1264,
63,
401
]
],
[
[
610,
24,
104
],
[
104,
24,
401
]
],
[
[
610,
6,
4973
],
[
4973,
... | [
[
[
"Enalapril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
]
],
[
[
"Enalapril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
[
... | Enalapril may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Promethazine
Enalapril may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine
Enalapril (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Promethazine (Compound)
Enalapril (Compound) causes Decreased appetite (Side Effect) and Decreased appetite (Side Effect) is caused by Promethazine (Compound)
Enalapril may cause a minor interaction that can limit clinical effects when taken with Magnesium carbonate and Magnesium carbonate may cause a minor interaction that can limit clinical effects when taken with Promethazine
Enalapril (Compound) resembles Captopril (Compound) and Captopril may cause a moderate interaction that could exacerbate diseases when taken with Promethazine
Enalapril may cause a moderate interaction that could exacerbate diseases when taken with Nabilone and Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Promethazine
Enalapril (Compound) resembles Lisinopril (Compound) and Lisinopril may cause a moderate interaction that could exacerbate diseases when taken with Promethazine
Enalapril (Compound) resembles Moexipril (Compound) and Moexipril may cause a moderate interaction that could exacerbate diseases when taken with Promethazine |
DB00277 | DB00357 | 1,031 | 1,051 | [
"DDInter1791",
"DDInter71"
] | Theophylline | Aminoglutethimide | A methylxanthine derivative from tea with diuretic, smooth muscle relaxant, bronchial dilation, cardiac and central nervous system stimulant activities. Mechanistically, theophylline acts as a phosphodiesterase inhibitor, adenosine receptor blocker, and histone deacetylase activator. Theophylline is marketed under several brand names such as Uniphyl and Theochron, and it is indicated mainly for asthma, bronchospasm, and COPD. | An aromatase inhibitor that produces a state of "medical" adrenalectomy by blocking the production of adrenal steroids. It also blocks the conversion of androgens to estrogens. Aminoglutethimide has been used in the treatment of advanced breast and prostate cancer. It was formerly used for its weak anticonvulsant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p454) | Moderate | 1 | [
[
[
1031,
24,
1051
]
],
[
[
1031,
6,
8374
],
[
8374,
45,
1051
]
],
[
[
1031,
21,
28681
],
[
28681,
60,
1051
]
],
[
[
1031,
24,
1056
],
[
1... | [
[
[
"Theophylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aminoglutethimide"
]
],
[
[
"Theophylline",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (... | Theophylline (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Aminoglutethimide (Compound)
Theophylline (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Aminoglutethimide (Compound)
Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Telithromycin and Telithromycin may cause a moderate interaction that could exacerbate diseases when taken with Aminoglutethimide
Theophylline may cause a minor interaction that can limit clinical effects when taken with Atazanavir and Atazanavir may cause a moderate interaction that could exacerbate diseases when taken with Aminoglutethimide
Theophylline may lead to a major life threatening interaction when taken with Riociguat and Riociguat may cause a moderate interaction that could exacerbate diseases when taken with Aminoglutethimide
Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Etonogestrel and Etonogestrel may cause a moderate interaction that could exacerbate diseases when taken with Aminoglutethimide
Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Nelfinavir and Nelfinavir may cause a moderate interaction that could exacerbate diseases when taken with Aminoglutethimide
Theophylline (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Bortezomib (Compound) and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Aminoglutethimide
Theophylline (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Benzocaine (Compound) and Benzocaine (Compound) resembles Aminoglutethimide (Compound) |
DB00559 | DB06603 | 152 | 39 | [
"DDInter223",
"DDInter1387"
] | Bosentan | Panobinostat | Bosentan is a dual endothelin receptor antagonist marketed under the trade name Tracleer by Actelion Pharmaceuticals. Bosentan is used to treat pulmonary hypertension by blocking the action of endothelin molecules that would otherwise promote narrowing of the blood vessels and lead to high blood pressure. | Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress of being conducted. Panobinostat is marketed by Novartis under the brand name Farydak. Panobinostat acts as a non-selective histone deacetylase inhibitor (pan-HDAC inhibitor) and it is the most potent DAC inhibiting agent available on the market. | Moderate | 1 | [
[
[
152,
24,
39
]
],
[
[
152,
24,
112
],
[
112,
23,
39
]
],
[
[
152,
63,
912
],
[
912,
24,
39
]
],
[
[
152,
24,
578
],
[
578,
63,
... | [
[
[
"Bosentan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Panobinostat"
]
],
[
[
"Bosentan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
[
... | Bosentan may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Panobinostat
Bosentan may cause a moderate interaction that could exacerbate diseases when taken with Interferon beta-1a and Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Panobinostat
Bosentan may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Panobinostat
Bosentan may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Panobinostat
Bosentan may lead to a major life threatening interaction when taken with Lorlatinib and Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Panobinostat
Bosentan may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Panobinostat
Bosentan may lead to a major life threatening interaction when taken with Bosutinib and Bosutinib may lead to a major life threatening interaction when taken with Panobinostat
Bosentan may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib and Tofacitinib may lead to a major life threatening interaction when taken with Panobinostat
Bosentan may cause a moderate interaction that could exacerbate diseases when taken with Terfenadine and Terfenadine may lead to a major life threatening interaction when taken with Panobinostat |
DB00863 | DB01066 | 1,194 | 1,462 | [
"DDInter1568",
"DDInter316"
] | Ranitidine | Cefditoren | Ranitidine is a commonly used drug, classified as a histamine H2-receptor antagonist, and belongs to the same drug class as [cimetidine] and [famotidine]. This drug helps to prevent and treat gastric-acid associated conditions, including ulcers, because of its ability to decrease gastric acid secretion.[A176759,L10818] Ranitidine is often referred to as Zantac, and is available in various forms, including tablet, injection, and effervescent tablet preparations.[L10818,F4253] The prevalence of GERD is thought to be 10-20% in western countries. Ranitidine has proven to be an effective treatment for relieving uncomfortable symptoms of gastric acid associated conditions and is therefore widely used in GERD and other gastric-acid related conditions.[A176849,L10818] | Cefditoren is an oral third-generation cephalosporin. It is commonly marketed under the trade name Spectracef by Cornerstone BioPharma. | Moderate | 1 | [
[
[
1194,
24,
1462
]
],
[
[
1194,
24,
665
],
[
665,
40,
1462
]
],
[
[
1194,
23,
115
],
[
115,
63,
1462
]
],
[
[
1194,
63,
126
],
[
126,
... | [
[
[
"Ranitidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cefditoren"
]
],
[
[
"Ranitidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cefuroxime"
],
[
... | Ranitidine may cause a moderate interaction that could exacerbate diseases when taken with Cefuroxime and Cefuroxime (Compound) resembles Cefditoren (Compound)
Ranitidine may cause a minor interaction that can limit clinical effects when taken with Aluminum hydroxide and Aluminum hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Cefditoren
Ranitidine may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Cefditoren
Ranitidine (Compound) resembles Nizatidine (Compound) and Nizatidine may cause a moderate interaction that could exacerbate diseases when taken with Cefditoren
Ranitidine may cause a moderate interaction that could exacerbate diseases when taken with Cefuroxime and Cefuroxime (Compound) resembles Cefepime (Compound) and Cefepime (Compound) resembles Cefditoren (Compound)
Ranitidine may cause a minor interaction that can limit clinical effects when taken with Aluminum hydroxide and Aluminum hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Cefuroxime and Cefuroxime (Compound) resembles Cefditoren (Compound)
Ranitidine may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Cefepime and Cefepime (Compound) resembles Cefditoren (Compound)
Ranitidine (Compound) causes Pneumonia (Side Effect) and Pneumonia (Side Effect) is caused by Cefepime (Compound) and Cefepime (Compound) resembles Cefditoren (Compound)
Ranitidine (Compound) resembles Nizatidine (Compound) and Nizatidine may cause a moderate interaction that could exacerbate diseases when taken with Cefuroxime and Cefuroxime (Compound) resembles Cefditoren (Compound) |
DB00792 | DB06700 | 832 | 643 | [
"DDInter1878",
"DDInter511"
] | Tripelennamine | Desvenlafaxine | A histamine H1 antagonist with low sedative action but frequent gastrointestinal irritation. It is used to treat asthma; HAY fever; urticaria; and rhinitis; and also in veterinary applications. Tripelennamine is administered by various routes, including topically. | Desvenlafaxine (O-desmethylvenlafaxine) is the 0-demetyhlated active metabolite of [venlafaxine]. Like its parent drug, desvenlafaxine is also an antidepressant belonging to the class of serotonin-norepinephrine reuptake inhibitor (SNRI) class.[A261266,A261266] It was approved by the FDA in 2008 for the treatment of adults with major depressive disorder (MDD).[L6016,A261271] MDD is a highly prevalent psychiatric disorder, with a lifetime prevalence estimate of 16% in the US alone and 12.8% in Europe. Although the exact mechanism of pathophysiology is still unknown, imbalances or deficiencies of monoamines have been heavily implicated, thus the rationale behind the use of SNRI to treat MDD. Desvenlafaxine has a very similar pharmacological, efficacy, and safety profile as [venlafaxine]. The major difference is the potential for drug interaction since venlafaxine is mainly metabolized by CYP2D6 while desvenlafaxine is conjugated by UGT; therefore, desvenlafaxine is less likely to cause drug-drug interaction when taken with medications affecting the CYP2D6 pathway. | Moderate | 1 | [
[
[
832,
24,
643
]
],
[
[
832,
63,
1100
],
[
1100,
1,
643
]
],
[
[
832,
24,
1311
],
[
1311,
24,
643
]
],
[
[
832,
63,
530
],
[
530,
... | [
[
[
"Tripelennamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Desvenlafaxine"
]
],
[
[
"Tripelennamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Venlafaxine"
... | Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Venlafaxine and Venlafaxine (Compound) resembles Desvenlafaxine (Compound)
Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Metoclopramide and Metoclopramide may cause a moderate interaction that could exacerbate diseases when taken with Desvenlafaxine
Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Dronabinol and Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Desvenlafaxine
Tripelennamine (Compound) resembles Chlorpheniramine (Compound) and Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine and Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Desvenlafaxine
Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium may cause a moderate interaction that could exacerbate diseases when taken with Desvenlafaxine
Tripelennamine (Compound) resembles Clofedanol (Compound) and Clofedanol may cause a moderate interaction that could exacerbate diseases when taken with Desvenlafaxine
Tripelennamine (Compound) resembles Carbinoxamine (Compound) and Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Desvenlafaxine
Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Dextromethorphan and Dextromethorphan may lead to a major life threatening interaction when taken with Desvenlafaxine
Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Procarbazine and Procarbazine may lead to a major life threatening interaction when taken with Desvenlafaxine |
DB01246 | DB01591 | 820 | 667 | [
"DDInter45",
"DDInter1696"
] | Alimemazine | Solifenacin | A phenothiazine derivative that is used as an antipruritic. | Solifenacin is a competitive muscarinic receptor antagonist indicated to treat an overactive bladder with urinary incontinence, urgency, and frequency. It has a long duration of action as it is usually taken once daily. Solifenacin was granted FDA approval on 19 November 2004. | Moderate | 1 | [
[
[
820,
24,
667
]
],
[
[
820,
40,
11220
],
[
11220,
1,
667
]
],
[
[
820,
6,
8374
],
[
8374,
45,
667
]
],
[
[
820,
21,
28643
],
[
28643,
... | [
[
[
"Alimemazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Solifenacin"
]
],
[
[
"Alimemazine",
"{u} (Compound) resembles {v} (Compound)",
"Mequitazine"
],
[
"Mequitazine",
"{u} (Compound) res... | Alimemazine (Compound) resembles Mequitazine (Compound) and Mequitazine (Compound) resembles Solifenacin (Compound)
Alimemazine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Solifenacin (Compound)
Alimemazine (Compound) causes Infection (Side Effect) and Infection (Side Effect) is caused by Solifenacin (Compound)
Alimemazine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Solifenacin
Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Degarelix and Degarelix may cause a moderate interaction that could exacerbate diseases when taken with Solifenacin
Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib and Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Solifenacin
Alimemazine (Compound) resembles Methdilazine (Compound) and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Solifenacin
Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Propantheline and Propantheline may cause a moderate interaction that could exacerbate diseases when taken with Solifenacin
Alimemazine may lead to a major life threatening interaction when taken with Metoclopramide and Metoclopramide may cause a moderate interaction that could exacerbate diseases when taken with Solifenacin |
DB00377 | DB06589 | 1,494 | 1,250 | [
"DDInter1382",
"DDInter1400"
] | Palonosetron | Pazopanib | Palonosetron (INN, trade name Aloxi) is an antagonist of 5-HT3 receptors that is indicated for the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV). It is the most effective of the 5-HT3 antagonists in controlling delayed CINV nausea and vomiting that appear more than 24 hours after the first dose of a course of chemotherapy and is the only drug of its class approved for this use by the U.S. Food and Drug Administration. As of 2008, it is the most recent 5-HT3 antagonist to enter clinical use. | Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009. | Moderate | 1 | [
[
[
1494,
24,
1250
]
],
[
[
1494,
6,
7950
],
[
7950,
45,
1250
]
],
[
[
1494,
21,
29203
],
[
29203,
60,
1250
]
],
[
[
1494,
23,
1247
],
[
1... | [
[
[
"Palonosetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pazopanib"
]
],
[
[
"Palonosetron",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compound... | Palonosetron (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Pazopanib (Compound)
Palonosetron (Compound) causes Aspartate aminotransferase increased (Side Effect) and Aspartate aminotransferase increased (Side Effect) is caused by Pazopanib (Compound)
Palonosetron may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Pazopanib
Palonosetron may cause a moderate interaction that could exacerbate diseases when taken with Donepezil and Donepezil may cause a minor interaction that can limit clinical effects when taken with Pazopanib
Palonosetron may cause a moderate interaction that could exacerbate diseases when taken with Perphenazine and Perphenazine may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib
Palonosetron may cause a moderate interaction that could exacerbate diseases when taken with Bisacodyl and Bisacodyl may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib
Palonosetron may lead to a major life threatening interaction when taken with Fluoxetine and Fluoxetine may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib
Palonosetron may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib
Palonosetron may lead to a major life threatening interaction when taken with Fluvoxamine and Fluvoxamine may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib |
DB00692 | DB01246 | 274 | 820 | [
"DDInter1448",
"DDInter45"
] | Phentolamine | Alimemazine | Phentolamine is a reversible, non-selective alpha-adrenergic blocker that induces vasodilation. While initially introduced to the market for the treatment of hypertension, this clinical use was halted due to cardiovascular and gastrointestinal adverse effects with the prolonged use of large oral doses of phentolamine.[A261781, A261786] It has several therapeutic uses, including the treatment of hypertensive episodes, prevention of norepinephrine-induced extravasation, diagnosis of pheochromocytoma, reversal of soft-tissue anesthesia, and treatment of pharmacologically-induced mydriasis.[L48420, L48415, L48390] Phentolamine is administered intravenously, intramuscularly, submucosally, and topically. | A phenothiazine derivative that is used as an antipruritic. | Moderate | 1 | [
[
[
274,
24,
820
]
],
[
[
274,
24,
358
],
[
358,
24,
820
]
],
[
[
274,
24,
104
],
[
104,
40,
820
]
],
[
[
274,
63,
675
],
[
675,
25,... | [
[
[
"Phentolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
]
],
[
[
"Phentolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Orphenadrine"
],
... | Phentolamine may cause a moderate interaction that could exacerbate diseases when taken with Orphenadrine and Orphenadrine may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine
Phentolamine may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine (Compound) resembles Alimemazine (Compound)
Phentolamine may cause a moderate interaction that could exacerbate diseases when taken with Dextropropoxyphene and Dextropropoxyphene may lead to a major life threatening interaction when taken with Alimemazine
Phentolamine may cause a moderate interaction that could exacerbate diseases when taken with Promazine and Promazine (Compound) resembles Alimemazine (Compound)
Phentolamine may cause a moderate interaction that could exacerbate diseases when taken with Methotrimeprazine and Methotrimeprazine (Compound) resembles Alimemazine (Compound)
Phentolamine (Compound) causes Nervous system disorder (Side Effect) and Nervous system disorder (Side Effect) is caused by Alimemazine (Compound)
Phentolamine may cause a moderate interaction that could exacerbate diseases when taken with Hydroxyzine and Hydroxyzine may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine
Phentolamine may cause a moderate interaction that could exacerbate diseases when taken with Lithium carbonate and Lithium carbonate may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine
Phentolamine may cause a minor interaction that can limit clinical effects when taken with Insulin glargine and Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine |
DB00683 | DB04868 | 1,382 | 478 | [
"DDInter1212",
"DDInter1293"
] | Midazolam | Nilotinib | Midazolam is a short-acting hypnotic-sedative drug with anxiolytic, muscle relaxant, anticonvulsant, sedative, hypnotic, and amnesic properties. It belongs to a class of drugs called _benzodiazepines_. This drug is unique from others in this class due to its rapid onset of effects and short duration of action. Midazolam is available by oral, rectal, intranasal, intramuscular (IM), and intravenous (IV) routes and has been used in various biomedical applications, including dentistry, cardiac surgery, and endoscopic procedures as pre-anesthetic medication, and as an adjunct to local anesthesia. This drug was initially approved by the US FDA in 1985, and has been approved for various indications since. In late 2018, the intramuscular preparation was approved by the FDA for the treatment of status epilepticus in adults. In May 2019 | Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to treatment with imatinib (Gleevec), another tyrosine kinase inhibitor used as a first-line treatment for CML. | Moderate | 1 | [
[
[
1382,
24,
478
]
],
[
[
1382,
6,
4973
],
[
4973,
45,
478
]
],
[
[
1382,
21,
28963
],
[
28963,
60,
478
]
],
[
[
1382,
24,
1040
],
[
1040... | [
[
[
"Midazolam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
]
],
[
[
"Midazolam",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
... | Midazolam (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Nilotinib (Compound)
Midazolam (Compound) causes Anxiety (Side Effect) and Anxiety (Side Effect) is caused by Nilotinib (Compound)
Midazolam may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib and Dabrafenib may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib
Midazolam may cause a moderate interaction that could exacerbate diseases when taken with Ranitidine and Ranitidine may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib
Midazolam may cause a minor interaction that can limit clinical effects when taken with Methylprednisolone and Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib
Midazolam may cause a minor interaction that can limit clinical effects when taken with Prednisone and Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib
Midazolam (Compound) resembles Clonazepam (Compound) and Clonazepam may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib
Midazolam may cause a moderate interaction that could exacerbate diseases when taken with Anakinra and Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib
Midazolam may cause a minor interaction that can limit clinical effects when taken with Magaldrate and Magaldrate may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib |
DB01181 | DB01206 | 1,532 | 37 | [
"DDInter906",
"DDInter1086"
] | Ifosfamide | Lomustine | Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppressive agent. | An alkylating agent of value against both hematologic malignancies and solid tumors. | Moderate | 1 | [
[
[
1532,
24,
37
]
],
[
[
1532,
5,
11555
],
[
11555,
44,
37
]
],
[
[
1532,
6,
8374
],
[
8374,
45,
37
]
],
[
[
1532,
54,
19138
],
[
19138,
... | [
[
[
"Ifosfamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lomustine"
]
],
[
[
"Ifosfamide",
"{u} (Compound) treats {v} (Disease)",
"hematologic cancer"
],
[
"hematologic cancer",
"{u} (Disease... | Ifosfamide (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Lomustine (Compound)
Ifosfamide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Lomustine (Compound)
Ifosfamide (Compound) is included by Alkylating Activity (Pharmacologic Class) and Alkylating Activity (Pharmacologic Class) includes Lomustine (Compound)
Ifosfamide (Compound) causes Visual impairment (Side Effect) and Visual impairment (Side Effect) is caused by Lomustine (Compound)
Ifosfamide may cause a minor interaction that can limit clinical effects when taken with Moxifloxacin and Moxifloxacin may cause a minor interaction that can limit clinical effects when taken with Lomustine
Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Grepafloxacin and Grepafloxacin may cause a minor interaction that can limit clinical effects when taken with Lomustine
Ifosfamide may cause a minor interaction that can limit clinical effects when taken with Delafloxacin and Delafloxacin may cause a minor interaction that can limit clinical effects when taken with Lomustine
Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Filgrastim and Filgrastim may cause a moderate interaction that could exacerbate diseases when taken with Lomustine
Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Radium Ra 223 dichloride and Radium Ra 223 dichloride may cause a moderate interaction that could exacerbate diseases when taken with Lomustine |
DB00807 | DB06608 | 1,120 | 1,185 | [
"DDInter1536",
"DDInter1739"
] | Proparacaine (ophthalmic) | Tafenoquine | Proparacaine is a benzoate ester. | Tafenoquine is an 8-aminoquinoline analogue of primaquine which varies only on the presence of a 5-phenoxy group.[A35671, A35690] It was discovered by the scientists at the Walter Reed Army Institute of Research in 1978 as a substitute for primaquine that would be more effective against relapsing vivax malaria. Tafenoquine was further developed collaboratively between GlaxoSmithKline and Medicines for Malaria Venture. It was FDA approved on July 20, 2018. | Moderate | 1 | [
[
[
1120,
24,
1185
]
],
[
[
1120,
24,
1520
],
[
1520,
63,
10
],
[
10,
24,
1185
]
],
[
[
1120,
1,
33
],
[
33,
63,
10
],
[
10,
24,
1... | [
[
[
"Proparacaine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tafenoquine"
]
],
[
[
"Proparacaine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Primaquine"
],
... | Proparacaine may cause a moderate interaction that could exacerbate diseases when taken with Tafenoquine
Proparacaine may cause a moderate interaction that could exacerbate diseases when taken with Primaquine and Primaquine may cause a moderate interaction that could exacerbate diseases when taken with Dapsone and Dapsone may cause a moderate interaction that could exacerbate diseases when taken with Tafenoquine
Proparacaine (Compound) resembles Amiodarone (Compound) and Amiodarone may cause a moderate interaction that could exacerbate diseases when taken with Dapsone and Dapsone may cause a moderate interaction that could exacerbate diseases when taken with Tafenoquine
Proparacaine may cause a moderate interaction that could exacerbate diseases when taken with Primaquine and Primaquine may lead to a major life threatening interaction when taken with Dofetilide and Dofetilide may lead to a major life threatening interaction when taken with Tafenoquine
Proparacaine may cause a moderate interaction that could exacerbate diseases when taken with Quinine and Quinine may cause a moderate interaction that could exacerbate diseases when taken with Dapsone and Dapsone may cause a moderate interaction that could exacerbate diseases when taken with Tafenoquine
Proparacaine may cause a moderate interaction that could exacerbate diseases when taken with Quinine and Quinine may lead to a major life threatening interaction when taken with Dofetilide and Dofetilide may lead to a major life threatening interaction when taken with Tafenoquine
Proparacaine may cause a moderate interaction that could exacerbate diseases when taken with Primaquine and Primaquine may lead to a major life threatening interaction when taken with Nitrous acid and Nitrous acid may lead to a major life threatening interaction when taken with Tafenoquine
Proparacaine (Compound) causes Iritis (Side Effect) and Iritis (Side Effect) is caused by Guanfacine (Compound) and Guanfacine may cause a moderate interaction that could exacerbate diseases when taken with Tafenoquine
Proparacaine may cause a moderate interaction that could exacerbate diseases when taken with Quinine and Quinine may lead to a major life threatening interaction when taken with Prilocaine and Prilocaine may lead to a major life threatening interaction when taken with Tafenoquine
Proparacaine may cause a moderate interaction that could exacerbate diseases when taken with Quinine and Quinine may lead to a major life threatening interaction when taken with Nitrous acid and Nitrous acid may lead to a major life threatening interaction when taken with Tafenoquine |
DB00284 | DB01284 | 1,647 | 1,042 | [
"DDInter11",
"DDInter1782"
] | Acarbose | Tetracosactide | Acarbose is a complex oligosaccharide that acts as an inhibitor of several enzymes responsible for the breakdown of complex carbohydrates in the intestines. It inhibits both pancreatic alpha-amylase and membrane-bound alpha-glucosidases - including intestinal glucoamylase, sucrase, maltase, and isomaltase - which are responsible for the metabolism of complex starches and oligo-, tri-, and disaccharides into absorbable simple sugars.[L31633,A37868] By inhibiting the activity of these enzymes, acarbose limits the absorption of dietary carbohydrates and the subsequent postprandial increase in blood glucose and insulin levels. Acarbose is therefore used in conjunction with diet, exercise, and other pharmacotherapies for the management of blood sugar levels in patients with type 2 diabetes.[L31628,L31633] Acarbose is one of only two approved alpha-glucosidase inhibitors (the other being | Tetracosactide (also known as Cosyntropin) is a synthetic peptide that is identical to the 24-amino acid segment (sequence: SYSMEHFRWGKPVGKKRRPVKVYP) at the N-terminal of adrenocorticotropic hormone. ACTH (1-24), a segment similar in all species, contains the biological activity that stimulates production of corticosteroids in the adrenal cortex. Tetracosactide exhibits the same activity as natural ACTH with regard to all its biological activities. The complex results in a product whose absorption in man is effected over a longer period of time as compared to corticotropin. Therefore, therapy may be maintained with less frequent administration. | Moderate | 1 | [
[
[
1647,
24,
1042
]
],
[
[
1647,
24,
455
],
[
455,
23,
1042
]
],
[
[
1647,
24,
659
],
[
659,
62,
1042
]
],
[
[
1647,
24,
811
],
[
811,
... | [
[
[
"Acarbose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetracosactide"
]
],
[
[
"Acarbose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salmeterol"
],
[
... | Acarbose may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol and Salmeterol may cause a minor interaction that can limit clinical effects when taken with Tetracosactide
Acarbose may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol and Vilanterol may cause a minor interaction that can limit clinical effects when taken with Tetracosactide
Acarbose may cause a moderate interaction that could exacerbate diseases when taken with Metolazone and Metolazone may cause a moderate interaction that could exacerbate diseases when taken with Tetracosactide
Acarbose may cause a moderate interaction that could exacerbate diseases when taken with Quinestrol and Quinestrol may cause a moderate interaction that could exacerbate diseases when taken with Tetracosactide
Acarbose may cause a minor interaction that can limit clinical effects when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Tetracosactide
Acarbose may cause a minor interaction that can limit clinical effects when taken with Albiglutide and Albiglutide may cause a moderate interaction that could exacerbate diseases when taken with Tetracosactide
Acarbose may cause a moderate interaction that could exacerbate diseases when taken with Torasemide and Torasemide may cause a moderate interaction that could exacerbate diseases when taken with Tetracosactide
Acarbose (Compound) resembles Lactulose (Compound) and Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Tetracosactide
Acarbose may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Tetracosactide |
DB00549 | DB01166 | 522 | 477 | [
"DDInter1955",
"DDInter379"
] | Zafirlukast | Cilostazol | Zafirlukast is an oral leukotriene receptor antagonist (LTRA) for the maintenance treatment of asthma, often used in conjunction with an inhaled steroid and/or long-acting bronchodilator. It is available as a tablet and is usually dosed twice daily. Another leukotriene receptor antagonist is montelukast (Singulair), which is usually taken just once daily. Zafirlukast blocks the action of the cysteinyl leukotrienes on the CysLT1 receptors, thus reducing constriction of the airways, build-up of mucus in the lungs and inflammation of the breathing passages. | Cilostazol is a quinolinone derivative and antiplatelet agent with vasodilating properties that has been used in the symptomatic treatment of intermittent claudication in patients with peripheral ischaemia. It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both primary and secondary aggregation and reducing calcium-induced contractions. | Moderate | 1 | [
[
[
522,
24,
477
]
],
[
[
522,
6,
8374
],
[
8374,
45,
477
]
],
[
[
522,
21,
28658
],
[
28658,
60,
477
]
],
[
[
522,
24,
112
],
[
112,
... | [
[
[
"Zafirlukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cilostazol"
]
],
[
[
"Zafirlukast",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)... | Zafirlukast (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Cilostazol (Compound)
Zafirlukast (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Cilostazol (Compound)
Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Cilostazol
Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Etravirine and Etravirine may cause a moderate interaction that could exacerbate diseases when taken with Cilostazol
Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Cilostazol
Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli and Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Cilostazol
Zafirlukast may cause a minor interaction that can limit clinical effects when taken with Clopidogrel and Clopidogrel may cause a moderate interaction that could exacerbate diseases when taken with Cilostazol
Zafirlukast may cause a minor interaction that can limit clinical effects when taken with Citalopram and Citalopram may cause a moderate interaction that could exacerbate diseases when taken with Cilostazol
Zafirlukast may cause a minor interaction that can limit clinical effects when taken with Escitalopram and Escitalopram may cause a moderate interaction that could exacerbate diseases when taken with Cilostazol |
DB08868 | DB11793 | 1,011 | 738 | [
"DDInter737",
"DDInter1297"
] | Fingolimod | Niraparib | Multiple sclerosis, or MS, is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of relapsing-remitting multiple sclerosis. It was developed by Novartis and initially approved by the FDA in 2010. Fingolimod was also studied for the treatment of COVID-19, the disease caused by infection with the SARS-CoV-2 virus.[L12654,L12657] | Niraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells. Niraparib is selective towards PARP-1 and PARP-2. First approved by the FDA on March 27, 2017, niraparib is used to treat epithelial ovarian, fallopian tube, or primary peritoneal cancer. Niraparib was approved by the European Commission on November 16, 2017 and by Health Canada on June 27, 2019. | Major | 2 | [
[
[
1011,
25,
738
]
],
[
[
1011,
64,
1213
],
[
1213,
24,
738
]
],
[
[
1011,
24,
496
],
[
496,
24,
738
]
],
[
[
1011,
25,
1619
],
[
1619,
... | [
[
[
"Fingolimod",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Niraparib"
]
],
[
[
"Fingolimod",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dasatinib"
],
[
"Dasatinib",
"{u} may ... | Fingolimod may lead to a major life threatening interaction when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Niraparib
Fingolimod may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine and Hepatitis A Vaccine may cause a moderate interaction that could exacerbate diseases when taken with Niraparib
Fingolimod may lead to a major life threatening interaction when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Niraparib
Fingolimod may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Niraparib
Fingolimod may cause a minor interaction that can limit clinical effects when taken with Ticagrelor and Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Niraparib
Fingolimod may cause a moderate interaction that could exacerbate diseases when taken with Human adenovirus e serotype 4 strain cl-68578 antigen and Human adenovirus e serotype 4 strain cl-68578 antigen may cause a moderate interaction that could exacerbate diseases when taken with Niraparib
Fingolimod may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T and Sipuleucel-T may cause a moderate interaction that could exacerbate diseases when taken with Niraparib
Fingolimod may lead to a major life threatening interaction when taken with Natalizumab and Natalizumab may lead to a major life threatening interaction when taken with Niraparib
Fingolimod may lead to a major life threatening interaction when taken with Bacillus calmette-guerin substrain tice live antigen and Bacillus calmette-guerin substrain tice live antigen may lead to a major life threatening interaction when taken with Niraparib |
DB01073 | DB15091 | 1,488 | 676 | [
"DDInter745",
"DDInter1901"
] | Fludarabine | Upadacitinib | Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara. | Upadacitinib is an oral Janus kinase (JAK)1-selective inhibitor and a disease-modifying antirheumatic drug (DMARD) used in the treatment of rheumatoid arthritis to slow down disease progression. Rheumatoid arthritis is a chronic autoimmune inflammatory disease affecting the peripheral joints. It is characterized by synovial inflammation and hyperplasia, autoantibody production, cartilage damage and bone destruction, leading to co-morbidities. Despite a variety of therapeutic agents available for treatment, up to 40% of the patients do not respond to current therapies, including biological therapies. The etiology of the disease is mostly unknown; however, the role of JAK as a driver of immune-mediated conditions was discovered, leading to the use of JAK as therapeutic targets for rheumatoid arthritis. To reduce dose-related toxicity (as seen with some pan-JAK inhibitors) without significantly affecting efficacy, more selective JAK1 inhibitors, upadacitinib and [filgotinib], were developed. The FDA approved upadacitinib in August 2019 and it is used for the treatment of active rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, ulcerative colitis, and ankylosing spondylitis. In December 2019, it was additionally approved by the European Commission and Health Canada.[L10899,L42540] Upadacitinib is marketed under the brand name RINVOQ for oral administration. | Major | 2 | [
[
[
1488,
25,
676
]
],
[
[
1488,
63,
1461
],
[
1461,
23,
676
]
],
[
[
1488,
24,
1430
],
[
1430,
24,
676
]
],
[
[
1488,
63,
563
],
[
563,
... | [
[
[
"Fludarabine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
]
],
[
[
"Fludarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
"Vitamin... | Fludarabine may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Upadacitinib
Fludarabine may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T and Sipuleucel-T may cause a moderate interaction that could exacerbate diseases when taken with Upadacitinib
Fludarabine may cause a moderate interaction that could exacerbate diseases when taken with Ganciclovir and Ganciclovir may cause a moderate interaction that could exacerbate diseases when taken with Upadacitinib
Fludarabine may cause a moderate interaction that could exacerbate diseases when taken with Anakinra and Anakinra may lead to a major life threatening interaction when taken with Upadacitinib
Fludarabine may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab and Ocrelizumab may lead to a major life threatening interaction when taken with Upadacitinib
Fludarabine (Compound) resembles Cladribine (Compound) and Fludarabine may lead to a major life threatening interaction when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Upadacitinib
Fludarabine may lead to a major life threatening interaction when taken with Natalizumab and Natalizumab may lead to a major life threatening interaction when taken with Upadacitinib
Fludarabine may lead to a major life threatening interaction when taken with Measles virus vaccine live attenuated and Measles virus vaccine live attenuated may lead to a major life threatening interaction when taken with Upadacitinib
Fludarabine (Compound) resembles Azacitidine (Compound) and Azacitidine may lead to a major life threatening interaction when taken with Upadacitinib |
DB01100 | DB01246 | 1,568 | 820 | [
"DDInter1470",
"DDInter45"
] | Pimozide | Alimemazine | A diphenylbutylpiperidine that is effective as an antipsychotic agent and as an alternative to haloperidol for the suppression of vocal and motor tics in patients with Tourette syndrome. Although the precise mechanism of action is unknown, blockade of postsynaptic dopamine receptors has been postulated. (From AMA Drug Evaluations Annual, 1994, p403) | A phenothiazine derivative that is used as an antipruritic. | Major | 2 | [
[
[
1568,
25,
820
]
],
[
[
1568,
63,
104
],
[
104,
40,
820
]
],
[
[
1568,
64,
401
],
[
401,
24,
820
]
],
[
[
1568,
24,
649
],
[
649,
... | [
[
[
"Pimozide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Alimemazine"
]
],
[
[
"Pimozide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
],
[
"Methdilazin... | Pimozide may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine (Compound) resembles Alimemazine (Compound)
Pimozide may lead to a major life threatening interaction when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine
Pimozide may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and Clofedanol (Compound) resembles Alimemazine (Compound)
Pimozide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Alimemazine (Compound)
Pimozide (Compound) upregulates IDI1 (Gene) and IDI1 (Gene) is upregulated by Alimemazine (Compound)
Pimozide (Compound) downregulates CYCS (Gene) and CYCS (Gene) is downregulated by Alimemazine (Compound)
Pimozide (Compound) causes Tremor (Side Effect) and Tremor (Side Effect) is caused by Alimemazine (Compound)
Pimozide may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide and Magnesium hydroxide may cause a minor interaction that can limit clinical effects when taken with Alimemazine
Pimozide may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Alimemazine |
DB01050 | DB01254 | 848 | 1,213 | [
"DDInter900",
"DDInter484"
] | Ibuprofen | Dasatinib | Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics. The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin. Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID. On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than | Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.[A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the breakpoint cluster region (BCR) gene transcribe the chimeric protein BCR-ABL. BCR-ABL is associated with the uncontrolled activity of the ABL tyrosine kinase and is involved in the pathogenesis of CML and 15-30% of ALL cases.[A11377,A33432] Dasatinib also inhibits a spectrum of kinases involved in cancer, including several SRC-family kinases. Unlike [imatinib], another tyrosine kinase used for the treatment of CML and Ph-positive ALL, dasatinib inhibits the active and inactive conformations of the ABL kinase domain.[A2226,A11377] Also, mutations in the kinase domain of BCR-ABL may lead to relapse during imatinib treatment. Since dasatinib does not interact with some of the residues involved in those mutations, the use of this drug represents a therapeutic alternative for patients with cancers that have developed imatinib-resistance. The use of dasatinib was first approved by the FDA in 2006.[L45171,L45186] | Major | 2 | [
[
[
848,
25,
1213
]
],
[
[
848,
6,
4973
],
[
4973,
45,
1213
]
],
[
[
848,
6,
4789
],
[
4789,
57,
1213
]
],
[
[
848,
21,
28956
],
[
28956,
... | [
[
[
"Ibuprofen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dasatinib"
]
],
[
[
"Ibuprofen",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Dasatinib"
... | Ibuprofen (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Dasatinib (Compound)
Ibuprofen (Compound) binds PPARG (Gene) and PPARG (Gene) is downregulated by Dasatinib (Compound)
Ibuprofen (Compound) causes Palpitations (Side Effect) and Palpitations (Side Effect) is caused by Dasatinib (Compound)
Ibuprofen may cause a minor interaction that can limit clinical effects when taken with Donepezil and Donepezil may cause a minor interaction that can limit clinical effects when taken with Dasatinib
Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Niraparib and Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib
Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin and Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib
Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Clomipramine and Clomipramine may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib
Ibuprofen may lead to a major life threatening interaction when taken with Lithium carbonate and Lithium carbonate may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib
Ibuprofen may lead to a major life threatening interaction when taken with Sirolimus and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib |
DB00782 | DB01036 | 1,123 | 211 | [
"DDInter1535",
"DDInter1832"
] | Propantheline | Tolterodine | A muscarinic antagonist used as an antispasmodic, in rhinitis, in urinary incontinence, and in the treatment of ulcers. At high doses it has nicotinic effects resulting in neuromuscular blocking. | Tolterodine is an antimuscarinic drug that is used to treat urinary incontinence. Tolterodine acts on M2 and M3 subtypes of muscarinic receptors. | Moderate | 1 | [
[
[
1123,
24,
211
]
],
[
[
1123,
24,
358
],
[
358,
40,
211
]
],
[
[
1123,
63,
1523
],
[
1523,
40,
211
]
],
[
[
1123,
63,
128
],
[
128,
... | [
[
[
"Propantheline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolterodine"
]
],
[
[
"Propantheline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Orphenadrine"
],... | Propantheline may cause a moderate interaction that could exacerbate diseases when taken with Orphenadrine and Orphenadrine (Compound) resembles Tolterodine (Compound)
Propantheline may cause a moderate interaction that could exacerbate diseases when taken with Labetalol and Labetalol (Compound) resembles Tolterodine (Compound)
Propantheline may cause a moderate interaction that could exacerbate diseases when taken with Dexbrompheniramine and Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Tolterodine
Propantheline may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine and Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Tolterodine
Propantheline (Compound) binds CHRM2 (Gene) and CHRM2 (Gene) is bound by Tolterodine (Compound)
Propantheline (Compound) causes Dry mouth (Side Effect) and Dry mouth (Side Effect) is caused by Tolterodine (Compound)
Propantheline may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Tolterodine
Propantheline may lead to a major life threatening interaction when taken with Potassium chloride and Potassium chloride may lead to a major life threatening interaction when taken with Tolterodine
Propantheline may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine and Chlorpheniramine (Compound) resembles Tolterodine (Compound) and Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Tolterodine |
DB01156 | DB09068 | 593 | 1,427 | [
"DDInter252",
"DDInter1948"
] | Bupropion | Vortioxetine | Bupropion (also known as the brand name product Wellbutrin®) is a norepinephrine/dopamine-reuptake inhibitor (NDRI) used most commonly for the management of Major Depressive Disorder (MDD), Seasonal Affective Disorder (SAD), and as an aid for smoking cessation. Bupropion exerts its pharmacological effects by weakly inhibiting the enzymes involved in the uptake of the neurotransmitters norepinephrine and dopamine from the synaptic cleft, therefore prolonging their duration of action within the neuronal synapse and the downstream effects of these neurotransmitters. More specifically, bupropion binds to the norepinephrine transporter (NET) and the dopamine transporter (DAT).[A6399,A178810] Bupropion was originally classified as an "atypical" antidepressant because it does not exert the same effects as the classical antidepressants such as Monoamine Oxidase Inhibitors (MA | Vortioxetine is an antidepressant medication indicated for the treatment of major depressive disorder (MDD). It is classified as a serotonin modulator and stimulator (SMS) as it has a multimodal mechanism of action towards the serotonin neurotransmitter system whereby it simultaneously modulates one or more serotonin receptors and inhibits the reuptake of serotonin. More specifically, vortioxetine acts via the following biological mechanisms: as a serotonin reuptake inhibitor (SRI) through inhibition of the serotonin transporter, as a partial agonist of the 5-HT1B receptor, an agonist of 5-HT1A, and an antagonist of the 5-HT3, 5-HT1D, and 5-HT7 receptors. SMSs were developed because there are many different subtypes of serotonin receptors, however, not all of these receptors appear to be involved in the antidepressant effects of SRIs. Some serotonin receptors seem to play a relatively neutral or insignificant role in the regulation of mood, but others, such as 5-HT1A autoreceptors and 5-HT7 receptors, appear to play an oppositional role in the efficacy of SRIs in treating depression. | Major | 2 | [
[
[
593,
25,
1427
]
],
[
[
593,
23,
256
],
[
256,
24,
1427
]
],
[
[
593,
24,
1604
],
[
1604,
63,
1427
]
],
[
[
593,
25,
1220
],
[
1220,
... | [
[
[
"Bupropion",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vortioxetine"
]
],
[
[
"Bupropion",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Prasugrel"
],
[
"Prasugrel",
... | Bupropion may cause a minor interaction that can limit clinical effects when taken with Prasugrel and Prasugrel may cause a moderate interaction that could exacerbate diseases when taken with Vortioxetine
Bupropion may cause a moderate interaction that could exacerbate diseases when taken with Lumacaftor and Lumacaftor may cause a moderate interaction that could exacerbate diseases when taken with Vortioxetine
Bupropion may lead to a major life threatening interaction when taken with Dexamethasone and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Vortioxetine
Bupropion may cause a moderate interaction that could exacerbate diseases when taken with Ticlopidine and Ticlopidine may cause a moderate interaction that could exacerbate diseases when taken with Vortioxetine
Bupropion may lead to a major life threatening interaction when taken with Apalutamide and Apalutamide may cause a moderate interaction that could exacerbate diseases when taken with Vortioxetine
Bupropion may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide and Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Vortioxetine
Bupropion may lead to a major life threatening interaction when taken with Lindane and Lindane may cause a moderate interaction that could exacerbate diseases when taken with Vortioxetine
Bupropion may lead to a major life threatening interaction when taken with Doxepin and Doxepin may lead to a major life threatening interaction when taken with Vortioxetine
Bupropion may lead to a major life threatening interaction when taken with Dexfenfluramine and Dexfenfluramine may lead to a major life threatening interaction when taken with Vortioxetine |
DB00959 | DB06448 | 1,486 | 171 | [
"DDInter1191",
"DDInter1087"
] | Methylprednisolone | Lonafarnib | Methylprednisolone is a [prednisolone] derivative glucocorticoid with higher potency than [prednisone]. It was first described in the literature in the late 1950s.[A188811,A188814] Methylprednisolone was granted FDA approval on 24 October 1957. In the outbreak of COVID-19, low dose methylprednisolone-based therapy was successful in treating COVID-19-associated pneumonia in one patient with long-term immunosuppression. The efficacy of methylprednisolone in novel coronavirus pneumonia is being investigated further in clinical trials. | Hutchinson-Gilford progeria syndrome (HGPS) is a rare autosomal dominant disorder estimated to affect approximately one in 20 million individuals resulting in adverse symptoms associated with premature ageing: skeletal dysplasia, joint contractures, atherosclerosis, myocardial fibrosis/dysfunction, scleroderma-like cutaneous effects, lipoatrophy, alopecia, and a severe failure to thrive; HGPS is uniformly fatal.[A224379, A224384, A224389, A224394, A224399] Mechanistically, HGPS is underpinned by a single heterozygous C-to-T mutation at position 1824 of the _LMNA_ gene, which results in the accumulation of an aberrant farnesylated form of lamin A called progerin in the inner nuclear membrane.[A224379, A224394] Lonafarnib is a farnesyl transferase (FTase) inhibitor (FTI), which reduces the farnesylation of numerous cellular proteins, including progerin; as progerin farnesylation is important for localization to the nuclear membrane, lonafarnib inhibits progerin accumulation and improves symptoms in HGPS patients.[A224379, A224414, A224419, L23414] Merck originally developed Lonafarnib and subsequently licensed it to Eiger Biopharmaceuticals Inc., which currently markets it under the trademark ZOKINVY™.[L23414, L23544] Lonafarnib was granted FDA approval on November 20, 2020, and is the first FDA-approved treatment for HGPS and other related progeroid laminopathies.[L23414, L23549] | Major | 2 | [
[
[
1486,
25,
171
]
],
[
[
1486,
40,
1351
],
[
1351,
24,
171
]
],
[
[
1486,
63,
473
],
[
473,
24,
171
]
],
[
[
1486,
24,
761
],
[
761,
... | [
[
[
"Methylprednisolone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lonafarnib"
]
],
[
[
"Methylprednisolone",
"{u} (Compound) resembles {v} (Compound)",
"Flunisolide"
],
[
"Flunisolide",
"{u} may cause a mode... | Methylprednisolone (Compound) resembles Flunisolide (Compound) and Flunisolide may cause a moderate interaction that could exacerbate diseases when taken with Lonafarnib
Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Repaglinide and Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Lonafarnib
Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin and Saxagliptin may cause a moderate interaction that could exacerbate diseases when taken with Lonafarnib
Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Somatrem and Somatrem may cause a moderate interaction that could exacerbate diseases when taken with Lonafarnib
Methylprednisolone may lead to a major life threatening interaction when taken with Cladribine and Cladribine may cause a moderate interaction that could exacerbate diseases when taken with Lonafarnib
Methylprednisolone may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may cause a moderate interaction that could exacerbate diseases when taken with Lonafarnib
Methylprednisolone may cause a minor interaction that can limit clinical effects when taken with Vilanterol and Vilanterol may cause a moderate interaction that could exacerbate diseases when taken with Lonafarnib
Methylprednisolone (Compound) resembles Medroxyprogesterone acetate (Compound) and Medroxyprogesterone acetate may cause a moderate interaction that could exacerbate diseases when taken with Lonafarnib
Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may lead to a major life threatening interaction when taken with Lonafarnib |
DB00863 | DB01115 | 1,194 | 336 | [
"DDInter1568",
"DDInter1291"
] | Ranitidine | Nifedipine | Ranitidine is a commonly used drug, classified as a histamine H2-receptor antagonist, and belongs to the same drug class as [cimetidine] and [famotidine]. This drug helps to prevent and treat gastric-acid associated conditions, including ulcers, because of its ability to decrease gastric acid secretion.[A176759,L10818] Ranitidine is often referred to as Zantac, and is available in various forms, including tablet, injection, and effervescent tablet preparations.[L10818,F4253] The prevalence of GERD is thought to be 10-20% in western countries. Ranitidine has proven to be an effective treatment for relieving uncomfortable symptoms of gastric acid associated conditions and is therefore widely used in GERD and other gastric-acid related conditions.[A176849,L10818] | Nifedipine, or BAY a 1040, is a first generation dihydropyridine L-type calcium channel blocker, similar to [nicardipine].[A190210,A190273,A175390,L11383] Nifedipine was developed by Bayer and first described in the literature, along with other dihydropyridines, in 1972.[A175390,A190276] Since nifedipine's development, second and third generation dihydropyridines have been developed with slower onsets and longer durations of action. The most popular of the third generation dihydropyridines is [amlodipine]. Nifedipine was granted FDA approval on 31 December 1981. | Minor | 0 | [
[
[
1194,
23,
336
]
],
[
[
1194,
6,
7950
],
[
7950,
45,
336
]
],
[
[
1194,
21,
28695
],
[
28695,
60,
336
]
],
[
[
1194,
63,
1031
],
[
1031... | [
[
[
"Ranitidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Nifedipine"
]
],
[
[
"Ranitidine",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compound)",
... | Ranitidine (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Nifedipine (Compound)
Ranitidine (Compound) causes Dyspnoea (Side Effect) and Dyspnoea (Side Effect) is caused by Nifedipine (Compound)
Ranitidine may cause a moderate interaction that could exacerbate diseases when taken with Theophylline and Theophylline may cause a minor interaction that can limit clinical effects when taken with Nifedipine
Ranitidine may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib and Dabrafenib may cause a moderate interaction that could exacerbate diseases when taken with Nifedipine
Ranitidine may lead to a major life threatening interaction when taken with Pazopanib and Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Nifedipine
Ranitidine may cause a moderate interaction that could exacerbate diseases when taken with Gefitinib and Gefitinib may cause a moderate interaction that could exacerbate diseases when taken with Nifedipine
Ranitidine may cause a minor interaction that can limit clinical effects when taken with Axitinib and Axitinib may cause a moderate interaction that could exacerbate diseases when taken with Nifedipine
Ranitidine may cause a minor interaction that can limit clinical effects when taken with Diclofenac and Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Nifedipine
Ranitidine may cause a minor interaction that can limit clinical effects when taken with Ibuprofen and Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Nifedipine |
DB00349 | DB11186 | 902 | 1,609 | [
"DDInter401",
"DDInter1427"
] | Clobazam | Pentoxyverine | Clobazam belongs to the 1,5-benzodiazepine class of drugs and is marketed under different names, Onfi, Frisium, Urbanyl, and others.. Clobazam was first synthesized in 1966 and first published in 1969, following the incidental synthesis and discovery of the first benzodiazepine chlordiazepoxide in the 1950s. Unlike older 1,4-benzodiazepines, clobazam has a better side-effects profile, particularly less sedative and amnesic effects.[A256963,A256868] This is likely because of clobazam's higher affinity to the α<sub>2</sub> subunit of the GABA<sub>A</sub> receptor, which mediates anxiolytic effects, than the α<sub>1</sub> subunit, which mediates sedative effect. Additionally, clobazam is believed | Pentoxyverine, also referred to as carbetapentane, is a non-opioid central acting antitussive with antimuscarinic, anticonvulsant , and local anesthetic properties. It is an active ingredient in over-the-counter cough suppressants in combination with guaifenesin and H1-receptor antagonists . Pentoxyverine acts on sigma-1 receptors, as well as kappa and mu-opioid receptors. The FDA withdrew the use of all oral gel drug products containing pentoxyverine citrate. Other forms of pentoxyverine citrate continue to be marketed. | Moderate | 1 | [
[
[
902,
24,
1609
]
],
[
[
902,
24,
104
],
[
104,
24,
1609
]
],
[
[
902,
40,
523
],
[
523,
24,
1609
]
],
[
[
902,
63,
701
],
[
701,
... | [
[
[
"Clobazam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentoxyverine"
]
],
[
[
"Clobazam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
],
[
... | Clobazam may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine
Clobazam (Compound) resembles Alprazolam (Compound) and Alprazolam may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine
Clobazam may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine
Clobazam may lead to a major life threatening interaction when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine
Clobazam may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Nalbuphine and Nalbuphine may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine
Clobazam may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazine and Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Nalbuphine and Nalbuphine may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine
Clobazam (Compound) resembles Alprazolam (Compound) and Alprazolam may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine
Clobazam (Compound) resembles Loxapine (Compound) and Loxapine (Compound) resembles Quetiapine (Compound) and Quetiapine may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine
Clobazam may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Nalbuphine and Nalbuphine may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine |
DB00189 | DB01041 | 459 | 770 | [
"DDInter691",
"DDInter1789"
] | Ethchlorvynol | Thalidomide | Ethchlorvynol is a sedative and hypnotic drug. It has been used to treat insomnia, but has been largely superseded and is only offered where an intolerance or allergy to other drugs exists. | A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating the release of inflammatory mediators like tumor necrosis factor-alpha (TNF-a) and other cytokine action. Due to severe teratogenicity, pregnancy must be excluded before the start of treatment and patients must enrol in the THALIDOMID Risk Evaluation and Mitigation Strategy (REMS) program to ensure contraception adherence. | Moderate | 1 | [
[
[
459,
24,
770
]
],
[
[
459,
24,
849
],
[
849,
63,
770
]
],
[
[
459,
24,
1614
],
[
1614,
24,
770
]
],
[
[
459,
25,
475
],
[
475,
2... | [
[
[
"Ethchlorvynol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
]
],
[
[
"Ethchlorvynol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
],
... | Ethchlorvynol may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide
Ethchlorvynol may cause a moderate interaction that could exacerbate diseases when taken with Nabilone and Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide
Ethchlorvynol may lead to a major life threatening interaction when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide
Ethchlorvynol may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide and Ifosfamide may lead to a major life threatening interaction when taken with Thalidomide
Ethchlorvynol may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may lead to a major life threatening interaction when taken with Thalidomide
Ethchlorvynol may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Entacapone and Entacapone may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide
Ethchlorvynol may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and Clofedanol may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide
Ethchlorvynol may cause a moderate interaction that could exacerbate diseases when taken with Nabilone and Nabilone (Compound) causes Loss of consciousness (Side Effect) and Loss of consciousness (Side Effect) is caused by Thalidomide (Compound)
Ethchlorvynol may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine and Chlorpheniramine (Compound) binds CYP3A5 (Gene) and CYP3A5 (Gene) is bound by Thalidomide (Compound) |
DB00208 | DB00261 | 1,018 | 702 | [
"DDInter1804",
"DDInter93"
] | Ticlopidine | Anagrelide | Ticlopidine is an effective inhibitor of platelet aggregation. It is a prodrug that is metabolised to an active form, which blocks the ADP receptor that is involved in GPIIb/IIIa receptor activation leading to platelet aggregation. Ticlopidine is marketed under the brand name Ticlid and is indicated for patients who cannot take aspirin or in whom aspirin has not worked to prevent a thrombotic stroke. The FDA label includes a black-box warning of neutropenia, aplastic anemia, thrombotic thrombocytopenia purpura, and agranulocytosis, so it is necessary to monitor patients' WBC and platelets when they are taking ticlopidine. | Anagrelide is a platelet-reducing agent used to lower dangerously elevated platelet levels (i.e. to treat thrombocythemia) in patients with myeloproliferative neoplasms. It is an oral imidazoquinazoline that was first approved for use in the US in 1997. It appears to carry a better response rate than other thrombocythemia treatments (e.g. [busulfan], [hydroxyurea]) and may be better tolerated. | Moderate | 1 | [
[
[
1018,
24,
702
]
],
[
[
1018,
6,
7950
],
[
7950,
45,
702
]
],
[
[
1018,
18,
10375
],
[
10375,
57,
702
]
],
[
[
1018,
21,
29549
],
[
295... | [
[
[
"Ticlopidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anagrelide"
]
],
[
[
"Ticlopidine",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compound)... | Ticlopidine (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Anagrelide (Compound)
Ticlopidine (Compound) downregulates RPS4Y1 (Gene) and RPS4Y1 (Gene) is downregulated by Anagrelide (Compound)
Ticlopidine (Compound) causes Osteoarthritis (Side Effect) and Osteoarthritis (Side Effect) is caused by Anagrelide (Compound)
Ticlopidine may cause a minor interaction that can limit clinical effects when taken with Capsicum and Capsicum may cause a minor interaction that can limit clinical effects when taken with Anagrelide
Ticlopidine may cause a moderate interaction that could exacerbate diseases when taken with Ketoprofen and Ketoprofen may cause a moderate interaction that could exacerbate diseases when taken with Anagrelide
Ticlopidine may cause a moderate interaction that could exacerbate diseases when taken with Fluvoxamine and Fluvoxamine may cause a moderate interaction that could exacerbate diseases when taken with Anagrelide
Ticlopidine may cause a minor interaction that can limit clinical effects when taken with Phenobarbital and Phenobarbital may cause a moderate interaction that could exacerbate diseases when taken with Anagrelide
Ticlopidine may lead to a major life threatening interaction when taken with Rasagiline and Rasagiline may cause a moderate interaction that could exacerbate diseases when taken with Anagrelide
Ticlopidine may lead to a major life threatening interaction when taken with Vorapaxar and Vorapaxar may lead to a major life threatening interaction when taken with Anagrelide |
DB00748 | DB11186 | 662 | 1,609 | [
"DDInter297",
"DDInter1427"
] | Carbinoxamine | Pentoxyverine | Carbinoxamine is a first generation antihistamine that competes with free histamine for binding at HA-receptor sites. This antagonizes the effects of histamine on HA-receptors, leading to a reduction of the negative symptoms brought on by histamine HA-receptor binding. The product label for carbinoxamine as an over the counter cough and cold medicine is being modified to state "do not use" in children under 4 years of age in order to prevent and reduce misuse, as many unapproved carbinoxamine-containing preparations contained inappropriate labeling, which promoted unapproved uses (including management of congestion, cough, the common cold, and the use in children under 2 years of age), which can potentially cause serious health risks. | Pentoxyverine, also referred to as carbetapentane, is a non-opioid central acting antitussive with antimuscarinic, anticonvulsant , and local anesthetic properties. It is an active ingredient in over-the-counter cough suppressants in combination with guaifenesin and H1-receptor antagonists . Pentoxyverine acts on sigma-1 receptors, as well as kappa and mu-opioid receptors. The FDA withdrew the use of all oral gel drug products containing pentoxyverine citrate. Other forms of pentoxyverine citrate continue to be marketed. | Moderate | 1 | [
[
[
662,
24,
1609
]
],
[
[
662,
24,
314
],
[
314,
24,
1609
]
],
[
[
662,
63,
556
],
[
556,
24,
1609
]
],
[
[
662,
25,
306
],
[
306,
... | [
[
[
"Carbinoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentoxyverine"
]
],
[
[
"Carbinoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nalbuphine"
],... | Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Nalbuphine and Nalbuphine may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine
Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Valproic acid and Valproic acid may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine
Carbinoxamine may lead to a major life threatening interaction when taken with Zonisamide and Zonisamide may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine
Carbinoxamine (Compound) resembles Clofedanol (Compound) and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and Clofedanol may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine
Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Brexanolone and Brexanolone may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine
Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Rasagiline and Rasagiline may lead to a major life threatening interaction when taken with Pentoxyverine
Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Nalbuphine and Nalbuphine may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine
Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Valproic acid and Valproic acid may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine
Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Promazine and Promazine (Compound) resembles Quetiapine (Compound) and Quetiapine may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine |
DB00220 | DB00959 | 798 | 1,486 | [
"DDInter1276",
"DDInter1191"
] | Nelfinavir | Methylprednisolone | Nelfinavir is a potent HIV-1 protease inhibitor. It is used in combination with other antiviral drugs in the treatment of HIV in both adults and children. Nelfinavir inhibits the HIV viral proteinase enzyme which prevents cleavage of the gag-pol polyprotein, resulting in noninfectious, immature viral particles. | Methylprednisolone is a [prednisolone] derivative glucocorticoid with higher potency than [prednisone]. It was first described in the literature in the late 1950s.[A188811,A188814] Methylprednisolone was granted FDA approval on 24 October 1957. In the outbreak of COVID-19, low dose methylprednisolone-based therapy was successful in treating COVID-19-associated pneumonia in one patient with long-term immunosuppression. The efficacy of methylprednisolone in novel coronavirus pneumonia is being investigated further in clinical trials. | Major | 2 | [
[
[
798,
25,
1486
]
],
[
[
798,
25,
175
],
[
175,
40,
1486
]
],
[
[
798,
24,
167
],
[
167,
1,
1486
]
],
[
[
798,
63,
1351
],
[
1351,
... | [
[
[
"Nelfinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methylprednisolone"
]
],
[
[
"Nelfinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Triamcinolone"
],
[
"Triamcinolone"... | Nelfinavir may lead to a major life threatening interaction when taken with Triamcinolone and Triamcinolone (Compound) resembles Methylprednisolone (Compound)
Nelfinavir may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone (Compound) resembles Methylprednisolone (Compound)
Nelfinavir may cause a moderate interaction that could exacerbate diseases when taken with Flunisolide and Flunisolide (Compound) resembles Methylprednisolone (Compound)
Nelfinavir may cause a moderate interaction that could exacerbate diseases when taken with Medroxyprogesterone acetate and Medroxyprogesterone acetate (Compound) resembles Methylprednisolone (Compound)
Nelfinavir (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Methylprednisolone (Compound)
Nelfinavir (Compound) upregulates DDIT4 (Gene) and DDIT4 (Gene) is upregulated by Methylprednisolone (Compound)
Nelfinavir (Compound) causes Ill-defined disorder (Side Effect) and Ill-defined disorder (Side Effect) is caused by Methylprednisolone (Compound)
Nelfinavir may lead to a major life threatening interaction when taken with Salmeterol and Salmeterol may cause a minor interaction that can limit clinical effects when taken with Methylprednisolone
Nelfinavir may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol and Vilanterol may cause a minor interaction that can limit clinical effects when taken with Methylprednisolone |
DB01030 | DB06317 | 869 | 1,626 | [
"DDInter1835",
"DDInter630"
] | Topotecan | Elotuzumab | An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA topoisomerases, type I. | Elotuzumab is a humanized IgG1 (Immunoglobulin G) monoclonal antibody indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies. Elotuzumab targets SLAMF7, also known as Signaling Lymphocytic Activation Molecule Family member 7, a cell surface glycoprotein. Elotuzumab consists of the complementary determining regions (CDR) of the mouse antibody, MuLuc63, grafted onto human IgG1 heavy and kappa light chain frameworks. Elotuzumab is produced in NS0 cells by recombinant DNA technology. Elotuzumab has a theoretical mass of 148.1 kDa for the intact antibody. Elotuzumab was approved on November 30, 2015 by the U.S. Food and Drug Administration. Elotuzumab is marketed under the brand Empliciti™ by Bristol-Myers Squibb. | Moderate | 1 | [
[
[
869,
24,
1626
]
],
[
[
869,
24,
973
],
[
973,
24,
1626
]
],
[
[
869,
63,
597
],
[
597,
24,
1626
]
],
[
[
869,
24,
200
],
[
200,
... | [
[
[
"Topotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elotuzumab"
]
],
[
[
"Topotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
],
[
... | Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel and Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Elotuzumab
Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol and Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Elotuzumab
Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans and Candida albicans may cause a moderate interaction that could exacerbate diseases when taken with Elotuzumab
Topotecan may lead to a major life threatening interaction when taken with Oxaliplatin and Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Elotuzumab
Topotecan may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Elotuzumab
Topotecan may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may lead to a major life threatening interaction when taken with Elotuzumab
Topotecan may lead to a major life threatening interaction when taken with Samarium (153Sm) lexidronam and Samarium (153Sm) lexidronam may lead to a major life threatening interaction when taken with Elotuzumab
Topotecan may lead to a major life threatening interaction when taken with Etanercept and Etanercept may lead to a major life threatening interaction when taken with Elotuzumab
Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Lomitapide and Lomitapide may lead to a major life threatening interaction when taken with Elotuzumab |
DB00208 | DB04896 | 1,018 | 901 | [
"DDInter1804",
"DDInter1220"
] | Ticlopidine | Milnacipran | Ticlopidine is an effective inhibitor of platelet aggregation. It is a prodrug that is metabolised to an active form, which blocks the ADP receptor that is involved in GPIIb/IIIa receptor activation leading to platelet aggregation. Ticlopidine is marketed under the brand name Ticlid and is indicated for patients who cannot take aspirin or in whom aspirin has not worked to prevent a thrombotic stroke. The FDA label includes a black-box warning of neutropenia, aplastic anemia, thrombotic thrombocytopenia purpura, and agranulocytosis, so it is necessary to monitor patients' WBC and platelets when they are taking ticlopidine. | Milnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI) and like many agents in this category was originally developed for and continues to be approved and indicated for the treatment of depression [F3928, F3934, A175786, A175951]. Furthermore, in 2009 the US FDA approved milnacipran for the additional indication of treating fibromyalgia , although other regional regulatory authorities like the EMA, among others, have not yet approved the agent for such treatment, citing lack of robust evidence of efficacy, insufficient demonstration of maintenance of effect, and other concerns [F3928, F3934]. Nevertheless, milnacipran demonstrates a somewhat unique characteristic among SNRIs to elicit a relatively balanced reuptake inhibition of both serotonin and noradrenaline, with a somewhat increased preference for noradrenaline reuptake inhibition - which is potentially a point of interest given the plausible proposal that noradrenaline plays an important role in the mitigation of pain signals in the descending inhibitory pain pathways in the brain and spinal cord [A175759, A175843, A175846]. Moreover, recent research has shown that the levorotatory enantiomer of milnacipran, levomilnacipran, may have the capacity to inhibit the activity of beta-site amyloid precursor protein cleaving enzyme-1 (BACE-1), which has investigationally been associated with β-amyloid plaque formation - making the agent a possible course of treatment for Alzheimer's disease . | Moderate | 1 | [
[
[
1018,
24,
901
]
],
[
[
1018,
24,
41
],
[
41,
1,
901
]
],
[
[
1018,
21,
28722
],
[
28722,
60,
901
]
],
[
[
1018,
25,
405
],
[
405,
... | [
[
[
"Ticlopidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Milnacipran"
]
],
[
[
"Ticlopidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levomilnacipran"
],
... | Ticlopidine may cause a moderate interaction that could exacerbate diseases when taken with Levomilnacipran and Levomilnacipran (Compound) resembles Milnacipran (Compound)
Ticlopidine (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Milnacipran (Compound)
Ticlopidine may lead to a major life threatening interaction when taken with Acalabrutinib and Acalabrutinib may cause a moderate interaction that could exacerbate diseases when taken with Milnacipran
Ticlopidine may lead to a major life threatening interaction when taken with Enoxaparin and Enoxaparin may cause a moderate interaction that could exacerbate diseases when taken with Milnacipran
Ticlopidine may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Milnacipran
Ticlopidine may lead to a major life threatening interaction when taken with Ibritumomab tiuxetan and Ibritumomab tiuxetan may cause a moderate interaction that could exacerbate diseases when taken with Milnacipran
Ticlopidine may cause a moderate interaction that could exacerbate diseases when taken with Ibuprofen and Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Milnacipran
Ticlopidine may cause a moderate interaction that could exacerbate diseases when taken with Pegaspargase and Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Milnacipran
Ticlopidine may cause a moderate interaction that could exacerbate diseases when taken with Fenfluramine and Fenfluramine may lead to a major life threatening interaction when taken with Milnacipran |
DB00682 | DB05679 | 126 | 1,683 | [
"DDInter1951",
"DDInter1907"
] | Warfarin | Ustekinumab | Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors. | Ustekinumab is a human immunoglobulin (Ig) G1 kappa monoclonal antibody directed against interleukin(IL)-12 and IL-23, which are cytokines that are involved in immune and inflammatory responses. It was generated via recombinant human IL-12 immunization of human Ig (hu-Ig) transgenic mice. It is a targeted biologic disease-modifying anti-rheumatic drug (bDMARDs) that is used in the management of various inflammatory conditions that involve the activation of IL-12 and IL-23 signalling pathways. The therapeutic use of the drug started in Canada, the US, and Europe since 2009 when it was first approved for the treatment of adult patients with moderate to severe plaque psoriasis and active psoriatic arthritis, alone or in combination with [methotrexate]. In September 2016, ustekinumab was additionally approved for the management of moderate to severe Crohn's disease in selected adult patients. In October 2019, it was also approved by the FDA for use to manage moderately to severely active ulcerative colitis in adults. Ustekinumab is currently the first and only approved biologic therapy for ulcerative colitis that targets the interleukin (IL)-12 and IL-23 cytokines. The dosing regimen for ustekinumab is based on the patient's weight and there are intravenous and subcutaneous formulations of the drug based on the dosing schedule and condition being treated. Ustekinumab is commonly marketed under the trade name STELARA. Ustekinumab biosimilars are available in some markets, including Wezlana (ustekinumab-auub) in the US and Jamteki (AVT04) in Canada. | Moderate | 1 | [
[
[
126,
24,
1683
]
],
[
[
126,
63,
1461
],
[
1461,
23,
1683
]
],
[
[
126,
24,
1042
],
[
1042,
24,
1683
]
],
[
[
126,
24,
1093
],
[
1093,
... | [
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
]
],
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
... | Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Ustekinumab
Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Tetracosactide and Tetracosactide may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab
Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Ixekizumab and Ixekizumab may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab
Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli and Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab
Warfarin may cause a minor interaction that can limit clinical effects when taken with Mechlorethamine and Mechlorethamine may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab
Warfarin may lead to a major life threatening interaction when taken with Amiodarone and Amiodarone may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab
Warfarin may lead to a major life threatening interaction when taken with Rivaroxaban and Rivaroxaban may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab
Warfarin may lead to a major life threatening interaction when taken with Ibritumomab tiuxetan and Ibritumomab tiuxetan may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab
Warfarin may cause a minor interaction that can limit clinical effects when taken with Simvastatin and Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab |
DB01142 | DB04896 | 1,264 | 901 | [
"DDInter593",
"DDInter1220"
] | Doxepin | Milnacipran | Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepressant but it is commonly associated with the class since it shares a lot of properties with members of the drug family including [amitriptyline], [clomipramine], [desipramine], [imipramine], [nortriptyline], [protriptyline] and [trimipramine]. Doxepin was developed by Pfizer and FDA approved in 1969 as an antidepressant. However, in 2010 it was approved for the treatment of insomnia. The latter | Milnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI) and like many agents in this category was originally developed for and continues to be approved and indicated for the treatment of depression [F3928, F3934, A175786, A175951]. Furthermore, in 2009 the US FDA approved milnacipran for the additional indication of treating fibromyalgia , although other regional regulatory authorities like the EMA, among others, have not yet approved the agent for such treatment, citing lack of robust evidence of efficacy, insufficient demonstration of maintenance of effect, and other concerns [F3928, F3934]. Nevertheless, milnacipran demonstrates a somewhat unique characteristic among SNRIs to elicit a relatively balanced reuptake inhibition of both serotonin and noradrenaline, with a somewhat increased preference for noradrenaline reuptake inhibition - which is potentially a point of interest given the plausible proposal that noradrenaline plays an important role in the mitigation of pain signals in the descending inhibitory pain pathways in the brain and spinal cord [A175759, A175843, A175846]. Moreover, recent research has shown that the levorotatory enantiomer of milnacipran, levomilnacipran, may have the capacity to inhibit the activity of beta-site amyloid precursor protein cleaving enzyme-1 (BACE-1), which has investigationally been associated with β-amyloid plaque formation - making the agent a possible course of treatment for Alzheimer's disease . | Major | 2 | [
[
[
1264,
25,
901
]
],
[
[
1264,
25,
41
],
[
41,
1,
901
]
],
[
[
1264,
64,
1349
],
[
1349,
40,
901
]
],
[
[
1264,
6,
6112
],
[
6112,
... | [
[
[
"Doxepin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Milnacipran"
]
],
[
[
"Doxepin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Levomilnacipran"
],
[
"Levomilnacipran",
"... | Doxepin may lead to a major life threatening interaction when taken with Levomilnacipran and Levomilnacipran (Compound) resembles Milnacipran (Compound)
Doxepin may lead to a major life threatening interaction when taken with Meperidine and Meperidine (Compound) resembles Milnacipran (Compound)
Doxepin (Compound) binds SLC6A4 (Gene) and SLC6A4 (Gene) is bound by Milnacipran (Compound)
Doxepin (Compound) causes Migraine (Side Effect) and Migraine (Side Effect) is caused by Milnacipran (Compound)
Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Cyproheptadine and Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Milnacipran
Doxepin may lead to a major life threatening interaction when taken with Phenylephrine and Phenylephrine may cause a moderate interaction that could exacerbate diseases when taken with Milnacipran
Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Metoclopramide and Metoclopramide may cause a moderate interaction that could exacerbate diseases when taken with Milnacipran
Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol and Olodaterol may cause a moderate interaction that could exacerbate diseases when taken with Milnacipran
Doxepin may lead to a major life threatening interaction when taken with Ephedrine and Ephedrine may cause a moderate interaction that could exacerbate diseases when taken with Milnacipran |
DB01309 | DB08822 | 1,254 | 911 | [
"DDInter933",
"DDInter156"
] | Insulin glulisine | Azilsartan medoxomil | Insulin glulisine is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promotes glucose metabolism. Insulin is released from the pancreas following a meal to promote the uptake of glucose from the blood into internal organs and tissues such as the liver, fat cells, and skeletal muscle. Absorption of glucose into cells allows for its transformation into glycogen or fat for storage. Insulin also inhibits hepatic glucose production, enhances protein synthesis, and inhibits lipolysis and proteolysis among many other functions. Insulin is an important treatment in the management of Type 1 Diabetes (T1D) which is caused by an autoimmune reaction that destroys the beta cells of the pancreas, resulting in the body not being | Azilsartan medoxomil is a prodrug that is broken down to azilsartan, which belongs in the angiotensin-receptor blocking (ARB) drug class. It is a selective AT1 subtype angiotensin II receptor antagonist. Azilsartan medoxomil is a relatively recently-developed antihypertensive drug that was first approved by the FDA in February 2011. Many guidelines recommend the use of ARBs as first-line therapy when initiating antihypertensive therapy and indicate that the clinical efficacy of ARBs is comparable to angiotensin-converting enzyme (ACE) inhibitors that are also used as first-line treatment for hypertension. Azilsartan medoxomil is marketed under the brand name Edarbi. It is used to treat hypertension as monotherapy or in combination with other antihypertensive drugs. It is also available in a combination product with [chlorthalidone]. As hypertension is a major risk factor for cardiovascular disease, early management of hypertension has several implications on patients' survival rate and quality of life in the future. Lowering blood pressure is associated with a reduced risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. Azilsartan medoxomil is thus speculated to lower mortality rates and the onset of cardiovascular disease. Although there is no clinical significance yet determined, azilsartan medoxomil may have potential off-label uses in patients with a history of myocardial infarction or heart failure. | Moderate | 1 | [
[
[
1254,
24,
911
]
],
[
[
1254,
63,
217
],
[
217,
1,
911
]
],
[
[
1254,
24,
1450
],
[
1450,
63,
911
]
],
[
[
1254,
24,
549
],
[
549,
... | [
[
[
"Insulin glulisine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Azilsartan medoxomil"
]
],
[
[
"Insulin glulisine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olm... | Insulin glulisine may cause a moderate interaction that could exacerbate diseases when taken with Olmesartan and Olmesartan (Compound) resembles Azilsartan medoxomil (Compound)
Insulin glulisine may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin and Empagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Azilsartan medoxomil
Insulin glulisine may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin and Dapagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Azilsartan medoxomil
Insulin glulisine may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazine and Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Azilsartan medoxomil
Insulin glulisine may cause a minor interaction that can limit clinical effects when taken with Potassium chloride and Potassium chloride may lead to a major life threatening interaction when taken with Azilsartan medoxomil
Insulin glulisine may cause a minor interaction that can limit clinical effects when taken with Potassium gluconate and Potassium gluconate may lead to a major life threatening interaction when taken with Azilsartan medoxomil
Insulin glulisine may cause a moderate interaction that could exacerbate diseases when taken with Olmesartan and Olmesartan (Compound) resembles Tasosartan (Compound) and Tasosartan (Compound) resembles Azilsartan medoxomil (Compound)
Insulin glulisine may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin and Empagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Olmesartan and Olmesartan (Compound) resembles Azilsartan medoxomil (Compound)
Insulin glulisine may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazine and Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Olmesartan and Olmesartan (Compound) resembles Azilsartan medoxomil (Compound) |
DB01579 | DB06704 | 341 | 247 | [
"DDInter1439",
"DDInter951"
] | Phendimetrazine | Iobenguane (I-123) | Phendimetrazine is a weight loss medication. Phendimetrazine is chemically related to amphetamines and is a Schedule III drug under the Convention on Psychotropic Substances and in the US since 1970. | 2-[(3-iodophenyl)methyl]guanidine is an organoiodine compound. | Moderate | 1 | [
[
[
341,
37,
247
]
],
[
[
341,
6,
7390
],
[
7390,
45,
247
]
],
[
[
341,
21,
28921
],
[
28921,
60,
247
]
],
[
[
341,
63,
820
],
[
820,
... | [
[
[
"Phendimetrazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening interaction when taken with {v}",
"Iobenguane"
]
],
[
[
"Phendimetrazine",
"{u} (Compound) binds {v} (Gene)",
... | Phendimetrazine may cause a moderate interaction that could exacerbate diseases when taken with Iobenguane and Phendimetrazine may lead to a major life threatening interaction when taken with Iobenguane
Phendimetrazine (Compound) binds SLC6A2 (Gene) and SLC6A2 (Gene) is bound by Iobenguane (Compound)
Phendimetrazine (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Iobenguane (Compound)
Phendimetrazine may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Iobenguane
Phendimetrazine may lead to a major life threatening interaction when taken with Methylene blue and Methylene blue may lead to a major life threatening interaction when taken with Iobenguane
Phendimetrazine may lead to a major life threatening interaction when taken with Iohexol and Iohexol may lead to a major life threatening interaction when taken with Iobenguane
Phendimetrazine may cause a moderate interaction that could exacerbate diseases when taken with Pseudoephedrine and Pseudoephedrine may cause a moderate interaction that could exacerbate diseases when taken with Iobenguane and Pseudoephedrine may lead to a major life threatening interaction when taken with Iobenguane
Phendimetrazine may lead to a major life threatening interaction when taken with Cocaine and Cocaine may cause a moderate interaction that could exacerbate diseases when taken with Iobenguane and Cocaine may lead to a major life threatening interaction when taken with Iobenguane
Phendimetrazine (Compound) binds SLC6A2 (Gene) and SLC6A2 (Gene) is bound by Nefazodone (Compound) and Nefazodone may cause a moderate interaction that could exacerbate diseases when taken with Iobenguane
Phendimetrazine (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Ganciclovir (Compound) and Ganciclovir may cause a moderate interaction that could exacerbate diseases when taken with Iobenguane |
DB11642 | DB11691 | 938 | 1,499 | [
"DDInter1480",
"DDInter1258"
] | Pitolisant | Naldemedine | Pitolisant is a selective antagonist or inverse agonist of the histamine H3 receptor used to treat type 1 or 2 narcolepsy. Narcolepsy is a chronic neurological disorder that affects 1 in 2,000 individuals and is characterized by excessive daytime sleepiness, abnormal REM sleep manifestations, sleep paralysis and hypnagogic hallucinations. About 60-70% of patients with narcolepsy experience cataplexy, which is a sudden loss of muscle tone triggered by positive or negative emotions. Histaminergic neuron signalling in the brain plays a role in maintaining wakefulness; by blocking histamine autoreceptors, pitolisant enhances the activity of histaminergic neurons, as well as increasing the signalling of other neurotransmitters in the brain. In a European clinical trial of adult patients with narcolepsy, there was a reduction in the Epworth Sleepiness Scale (ESS) score from pitolisant therapy compared to placebo. The therapeutic effectiveness of pit | Naldemedine is an opioid receptor antagonist [FDA Label]. It is a modified form of to which a side chain has been added to increase molecular weight and polar surface area resulting in restricted transport across the blood brain barrier. Naldemedine was approved in 2017 in both the US and Japan for the treatment of Opioid-induced Constipation. | Moderate | 1 | [
[
[
938,
24,
1499
]
],
[
[
938,
63,
1159
],
[
1159,
24,
1499
]
],
[
[
938,
64,
1593
],
[
1593,
24,
1499
]
],
[
[
938,
24,
283
],
[
283,
... | [
[
[
"Pitolisant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naldemedine"
]
],
[
[
"Pitolisant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methylnaltrexone"
],
... | Pitolisant may cause a moderate interaction that could exacerbate diseases when taken with Methylnaltrexone and Methylnaltrexone may cause a moderate interaction that could exacerbate diseases when taken with Naldemedine
Pitolisant may lead to a major life threatening interaction when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Naldemedine
Pitolisant may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Naldemedine
Pitolisant may lead to a major life threatening interaction when taken with Lorlatinib and Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Naldemedine
Pitolisant may lead to a major life threatening interaction when taken with Enzalutamide and Enzalutamide may lead to a major life threatening interaction when taken with Naldemedine
Pitolisant may lead to a major life threatening interaction when taken with Apalutamide and Apalutamide may lead to a major life threatening interaction when taken with Naldemedine
Pitolisant may cause a moderate interaction that could exacerbate diseases when taken with Methylnaltrexone and Methylnaltrexone may cause a moderate interaction that could exacerbate diseases when taken with Capmatinib and Capmatinib may cause a moderate interaction that could exacerbate diseases when taken with Naldemedine
Pitolisant may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may cause a minor interaction that can limit clinical effects when taken with Modafinil and Modafinil may cause a minor interaction that can limit clinical effects when taken with Naldemedine
Pitolisant may cause a moderate interaction that could exacerbate diseases when taken with Eliglustat and Eliglustat may cause a moderate interaction that could exacerbate diseases when taken with Modafinil and Modafinil may cause a minor interaction that can limit clinical effects when taken with Naldemedine |
DB00069 | DB09115 | 367 | 505 | [
"DDInter946",
"DDInter559"
] | Interferon alfacon-1 | Diiodohydroxyquinoline | Interferon alfacon-1 is a recombinant non-naturally occurring type-I interferon. The 166-amino acid sequence of Interferon alfacon-1 was derived by scanning the sequences of several natural interferon alpha subtypes and assigning the most frequently observed amino acid in each corresponding position. Four additional amino acid changes were made to facilitate the molecular construction, and a corresponding synthetic DNA sequence was constructed using chemical synthesis methodology. Interferon alfacon-1 differs from interferon alfa-2b at 20/166 amino acids (88% homology), and comparison with interferon-beta shows identity at over 30% of the amino acid positions. Interferon alfacon-1 is produced in Escherichia coli (E. coli) cells that have been genetically altered by insertion of a synthetically constructed sequence that codes for Interferon alfacon-1. Prior to final purification, Interferon alfacon- | Diiodohydroxyquinoline, also known as uidoquinol and iodoquinol, is a quinoline derivative that can be used in the treatment of amoebiasis. The exact mechanism of action is unknown. Iodoquinol is not currently available in any FDA-approved products. | Moderate | 1 | [
[
[
367,
24,
505
]
],
[
[
367,
24,
1593
],
[
1593,
24,
505
]
],
[
[
367,
25,
1510
],
[
1510,
24,
505
]
],
[
[
367,
24,
1434
],
[
1434,
... | [
[
[
"Interferon alfacon-1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diiodohydroxyquinoline"
]
],
[
[
"Interferon alfacon-1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
... | Interferon alfacon-1 may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Diiodohydroxyquinoline
Interferon alfacon-1 may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may cause a moderate interaction that could exacerbate diseases when taken with Diiodohydroxyquinoline
Interferon alfacon-1 may cause a moderate interaction that could exacerbate diseases when taken with Benznidazole and Benznidazole may cause a moderate interaction that could exacerbate diseases when taken with Diiodohydroxyquinoline
Interferon alfacon-1 may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon alfa-2a and Peginterferon alfa-2a may cause a moderate interaction that could exacerbate diseases when taken with Diiodohydroxyquinoline
Interferon alfacon-1 may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Simvastatin and Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Diiodohydroxyquinoline
Interferon alfacon-1 may cause a moderate interaction that could exacerbate diseases when taken with Simvastatin and Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Diiodohydroxyquinoline
Interferon alfacon-1 may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Diiodohydroxyquinoline
Interferon alfacon-1 may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Diiodohydroxyquinoline
Interferon alfacon-1 may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon alfa-2a and Peginterferon alfa-2a may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Diiodohydroxyquinoline |
DB00831 | DB12141 | 1,178 | 971 | [
"DDInter1866",
"DDInter817"
] | Trifluoperazine | Gilteritinib | A phenothiazine with actions similar to chlorpromazine. It is used as an antipsychotic and an antiemetic. | Gilteritinib, also known as ASP2215, is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and potency when compared with other agents from this group. It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression observed in other therapies. Gilteritinib was developed by Astellas Pharma and FDA approved on November 28, 2018. This drug was approved after being designed as an orphan drug with a fast track and priority review status. | Moderate | 1 | [
[
[
1178,
24,
971
]
],
[
[
1178,
23,
112
],
[
112,
23,
971
]
],
[
[
1178,
63,
485
],
[
485,
24,
971
]
],
[
[
1178,
24,
823
],
[
823,
... | [
[
[
"Trifluoperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
]
],
[
[
"Trifluoperazine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
... | Trifluoperazine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Gilteritinib
Trifluoperazine may cause a moderate interaction that could exacerbate diseases when taken with Pentamidine and Pentamidine may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib
Trifluoperazine may cause a moderate interaction that could exacerbate diseases when taken with Triclabendazole and Triclabendazole may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib
Trifluoperazine (Compound) resembles Alimemazine (Compound) and Trifluoperazine may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib
Trifluoperazine (Compound) resembles Clomipramine (Compound) and Clomipramine may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib
Trifluoperazine may cause a moderate interaction that could exacerbate diseases when taken with Famotidine and Famotidine may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib
Trifluoperazine (Compound) resembles Methotrimeprazine (Compound) and Methotrimeprazine may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib
Trifluoperazine may lead to a major life threatening interaction when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib
Trifluoperazine may lead to a major life threatening interaction when taken with Cisapride and Cisapride may lead to a major life threatening interaction when taken with Gilteritinib |
DB06694 | DB06704 | 31 | 247 | [
"DDInter1952",
"DDInter952"
] | Xylometazoline (nasal) | Iobenguane (I-131) | Xylometazoline is an alkylbenzene. | 2-[(3-iodophenyl)methyl]guanidine is an organoiodine compound. | Major | 2 | [
[
[
31,
25,
247
]
],
[
[
31,
63,
1161
],
[
1161,
25,
247
]
],
[
[
31,
24,
1629
],
[
1629,
64,
247
]
],
[
[
31,
63,
1100
],
[
1100,
3... | [
[
[
"Xylometazoline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iobenguane"
]
],
[
[
"Xylometazoline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Selegiline"
],
[
"Se... | Xylometazoline may lead to a major life threatening interaction when taken with Iobenguane
Xylometazoline may cause a moderate interaction that could exacerbate diseases when taken with Selegiline and Selegiline may lead to a major life threatening interaction when taken with Iobenguane
Xylometazoline may cause a moderate interaction that could exacerbate diseases when taken with Methylene blue and Methylene blue may lead to a major life threatening interaction when taken with Iobenguane
Xylometazoline may cause a moderate interaction that could exacerbate diseases when taken with Venlafaxine and Venlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Iobenguane and Venlafaxine may lead to a major life threatening interaction when taken with Iobenguane
Xylometazoline may lead to a major life threatening interaction when taken with Ergotamine and Ergotamine may cause a moderate interaction that could exacerbate diseases when taken with Iobenguane and Ergotamine may lead to a major life threatening interaction when taken with Iobenguane
Xylometazoline may cause a moderate interaction that could exacerbate diseases when taken with Levomilnacipran and Levomilnacipran may cause a moderate interaction that could exacerbate diseases when taken with Iobenguane and Levomilnacipran may lead to a major life threatening interaction when taken with Iobenguane
Xylometazoline may cause a moderate interaction that could exacerbate diseases when taken with Desvenlafaxine and Desvenlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Iobenguane and Desvenlafaxine may lead to a major life threatening interaction when taken with Iobenguane
Xylometazoline may cause a moderate interaction that could exacerbate diseases when taken with Selegiline and Selegiline (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Iobenguane (Compound)
Xylometazoline may cause a moderate interaction that could exacerbate diseases when taken with Methylene blue and Methylene blue may lead to a major life threatening interaction when taken with Nefazodone and Nefazodone may cause a moderate interaction that could exacerbate diseases when taken with Iobenguane
Xylometazoline may cause a moderate interaction that could exacerbate diseases when taken with Venlafaxine and Venlafaxine (Compound) binds SLC6A2 (Gene) and SLC6A2 (Gene) is bound by Iobenguane (Compound) |
DB00562 | DB06203 | 1,014 | 1,002 | [
"DDInter188",
"DDInter51"
] | Benzthiazide | Alogliptin | Benzthiazide is used to treat hypertension and edema. Like other thiazides, benzthiazide promotes water loss from the body (diuretics). They inhibit Na+/Cl- reabsorption from the distal convoluted tubules in the kidneys. Thiazides also cause loss of potassium and an increase in serum uric acid. Thiazides are often used to treat hypertension, but their hypotensive effects are not necessarily due to their diuretic activity. Thiazides have been shown to prevent hypertension-related morbidity and mortality although the mechanism is not fully understood. Thiazides cause vasodilation by activating calcium-activated potassium channels (large conductance) in vascular smooth muscles and inhibiting various carbonic anhydrases in vascular tissue. | Alogliptin is a selective, orally-bioavailable inhibitor of enzymatic activity of dipeptidyl peptidase-4 (DPP-4). Chemically, alogliptin is prepared as a benzoate salt and exists predominantly as the R-enantiomer (>99%). It undergoes little or no chiral conversion in vivo to the (S)-enantiomer. FDA approved January 25, 2013. | Moderate | 1 | [
[
[
1014,
24,
1002
]
],
[
[
1014,
24,
1281
],
[
1281,
40,
1002
]
],
[
[
1014,
40,
504
],
[
504,
24,
1002
]
],
[
[
1014,
24,
401
],
[
401,
... | [
[
[
"Benzthiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alogliptin"
]
],
[
[
"Benzthiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Linagliptin"
],
... | Benzthiazide may cause a moderate interaction that could exacerbate diseases when taken with Linagliptin and Linagliptin (Compound) resembles Alogliptin (Compound)
Benzthiazide (Compound) resembles Hydrochlorothiazide (Compound) and Hydrochlorothiazide may cause a moderate interaction that could exacerbate diseases when taken with Alogliptin
Benzthiazide may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Alogliptin
Benzthiazide may cause a moderate interaction that could exacerbate diseases when taken with Insulin glargine and Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Alogliptin
Benzthiazide (Compound) resembles Chlorothiazide (Compound) and Chlorothiazide may cause a moderate interaction that could exacerbate diseases when taken with Alogliptin
Benzthiazide may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort and Deflazacort may cause a moderate interaction that could exacerbate diseases when taken with Alogliptin
Benzthiazide may cause a moderate interaction that could exacerbate diseases when taken with Linagliptin and Linagliptin (Compound) binds DPP4 (Gene) and DPP4 (Gene) is bound by Alogliptin (Compound)
Benzthiazide (Compound) resembles Hydrochlorothiazide (Compound) and Hydrochlorothiazide may cause a moderate interaction that could exacerbate diseases when taken with Linagliptin and Linagliptin (Compound) resembles Alogliptin (Compound)
Benzthiazide may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Linagliptin and Linagliptin (Compound) resembles Alogliptin (Compound) |
DB00295 | DB00405 | 475 | 128 | [
"DDInter1244",
"DDInter517"
] | Morphine | Dexbrompheniramine | Morphine, the main alkaloid of opium, was first obtained from poppy seeds in 1805. It is a potent analgesic, though its use is limited due to tolerance, withdrawal, and the risk of abuse. Morphine is still routinely used today, though there are a number of semi-synthetic opioids of varying strength such as [codeine], [fentanyl], [methadone], [hydrocodone], [hydromorphone], [meperidine], and [oxycodone]. Morphine was granted FDA approval in 1941. | Dexbrompheniramine maleate is an antihistamine agent that is used for the treatment of allergic conditions, such as hay fever or urticaria. | Moderate | 1 | [
[
[
475,
24,
128
]
],
[
[
475,
24,
662
],
[
662,
63,
128
]
],
[
[
475,
25,
508
],
[
508,
63,
128
]
],
[
[
475,
24,
556
],
[
556,
24,... | [
[
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexbrompheniramine"
]
],
[
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
],
... | Morphine may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Dexbrompheniramine
Morphine may lead to a major life threatening interaction when taken with Promazine and Promazine may cause a moderate interaction that could exacerbate diseases when taken with Dexbrompheniramine
Morphine may cause a moderate interaction that could exacerbate diseases when taken with Valproic acid and Valproic acid may cause a moderate interaction that could exacerbate diseases when taken with Dexbrompheniramine
Morphine may lead to a major life threatening interaction when taken with Pregabalin and Pregabalin may cause a moderate interaction that could exacerbate diseases when taken with Dexbrompheniramine
Morphine may lead to a major life threatening interaction when taken with Pentobarbital and Pentobarbital may cause a moderate interaction that could exacerbate diseases when taken with Dexbrompheniramine
Morphine may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin may cause a moderate interaction that could exacerbate diseases when taken with Dexbrompheniramine
Morphine (Compound) resembles Oxymorphone (Compound) and Morphine may lead to a major life threatening interaction when taken with Oxymorphone and Oxymorphone may cause a moderate interaction that could exacerbate diseases when taken with Dexbrompheniramine
Morphine (Compound) resembles Galantamine (Compound) and Galantamine may cause a moderate interaction that could exacerbate diseases when taken with Dexbrompheniramine
Morphine may lead to a major life threatening interaction when taken with Dextropropoxyphene and Dextropropoxyphene may lead to a major life threatening interaction when taken with Dexbrompheniramine |
DB06290 | DB11581 | 1,449 | 1,456 | [
"DDInter1673",
"DDInter1926"
] | Simeprevir | Venetoclax | Simeprevir is a hepatitis C virus (HCV) NS3/4A protease inhibitor indicated in patient's with HCV genotype 1 for the treatment of chronic hepatitis C virus (HCV) infection. HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, and affecting 72% of all chronic HCV patients. Like all NS3/4A inhibitors, simeprevir is a serine protease inhibitor in similarity to and but is classified as a second generation protease inhibitor. This class of antiviral drugs were the first direct acting antivirals approved but are associated with lower cure rates than newer drugs. Broad use of simeprevir occurred when it was used in combination with a newer drug,. Inhibiting HCV NS3/4A protease in a potent and highly specific manner, simeprevir is a direct- | Venetoclax is a BCL-2 inhibitor that was initially approved by the FDA in April 2016 [FDA label]. Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are important regulators of the apoptotic (programmed cell death) process , . Venetoclax is used to treat chronic lymphocytic leukemia (CLL) and certain types of small lymphocytic lymphoma [FDA label]. CLL is the most prevalent leukemia diagnosed in Western countries . Venetoclax was developed through reverse engineering of the BCL-2 protein family inhibitor, navitoclax . Venetoclax is approximately 10 times more potent than navitoclax with regard to induction of apoptosis in CLL cells . A new indication was approved in 2018 for the treatment patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion, who have received at least one prior therapy [FDA label]. Previously, this drug was indicated only for patients with 17p gene deletion . | Major | 2 | [
[
[
1449,
25,
1456
]
],
[
[
1449,
24,
466
],
[
466,
63,
1456
]
],
[
[
1449,
63,
126
],
[
126,
24,
1456
]
],
[
[
1449,
25,
498
],
[
498,
... | [
[
[
"Simeprevir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Venetoclax"
]
],
[
[
"Simeprevir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
],
[
"Daroluta... | Simeprevir may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a moderate interaction that could exacerbate diseases when taken with Venetoclax
Simeprevir may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Venetoclax
Simeprevir may lead to a major life threatening interaction when taken with Edoxaban and Edoxaban may cause a moderate interaction that could exacerbate diseases when taken with Venetoclax
Simeprevir may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin and Midostaurin may lead to a major life threatening interaction when taken with Venetoclax
Simeprevir may lead to a major life threatening interaction when taken with Apalutamide and Apalutamide may lead to a major life threatening interaction when taken with Venetoclax
Simeprevir may lead to a major life threatening interaction when taken with Cobicistat and Cobicistat may lead to a major life threatening interaction when taken with Venetoclax
Simeprevir may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin may lead to a major life threatening interaction when taken with Venetoclax
Simeprevir may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a moderate interaction that could exacerbate diseases when taken with Secobarbital and Secobarbital may cause a moderate interaction that could exacerbate diseases when taken with Venetoclax
Simeprevir may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may lead to a major life threatening interaction when taken with Secobarbital and Secobarbital may cause a moderate interaction that could exacerbate diseases when taken with Venetoclax |
DB00514 | DB04868 | 506 | 478 | [
"DDInter527",
"DDInter1293"
] | Dextromethorphan | Nilotinib | Dextromethorphan is a levorphanol derivative and codeine analog commonly used as a cough suppressant and also a drug of abuse. Although similar in structure to other opioids, it has minimal interaction with opioid receptors. Dextromethorphan was granted FDA approval before 3 December 1957.[A215412,L14997] | Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to treatment with imatinib (Gleevec), another tyrosine kinase inhibitor used as a first-line treatment for CML. | Moderate | 1 | [
[
[
506,
24,
478
]
],
[
[
506,
6,
6017
],
[
6017,
45,
478
]
],
[
[
506,
7,
3727
],
[
3727,
46,
478
]
],
[
[
506,
21,
28769
],
[
28769,
... | [
[
[
"Dextromethorphan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
]
],
[
[
"Dextromethorphan",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (... | Dextromethorphan (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Nilotinib (Compound)
Dextromethorphan (Compound) upregulates MAL (Gene) and MAL (Gene) is upregulated by Nilotinib (Compound)
Dextromethorphan (Compound) causes Feeling abnormal (Side Effect) and Feeling abnormal (Side Effect) is caused by Nilotinib (Compound)
Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Mirabegron and Mirabegron may cause a minor interaction that can limit clinical effects when taken with Nilotinib
Dextromethorphan may lead to a major life threatening interaction when taken with Lasmiditan and Lasmiditan may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib
Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Lurasidone and Lurasidone may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib
Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Clonazepam and Clonazepam may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib
Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Zolpidem and Zolpidem may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib
Dextromethorphan may lead to a major life threatening interaction when taken with Fenfluramine and Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.